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Preeclampsia   (PE)   remains   one   of   the   most   enigmatic   and   pervasive  
conditions  developed  during  pregnancy  and  is  a  leading  cause  of  maternal  and  
fetal   morbidity   and  mortality   throughout   the   world.   Afflicting   nearly   5-­‐‑8%   of  
pregnancies   in   the   Unites   States,   PE   is   most   commonly   characterized   by   an  
increase  in  blood  pressure  and  high  protein  excretion  near  or  after  the  20th  week  
of  gestation.  Unfortunately,   few  effective   treatments  are  available,  and  the  only  
“cure”   is  delivery.  While   the  molecular  pathogenesis  of  PE   remains  undefined,  
an  interruption  in  placental  blood  flow,  or  placental  ischemia,  is  widely  observed  
as   a   primary   contributor   to   the   syndrome   progression.   Furthermore,   to  
investigate  the  role  of  both  pharmacological  and  non-­‐‑pharmacological  modalities  
to   prevent   placental   ischemia   induced   hypertension,   we   employed   a   robust  
model  of  reduced  utero-­‐‑placental  perfusion  pressure  (RUPP)  in  the  pregnant  rat.  
v	  
	  
First,  in  Chapter  IV,  exercise  initiated  during  gestation  was  not  effective  in  
the  prevention  of  RUPP-­‐‑induced  hypertension,  whereas  exercise  training  prior  to  
and   continued   through   gestation   prevented   the   increase   in   blood   pressure.  
Though   the   molecular   contributions   to   this   effect   are   undefined,   the   effects  
appear  to  be  independent  of  angiogenic  balance  restoration.  
Finally,  in  Chapter  V,  administration  of  5-­‐‑aminoimidazole-­‐‑4-­‐‑carboxamide-­‐‑
1-­‐‑β-­‐‑D-­‐‑ribofuranoside   (AICAR)   was   explored   as   a   novel   pharmacological  
modality  to  prevent  the  onset  of  hypertension  and  endothelial  dysfunction  in  the  
RUPP   model.   As   hypothesized,   AICAR   ameliorated   the   RUPP-­‐‑induced  
hypertension,   and   the   anti-­‐‑hypertensive   effect   in   the   RUPP   appears   to   be  
dependent  on  the  restoration  of  angiogenic  balance  in  the  maternal  plasma.    
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“A  headache  accompanied  by  heaviness  and  convulsions  during  pregnancy  is  
considered  bad”  -­‐‑  Hippocrates,  400  B.C.  1  
HISTORICAL  PERSPECTIVE  
Near  the  beginning  of  my  graduate  career,  I  recall  a  striking  point  shared  
in  conversation  with  a  prominent  obstetrician,  Dr.  James  Martin,  in  which  he  
emphasized  that  preeclampsia  (PE)  has  been  observed  and  documented  for  
several  millennia;  yet,  we  have  only  really  begun  to  understand  cause  of  the  
symptoms  within  the  last  30-­‐‑40  years.  This  remark,  cemented  in  my  mind,  was  
equally  as  exciting  as  it  was  discouraging  for  a  young,  bright-­‐‑eyed  scientist.    To  
elaborate  on  Dr.  Martin’s  point,  preeclampsia  (PE)  remains  one  of  the  most  
enigmatic  and  feared  conditions  in  maternal  and  fetal  medicine  to  this  day,  
despite  over  4000  years  of  documented  research  and  observation  2.    With  the  
accepted  nomenclature,  etiology,  and  diagnostic  criteria  changing  several  times  
over  the  course  of  several  centuries,  treatment  and  prevention  of  PE  has  been  
unfortunately  limited.  
Much  of  the  remaining  mystery  of  PE  has  stemmed  from  its  predecessor,  
eclampsia,  in  which  violent  convulsions  and  pitting  edema  have  been  observed  
throughout  world  medical  history,  particularly  by  the  Indian,  Greek,  Egyptian,  
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and  Chinese  historians,  as  early  as  2000  B.C.  2-4.  First  described  by  François  
Boissier  de  Sauvages  de  Lacroix  in  the  18th  century,  the  term  “eclampsia”  is  
derived  from  the  Greek  word  eklampsis,  which  roughly  translates  “to  shine  forth”  
1,2.    It  is  unclear  why  this  term  was  used  to  describe  eclamptic  women,  but  the  
late  Dr.  Leon  Chesley  has  noted  in  his  elaborate  historical  reviews  2,3  the  term  
was  also  used  to  describe  non-­‐‑pregnant  epileptic  subjects,  which  points  to  its  
focus  on  suddenness  of  tonic-­‐‑clonic  seizures  shared  between  the  two  maladies.  
Interestingly,  Chesley  also  reported  that  the  Greeks  were  the  first  to  recognize  
the  harbingers  of  eclamptic  presentation,  in  which  the  women  would  report  of  
visual  or  cerebral  disturbances  such  as  headaches,  blurred  vision,  and  general  
malaise  prior  to  the  presentation  of  the  eclamptic  convulsions  later  in  their  
pregnancies  2.  Not  until  the  mid-­‐‑late  19th  century,  was  eclampsia  recognized  as  
“high  and  strong  pulse”  disorder  5  and  often  accompanied  by  high  protein  
content  in  the  urine  6,7.  Following  the  invention  and  clinical  integration  of  the  
sphygmomanometer  8,  Vaquez  and  Nobelcourt  are  credited  with  the  first  report  
of  high  blood  pressure  in  eclampsia  (and  the  undefined  preeclampsia)  3.  This  
may  be  the  most-­‐‑defining  moment  in  preeclampsia-­‐‑eclampsia  research,  as  it  gave  
physicians  a  measurement  to  predict  fits,  headaches,  and  convulsions  later  in  




Since  the  use  of  hypertension  and  proteinuria  to  define  the  PE  
development,  the  next  substantial  challenge  in  the  research  was  to  understand  
the  etiology  to  develop  possible  modalities  for  treatment  or  prevention.  
Unfortunately,  we  as  researchers  have  yet  to  define  the  exact  etiology  of  PE,  
which  remains  a  heavily  researched  topic  even  to  this  day  and  has  even  earned  
the  moniker  of  “the  disease  of  many  theories”  9,10.    
BACKGROUND  AND  SIGNIFICANCE  
While  the  exact  molecular  and  physiological  mechanism  of  PE  
development  remains  unclear,  placental  hypoperfusion  is  widely  regarded  to  be  
the  initiating  event  in  the  increase  in  blood  pressure  and  renal  dysfunction  in  
preeclampsia  11-13.  This  placental-­‐‑origin  hypothesis  was  based  primarily  on  the  
clinical  observation  of  symptom  remittance  following  the  delivery  of  the  
placenta,  as  fetal  delivery  alone  is  not  sufficient  9,10,14.  Further,  the  hypoperfusion,  
or  ischemia,  is  understood  to  be  caused  by  a  failure  of  the  placental-­‐‑derived  
trophoblast  cells  to  invade  the  spiral  arteries  of  the  uterus,  and  tapping  into  the  
maternal  arterial  blood  supply  during  placentation  15-18.  The  concomitant  cascade  
of  placental-­‐‑derived  signaling  in  response  to  ischemia  was  previously  recognized  
and  championed  by  Jim  Roberts  and  colleagues  11,  and  studies  performed  by  our  
laboratory  19  and  others  20  since  then  have  elegantly  shown  under  ischemic  
conditions,  the  placenta  secretes  anti-­‐‑angiogenic  factors,  most  notably  soluble  
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VEGF  receptor-­‐‑1  (sFlt-­‐‑1)  21-23.  Karumanchi  and  colleagues  were  the  first  to  
elucidate  the  role  of  sFlt-­‐‑1  in  the  ontology  of  preeclampsia  in  both  an  
experimental  and  clinical  setting  20,  and  has  since  then  been  one  of  the  most  
widely  studied  signaling  factors  in  PE  research.  Maynard  first  proposed  an  
increase  in  sFlt-­‐‑1  results  in  a  neutralization  of  circulating  vascular  endothelial  
growth  factor  (VEGF)  in  the  murine  model  or  placental  growth  factor  (PlGF)  in  
the  human,  which  results  in  a  decreased  pro-­‐‑angiogenic  factor  bioavailability.  
This  reduction  in  pro-­‐‑angiogenic  factor  bioavailability  is  often  referred  to  as  
angiogenic  imbalance  21,24.  In  turn,  this  imbalance  leads  to  decreased  vascular  
endothelial  function  and  health,  systemic  oxidative  stress,  renal  dysfunction,  and  
ultimately,  increased  blood  pressure  21-23.    
To  model  the  development  of  PE  through  placental  ischemia,  many    
laboratories  use  the  reduced  uterine  perfusion  pressure  (RUPP)  model  (Chapter  
III,  Figure  3.1),  a  well-­‐‑characterized  and  robust  model  of  the  placental  ischemia  
induced  hypertension  and  model  of  PE  25.  Moreover,  recent  studies  20,26-29  from  
our  laboratory  and  others  have  suggested  restoring  the  angiogenic  balance  by  
increasing  pro-­‐‑angiogenic  bioavailability  and/or  decreasing  anti-­‐‑angiogenic  
factor  levels  as  possible  target  to  mitigate  the  development  of  the  hypertension  in  
PE  through.  Despite  the  strong  evidence  marking  the  angiogenic  imbalance  as  a  
target  for  preeclamptic  symptom  treatment  or  prevention,  there  remains  a  gap  in  
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the  experimental  knowledge  and  clinical  practice  which  further  justifies  the  
specific  aims  proposed.    
Furthermore,  recent  clinical  and  experimental  studies  have  reported  
intriguing  effects  of  administering  a  pharmacological  “mimetic  of  exercise”  30  in  a  
pregnant  or  non-­‐‑pregnant  diabetic  state  complicated  by  a  primary/secondary  
hypertension  31-36,  but  these  studies  have  primarily  focused  on  the  improved  
glucose  handling  and  not  the  favorable  cardiovascular  or  renal  effects  in  the  
hypertensive  subjects.  As  the  observed  effects  of  these  compounds,  such  as  
AICAR  (5-­‐‑aminoimidazole-­‐‑4-­‐‑carboxamide-­‐‑1-­‐‑β-­‐‑D-­‐‑ribofuranoside)  and  other  
adenosine  monophosphate  activated  protein  kinase  (AMPK)-­‐‑activators,  are  
poorly  understood  37.  Furthermore,  there  is  a  clear  need  to  determine  the  
mechanism  and  effectiveness  of  AICAR  administration  in  experimental  models  
of  PE.  
STATEMENT  OF  PROBLEM  
Currently,  there  is  a  dearth  of  knowledge  in  the  mechanisms  by  which  
exercise  training  prior  to  and  during  gestation  mitigates  the  development  of  
preeclampsia.  Additionally,  there  is  also  a  substantial  gap  in  the  scientific  
literature  regarding  the  mechanisms  by  which  pharmaceutical  modalities  which  
mimic  components  of  exercise  may  be  beneficial  to  women  during  pregnancies  
complicated  by  placental  ischemia  and  hypertension.  Therefore,  the  proposed  
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studies  will  allow  the  following:  1)  increase  the  understanding  of  the  molecular  
and  physiological  basis  of  exercise  training  during  normal  and  hypertensive  
pregnancies  in  an  effort  to  develop  safe  and  efficacious  treatments  and  
preventative  modalities;  2)  elucidate  AMPK  as  a  potential  molecular  pathway  by  
which  exercise  training  prevents  the  onset  of  preeclamptic  hypertension  3)  
improve  the  understanding  of  the  clinical  application  of  AICAR,  an  AMPK-­‐‑
activating  compound,  for  treatment  of  hypertensive  disorders  during  pregnancy  
by  employing  a  unique  and  robust  animal  model  which  closely  mimics  the  
human  syndrome;  4)  extend  the  observations  of  exercise  and  AICAR  
administration  in  pregnancy  to  a  translational  application.  
PURPOSE  AND  HYPOTHESES  
The  purpose  of  this  dissertation  work  is  to  elucidate  the  potential  for  
exercise  training  and  “exercise  mimicking”  pharmaceuticals  in  the  treatment  
and/or  prevention  of  preeclampsia  using  a  robust  experimental  animal  model  of  
the  syndrome.  
Specific  Aim  1  
The  role  of  exercise  training  as  a  preventative  modality  for  preeclampsia,  
the  molecular  contributions  and  the  role  in  vascular  and  placental  physiology  is  
left  unclear.  It  has  previously  been  established  that  the  bioavailability  of  vascular  
endothelial  growth  factor  (VEGF)  is  crucial  for  the  maintenance  of  maternal  
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blood  pressure  and  vascular  function  in  pregnancy,  and  in  preeclampsia,  
circulating  free  VEGF  is  decreased.  Moreover,  an  intriguing  characteristic  of  
exercise  training  is  the  increase  of  VEGF  production,  and  these  levels  are  even  
further  increased  in  circulation  in  pregnant  women  and  rats  under  training  
protocols.  Therefore,  Aim  1  (see  Chapter  IV)  is  designed  to  test  the  hypothesis  
that  exercises  training:  (1)  prevents  the  decrease  in  VEGF  bioavailability  the  
onset  of  placental  ischemia  induced  hypertension  and  endothelial  dysfunction  in  
the  rat  RUPP  model;  and  (2)  the  effects  are  mediated  through  the  restoration  of  
angiogenic  balance  and  bioavailability  of  VEGF.  
Parts  1-­‐‑2  of  Chapter  IV  are  in  preparation  for  publication  with  Haley  E.  
Gillham,  Karen  W.  Needham,  and  Jeffrey  S.  Gilbert  as  co-­‐‑authors.  I  performed  
the  experimental  work  with  the  technical  assistance  of  co-­‐‑authors  H.E.  Gillham  
and  K.W.  Needham.  J.S.  Gilbert  provided  editorial  assistance  and  research  
funding.  
Specific  Aim  2  
   As  exercise  is  recognized  to  combat  and  prevent  hypertension  in  
gestation,  the  molecular  contributions  to  explain  this  effect  remain  undefined.  
One  potential  pathway  that  governs  much  of  cellular  energy  production  and  
usage  is  AMP-­‐‑activated  protein  kinase  (AMPK).  Many  studies  using  AMPK-­‐‑
agonists  such  as  Metformin  and  AICAR  in  a  model  of  primary  or  secondary  
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hypertension  suggest  an  anti-­‐‑hypertensive  effect  and  improvement  of  vascular  
function.  Moreover,  AMPK  and  its  downstream  signaling  targets  have  been  
reported  by  others  to  potentially  mediate  the  production  of  VEGF  following  
exercise  training,  but  the  role  of  AMPK  in  pregnancy-­‐‑induced  VEGF  production  
and  tissue  specific  stress  signaling  remains  uncertain.  Therefore,  Aim  2  (see  
Chapter  V)  is  designed  to  test  the  hypothesis  that  the  administration  of  the  
potent  AMPK-­‐‑activating  compound  AICAR:  (1)  will  improve  VEGF  
bioavailability  and  prevent  an  increase  in  arterial  pressure  and  vascular  
dysfunction  in  the  RUPP  model;  (2)  the  anti-­‐‑hypertensive  effects  will  be  
dependent  on  the  restoration  of  angiogenic  balance  and  VEGF  bioavailability;  
and  (3)  directly  improve  placental  and  vascular  endothelial  health  and  function  
through  prevention  of  cellular  stress  signaling.  
In  Chapter  V,  a  portion  of  the  data  in  Part  1  was  published  in  2012  in  the  
American  Journal  of  Physiology  -­‐‑  Heart  and  Circulation,  with  Ashley  J.  Bauer,  Karen  
W.  Needham,  Hans  C.  Dreyer,  and  Jeffrey  S.  Gilbert  as  co-­‐‑authors.  I  performed  
the  experimental  work  along  with  the  technical  assistance  of  A.J.  Bauer  and  K.W.  
Needham.  H.C.  Dreyer  and  J.S.  Gilbert  provided  editorial  assistance.  J.S.  Gilbert  
provided  the  research  funding.  
Parts  2-­‐‑3  of  Chapter  V  are  in  preparation  for  publication  with  Haley  E.  
Gillham,  Sarah  M.  Johnson,  Karen  W.  Needham,  and  Jeffrey  S.  Gilbert  as  co-­‐‑
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authors.  I  performed  the  experimental  work  with  the  technical  assistance  of  co-­‐‑
authors  H.E.  Gillham,  SM,  Johnson,  and  K.W.  Needham.  J.S.  Gilbert  provided  
editorial  assistance  and  research  funding.  





The  following  review  of  literature  is  focused  on  areas  germane  to  the  
research  topic  of  preeclampsia.  After  addressing  the  normal  cardiovascular  
physiology,  the  introduction  to  preeclampsia  pathophysiology  will  be  presented,  
along  with  a  leading  hypothesis  of  its  ontology.  Further,  current  treatments  and  
preventative  measures  will  be  presented  to  lay  the  foundation  for  the  remainder  
of  the  dissertation  data  chapters  (Chapters  IV  and  V),  in  which  pharmacological  
and  non-­‐‑pharmacological  modalities  will  be  addressed.  Finally,  the  dearth  of  
knowledge  in  regard  to  treatments  and  prevention  of  preeclampsia  will  be  
discussed,  establishing  the  need  for  the  current  research  presented,  as  well  as  
future  investigation.    
HYPERTENSION  IN  PREGNANCY  
To  begin  this  review,  it  is  essential  to  establish  the  definition  of  
hypertension,  or  high  (arterial)  blood  pressure.  First  and  foremost,  hypertension  
is  clinically  defined  by  the  repeated  measurement  of  140mmHg  systolic  and/or  
90mmHg  diastolic  38.  In  general,  hypertension  is  recognized  to  be  a  major  
contributor  and  predictor  of  cardiovascular  disease  related  morbidity  and  
mortality,  which  include  chronic  heart  failure,  acute  myocardial  infarction,  
stroke,  and  renal  failure  38.  Additionally,  hypertension  is  often  asymptomatic  and  
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difficult  to  diagnose  without  regular  measurement,  which  is  the  reason  it  has  
earned  the  moniker  of  the  “silent  killer”  39.  
  Unfortunately,  hypertension  during  pregnancy  is  one  of  the  leading  
complications  of  pregnancy,  which  affects  nearly  250,000  women,  or  up  to  10%  of  
pregnancies  in  the  USA,  annually  40.  Moreover,  the  timing  of  the  onset  of  
hypertension  in  pregnancy  is  important  to  the  clinical  diagnoses  and  further  
treatment.  Four  major  forms  of  hypertension  presentation  during  pregnancy  are  
currently  recognized  by  the  National  Institute  of  Health  (NIH)  Heart,  Lung,  and  
Blood  Institute  (NHLBI)  40:  Chronic  hypertension  (Preexisting  blood  pressure  of  
>140/90mmHg);  Gestational  Hypertension  (De  novo  hypertension  in  pregnancy,  
no  proteinuria);  Preeclampsia  (New-­‐‑onset  hypertension  ≥20  weeks,  high  protein  
excretion:  ≥300mg/24hr);  Preeclampsia  superimposed  on  preexisting  
hypertension  (arterial  pressure  before  gestation  >140/90mmHg,  de  novo  
proteinuria).    
Of  these  four,  preeclampsia  is  often  credited  as  the  major  clinical  concern,  
as  this  is  often  described  as  the  most  costly  in  terms  of  both  health  and  finance.  
Strikingly,  it  is  estimated  that  the  collective  financial  burden  produced  by  
preeclampsia  and  related  hypertensive  disorders  in  pregnancy  accounts  for  
nearly  $10  billion  annually  in  the  United  States  alone,  according  to  the  
Preeclampsia  Foundation  (USA).  Unfortunately,  the  diagnostic  criteria,  
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pathogenesis,  and  treatment  recommendations  for  preeclampsia  remain  
unknown  or  controversial  41,  which  warrants  further  investigation  into  this  
debilitating  and  costly  syndrome.  
PATHOPHYSIOLOGY  OF  PREECLAMPSIA  
As  described  briefly  above,  preeclampsia  (PE)  is  a  leading  contributor  to  
maternal  and  fetal  morbidity  and  mortality  in  both  the  United  States  and  
worldwide  40,42.  PE  has  long  been  diagnosed  at  presentation  of  hypertension  
(≥140/90mmHg)  and  proteinuria  (≥300mg/24hrs)  at  ≥20th  week  of  gestation,  but  
diagnosis  criteria  has  recently  changed  to  include  markers  of  thrombocytopenia,  
impaired  renal  and/or  liver  function,  pulmonary  edema,  and  cerebral/visual  
disturbances  as  secondary  confirmation  measurements  in  the  absence  of  
proteinuria  41.  While  the  past  several  decades  have  seen  a  rise  of  nearly  40%  in  
the  incidence  of  preeclampsia,  this  is  largely  thought  to  be  due  to  increases  in  the  
number  of  higher  order  pregnancies  (multiple  births),  and  the  age  at  onset  of  
pregnancy  and  rate  of  obesity  40,41.  Treatment  is  currently  limited  to  supportive  
care  (e.g.  bed  rest),  and  induction  of  delivery  if  symptoms  progress  to  life-­‐‑
threatening  conditions,  after  which  symptoms  typically  resolve  within  48–72  
hours  41,43,44.    
Despite  the  tremendous  recent  efforts  to  understand  the  pathophysiology  
of  preeclampsia,  the  current  molecular  mechanisms  behind  PE  etiology  remain  
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unsettled.  Though  the  molecular  pathophysiology  still  requires  further  
refinement,  PE  is  widely  acknowledged  to  initiate  from  poor  placental  perfusion  
(i.e.  ischemia)  and  insufficiency,  which  is  derived  primarily  from  an  interruption  
in  the  normal  remodeling  of  the  spiral  arteries  of  the  uterine  endometrium  45-48.  
Further,  the  resulting  placental  ischemia  leads  to  a  myriad  of  placental-­‐‑derived  
signaling  cascades  which  include  circulating  angiogenic  factor  imbalance,  innate  
and  adaptive  immune  activation,  and  increased  sympathetic  vasomotor  activity,  
which  jointly  result  in  an  increase  in  mean  arterial  pressure  49-51.  Furthermore,  
while  it  is  important  to  acknowledge  and  emphasize  the  significance  of  all  
contributing  pathways  in  PE  pathogenesis,  this  literature  review  and  the  
remainder  of  this  dissertation  will  focus  on  the  maintenance  and  restoration  of  
angiogenic  balance  through  both  pharmacological  and  non-­‐‑pharmacological  
means  in  PE  symptom  prevention.  
PLACENTAL  ISCHEMIA,  ANGIOGENIC  IMBALANCE,  AND  
PREECLAMPSIA  
Although  the  molecular  pathophysiology  of  preeclampsia  remains  
undefined,  poor  placental  perfusion,  or  placental  ischemia,  is  widely  regarded  as  
a  key  initiator  of  the  syndrome  11,18,52.  The  finite  mechanisms  by  which  placental  
ischemia  is  developed  remain  undefined  53,  but  inadequate  cytotrophoblast  
invasion  of  the  uterine  spiral  arteries  is  considered  to  be  a  primary  cause  of  
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placental  hypoperfusion  throughout  gestation  52.    
Specifically,  in  normal  pregnancy,  the  spiral  arteries  of  the  maternal  
myometrium  lining  of  the  uterus  remain  tortuous  and  have  a  high  resistance  to  
blood  flow  in  non-­‐‑pregnant  and  early  pregnancy  stages.  As  the  placenta  
progressively  develops  and  nutrient  supply  is  no  longer  sufficient,  placental-­‐‑
derived  cytotrophoblast  cells  migrate  and  begin  to  invade  the  spiral  arteries,  
replacing  the  endothelium  and  smooth  muscle  cells.  This  results  in  an  increased  
capacitance  for  blood  flow  and  a  loss  of  constrictive  properties  to  circulating  
vasoconstrictors  for  the  remainder  of  gestation  15-17.  Moreover,  an  interruption  in  
this  process,  possibly  mediated  through  innate  and  adaptive  immune  activation  
54-57,  allows  the  spiral  arteries  to  maintain  high  resistance  to  arterial  flow  and  thus  
resulting  in  a  decrease  in  placental  perfusion.  For  more  elaborate  discussion  of  
spiral  artery  remodeling  in  normal  pregnancy  and  PE,  the  reader  is  directed  to  
the  thorough  review  and  discussion  by  Zhou  and  colleagues  53.  Furthermore,  
though  the  mechanism  of  spiral  artery  reformation  is  vital  to  the  study  of  
preeclampsia,  our  laboratory  is  focused  on  the  signaling  following  the  onset  of  
placental  ischemia  and  the  production  of  placental-­‐‑derived  factors  in  response  to  
this  stress.  
Since  James  Roberts  and  colleagues  12  first  suggested  a  role  of  “soluble  
agents”  produced  by  an  ischemic  placenta,  there  have  been  an  extraordinary  
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number  of  studies  to  elucidate  potential  molecular  contributions  to  the  
endothelial  dysfunction  and  hypertension  in  PE.  Following,  a  myriad  of  “soluble  
agents”  have  since  been  isolated  and  implicated  in  the  development  of  PE  
hypertension,  which  include  angiogenic  factors,  various  cytokines  and  
adipokines  such  as  TNFα  and  interleukins,  adaptive  and  innate  immune  system  
activation,  and  production  of  agonistic  auto-­‐‑antibodies  such  as  the  angiotensin  II  
type  1  receptor-­‐‑auto  antibody  (AT1-­‐‑AA)  12,20,52,58,59.    
Of  the  panoply  of  placental-­‐‑derived  signaling  factors  studied,  few  have  
received  as  much  attention  as  the  anti-­‐‑angiogenic  soluble  splice  variant  of  Flt-­‐‑1  
(i.e.  VEGF  receptor-­‐‑1).  This  soluble  variant  of  Flt-­‐‑1,  or  sFlt-­‐‑1,  contains  the  
extracellular  ligand-­‐‑binding  domain  of  full  length  Flt-­‐‑1  and  acts  to  antagonize  
the  normal  signaling  of  the  pro-­‐‑angiogenic  ligands  vascular  endothelial  growth  
factor  (VEGF)  and  placental  growth  factor  (PlGF).  Under  ischemic  conditions,  the  
placenta  increases  its  secretion  of  sFlt-­‐‑1  into  the  maternal  circulation  60,  which  in  
turn  decreases  the  availability  of  free  VEGF  and  PlGF.  This  increase  in  
angiogenic  factor  antagonism,  or  decrease  in  active  or  available  pro-­‐‑angiogenic  
factor  production,  has  been  termed  as  “angiogenic  imbalance”  by  Karumanchi  





Moreover,  Karumanchi  and  colleagues  were  the  first  to  propose  the  
critical  role  of  sFlt-­‐‑1  in  the  development  of  PE,  where  they  observed  an  increased  
serum  sFlt-­‐‑1  in  preeclamptic  patients  20.  Additionally,  adenoviral-­‐‑mediated  
overproduction  of  sFlt-­‐‑1  directly  induced  hypertension  and  endothelial  
dysfunction  in  a  pregnancy  murine  model  20.  Several  studies  following  this  
report  23,24,61-69  strongly  support  the  hypothesis  that  the  ischemic  placenta  
contributes  to  endothelial  cell  dysfunction  in  the  maternal  vasculature  by  
inducing  an  alteration  in  the  balance  of  circulating  levels  of  angiogenic/anti-­‐‑
angiogenic  factors  such  as  vascular  endothelial  growth  factor  (VEGF)  and  
placental  growth  factor  (PlGF),  and  sFlt-­‐‑1.  Additionally,  replacement  of  
bioavailable  VEGF  through  exogenous  infusion  in  several  rodent  models  of  PE  
has  also  been  shown  to  mitigate  the  development  of  endothelial  dysfunction  and  
hypertension  28,70,71.  Further,  Banek  and  colleagues  have  recently  reported  an  
earlier  induction  of  placental  ischemia  (day  12  vs.  day  14  of  gestation)  results  in  a  
hypertension  without  the  presence  of  angiogenic  imbalance,  which  is  suggestive  
of  a  critical  role  in  timing  and  relative  ischemia  in  the  secretion  of  sFlt-­‐‑1  and  the  
concomitant  angiogenic  imbalance.  Although  recent  data  suggest  circulating  sFlt-­‐‑
1  concentrations  may  presage  the  clinical  onset  of  preeclamptic  symptoms  
23,67,72,73,  several  studies  indicate  that  placental  hypoxia  and  poor  placental  
perfusion  may  initiate  this  imbalance  of  angiogenic  factors  60,74.  Therefore,  it  
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remains  unclear  whether  impaired  placental  perfusion  initiates  preeclamptic  
symptoms  such  as  hypertension,  endothelial  dysfunction  and/or  increased  sFlt-­‐‑1,  
or  if  inadequate  placental  development  occurs  initially  and  is  followed  by  a  
pathological  rise  in  sFlt-­‐‑1  expression  and  secretion  68.  
Collectively,  these  reports  have  promoted  further  research  in  the  
treatment,  predication  and  prevention  of  PE  through  the  maintenance  and  
restoration  of  angiogenic  balance.  Of  the  several  published  exogenous  methods  
to  treat  angiogenic  imbalance  in  PE,  the  current  focus  this  dissertation  is  
specifically  on  the  use  of  voluntary  exercise  27,75,  a  widely-­‐‑recognized  stimulant  of  
VEGF  production  76-78.     
NITRIC  OXIDE  AND  OXIDATIVE  STRESS  IN  NORMAL  PREGNANCY  
AND  PREECLAMPSIA  
Recent  reports  have  indicated  NO  production  is  elevated  in  pregnancy  as  
compared  to  non-­‐‑pregnant  controls,  and  this  increase  is  required  for  normal  
arterial  and  renal  vasodilation  to  compensate  for  normal  blood  volume  
expansion  79.  Studies  from  several  groups  indicate  NOS  inhibition  in  pregnant  
rats  results  in  an  increase  in  arterial  pressure  as  well  as  an  increase  in  vascular  
resistance,  proteinuria,  intrauterine  growth  restriction,  and  increased  fetal  
morbidity  80-82.  Further,  as  vascular  function  and  maintenance  through  VEGF  
signaling  is  crucial  to  the  acute  and  chronic  production  NO  83-86,  disruption  of  
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normal  VEGF  signaling  results  in  a  decrease  in  endothelial  function  and  increase  
in  arterial  pressure  87,88.    
Recent  data  from  experimental  and  clinical  investigations  suggest  there  is  
an  intimate  relationship  between  NO  availability  and  oxidative  stress  in  
maintenance  of  vascular  function  and  blood  pressure  89,90.  Briefly,  oxidative  stress  
is  a  process  in  which  the  defense  mechanisms  of  a  tissue  are  overcome  by  an  
increasing  production  of  reactive  oxygen  species  (ROS).  In  regard  to  vascular  
function,  during  oxidative  stress,  an  imbalance  of  pro-­‐‑  and  anti-­‐‑oxidant  factors  
results  in  damage  of  the  endothelial  tissue  cells  91.  Oxidative  stress  may  mediate  
endothelial  cell  dysfunction  and  contribute  to  the  pathophysiology  of  
preeclampsia  based  on  evidence  of  increased  pro-­‐‑oxidant  activity  along  with  
decreased  anti-­‐‑oxidant  protection.     
Regular  exercise  training  in  healthy  and  hypertensive  individuals  has  
been  shown  to  improve  endothelial  function  via  improvement  of  NOS  
expression  and  NO  production  92-94.  Interestingly,  Ramirez-­‐‑Velez  and  colleagues  
have  recently  reported  an  improvement  of  eNOS  expression  and  NO  production  
in  placentas  from  pregnant  women  who  exercised  throughout  pregnancy  95.  
Further,  this  suggests  a  potential  mechanism  by  which  exercise  training  could  




While  NO  production  is  often  referred  to  as  a  beneficial  effect,  it  is  
important  to  acknowledge  the  duality  of  the  secondary  effects  of  accumulated  
ROS,  specifically  superoxide  anion  O2-­‐‑,  can  combine  with  NO  to  form  the  strong  
oxidative  and  nitrosylating  product,  peroxynitrite  (ONOO  -­‐‑)  96.  This  process  
decreases  the  bioavailability  of  NO,  and  causes  a  further,  and  cascading,  
oxidative  burst.  Unsurprisingly,  there  is  increased  oxidative  stress  and  
peroxynitrate  formation  in  the  hypertensive  pregnant  RUPP  rat  97-99  and  
preeclamptic  pregnancies  96,  which  can  be  resolved  by  the  administration  of  a  
superoxide  anion  scavenger,  Tempol  97,99.  However,  it  should  be  noted  the  
administration  of  an  antioxidant  cocktail  or  Vitamin  C/E  supplementation  during  
pregnancy  is  not  only  ineffective  in  preventing  PE  in  the  clinical  setting,  but  may  
increase  the  risk  of  fetal  growth  restriction  or  small  for  gestational  age  100,101.    
Additionally,  a  single  bout  of  exercise  in  an  exercise-­‐‑naïve  subject  results  
in  an  increase  in  oxidative  stress  102,103.  However,  in  repeated  exercise  training,  an  
overall  anti-­‐‑oxidative  shift  is  observed,  likely  through  the  accretion  of  a  robust  
buffer  of  antioxidants  and  oxidizing  agents  102.  Further,  this  anti-­‐‑oxidative  
training  effect  from  exercise  training  is  also  observed  in  pregnancy,  which  has  
been  suggested  to  contribute  the  decreased  incidence  of  preeclampsia  in  exercise-­‐‑
trained  women  104-106.  Moreover,  we  have  recently  reported  exercise  training  
before  and  during  gestation  ameliorates  markers  of  oxidative  stress  in  the  
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placenta  and  kidney  in  both  normal  pregnant  and  RUPP  rats  27.  Interestingly,  
examination  of  cytosolic  and  mitochondrial  isolations  in  placentas  of  women  
who  exercised  during  pregnancy  show  a  reduction  in  oxidative  stress,  measured  
by  O2-­‐‑  and  H2O2  production  95.  This  suggests  moderate-­‐‑mild  exercise  in  
pregnancy  directly  effects  placental  (anti)oxidant  production  and  regulation.  
While  regular  exercise  training  prior  to  and  during  pregnancy  has  been  shown  to  
improve  the  anti-­‐‑oxidative  potential  in  experimental  and  clinical  studies,  it  
remains  unclear  if  it  is  a  primary  or  secondary  mediator  of  increased  blood  
pressure  in  preeclamptic  subjects.    
EXERCISE  FOR  PREECLAMPSIA  PREVENTION  
Mild  to  moderate  exercise  training  in  the  non-­‐‑pregnant  state  is  widely  
recognized  to  combat  long-­‐‑term  high  blood  pressure,  and  also  decrease  the  
incidence  of  hypertension  107-109.  As  discussed  in  Chapters  I  and  IV,  similar  
observations  are  noted  in  pregnancy,  where  regular  mild/moderate  physical  
activity  during  normal  pregnancy  has  beneficial  effects  for  both  fetal  and  
maternal  health  throughout  and  following  pregnancy  110-113.  Further,  
epidemiological  studies  of  prenatal  exercise  and/or  continued/initiated  during  
pregnancy  report  a  lowered  incidence  of  morbidities  such  as  gestational  diabetes,  
gestational  hypertension,  fetal  growth  restriction,  and  preeclampsia  105,114-116.  
Despite  the  past  evidence  of  exercise  as  potential  prevention  of  PE,  few  
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hypothesis-­‐‑driven  mechanistic  and  molecular  experiments  have  been  reported.  
We  and  others  have  recently  observed  exercise  before  and  during  
gestation  increases  VEGF  in  rodents  27,75,  and  placental  growth  factor  (PlGF)  in  
women  117.  Further,  exercise  before  and  during  gestation  mitigates  hypertension  
in  several  experimental  models  27,118,119  of  PE.  Interestingly,  the  beneficial  effects  
of  exercise  training  before  and  during  gestation  remain  similar  across  these  two  
experimental  models  of  preeclampsia,  where  an  improvement  of  endothelial  
function  and  blood  pressure  was  also  associated  with  an  increase  in  circulating  
concentration  of  VEGF  and/or  decreased  sFlt-­‐‑1.  In  addition  to  this  story,  our  
preliminary  data  suggests  the  effects  of  exercise  initiated  at  the  beginning  
gestation  in  the  RUPP  model  are  slightly  different.  Though  we  observe  a  similar  
improvement  of  angiogenic  balance,  we  do  not  observe  expected  mitigation  of  
hypertension  and  endothelial  dysfunction.  This  is  further  discussed  in  Chapter  
IV.  
In  regard  to  fetal  or  placental  effects  we  have  recently  reported  that  
exercise  before  and  during  gestation  improved  placental  efficiency  (fetal  weight:  
placental  weight)  27,75  in  both  normal  pregnancy  and  in  RUPP  dams,  which  
suggests  an  improvement  of  placental  diffusion  capacity.  Others  have  reported  
various  effects  on  placental  growth,  and  this  may  be  due  to  the  variations  in  
timing,  intensity,  and  duration  of  exercise  between  these  studies  95,111,113,117-123.  
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Moreover,  consideration  of  exercise  naiveté  and  timing  of  exercise  training  may  
be  crucial.  As  Larry  Wolfe  and  colleagues  have  reported,  maternal  acid-­‐‑base  
regulation  and  metabolism  are  impaired  toward  late  stages  of  gestation,  and  
normal  carbohydrate  metabolism  and  lactic  acid  use  during  exercise  is  hindered  
124.  Further,  placental  tissue  samples  from  women  who  exercised  during  
pregnancy  show  an  increase  in  NO  production  and  decreased  reactive  oxygen  
species  when  compared  to  the  sedentary/low-­‐‑activity  controls  95.  
EXERCISE  AND  ANGIOGENIC  BALANCE:  GOVERNED  BY  AMPK?  
Activation  of  skeletal  muscle  during  exercise  has  been  widely  reported  to  
stimulate  the  heterotrimeric  serine/threonine  protein  kinase  AMPK  (AMP-­‐‑
activated  protein  kinase)  and  downstream  pathways,  in  an  intensity-­‐‑dependent  
manner  30,125.  Additionally,  the  role  of  AMPK  in  acute  and  chronic  training  
adaptations  following  exercise  has  been  well-­‐‑studied  and  discussed  30,126,127.  
Importantly,  activation  of  AMPK  in  exercising  skeletal  muscle  reportedly  
mediates  the  production  of  pro-­‐‑angiogenic  factors,  such  as  VEGF,  through  
mRNA  stabilization  127,128.  Specifically,  Zwetsloot  and  colleagues,  have  recently  
reported  a  central  role  of  AMPK  in  the  stimulation  of  VEGF  production  post-­‐‑
exercise  in  transgenic  model  of  muscle-­‐‑specific  AMPK  knockdown,  which  
suggests  other  tissues  may  utilize  this  AMPK-­‐‑regulatory  pathway  as  well.  
Interestingly,  tissues  of  high  metabolic  activity  (skeletal  muscle,  heart,  brain,  and  
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placenta)  express  a  specialized  γ2-­‐‑isoform  of  AMPK-­‐‑γ  subunit  129,  which  has  
been  suggested  to  tightly  regulate  AMPK  activation  because  if  its  increased  
sensitivity  to  AMP  levels  129,130.  Taken  together,  administration  of  AMPK  
activators  or  AMP  analogues  during  pregnancy  may  enhance  the  production  of  
VEGF/PlGF  through  the  stimulation  of  placental  AMPK.    Indeed,  the  crucial  
roles  of  AMPK  in  normal  and  pathological  placental  development,  and  the  
potential  regulation  of  VEGF/PlGF  production  are  currently  unclear.  Therefore,  
we  sought  to  elucidate  the  role  of  AMPK  activation  in  angiogenic  imbalance  in  
the  RUPP  model  through  administration  of  the  potent  AMPK-­‐‑activator  AICAR  
(5-­‐‑aminoimidazole-­‐‑4-­‐‑carboxamide  1-­‐‑β-­‐‑D-­‐‑ribofuranoside).        
Epidemiological  evidence  of  Metformin  (1,1-­‐‑dimethylbiguanide)  31,33,131  
and  low-­‐‑dose  aspirin  (salicylic  acid)  132-134  use  during  pregnancy  report  a  reduced  
risk  of  PE  and  other  pregnancy-­‐‑related  forms  of  hypertension.  Moreover,  
biguanides,  salicylates,  nucleosides,  and  others  drug  classes  alike  are  known  
stimulators  of  AMPK  with  anti-­‐‑oxidative,  anti-­‐‑inflammatory,  and  anti-­‐‑
hypertensive  effects  30,135,136.  AMPK  can  directly  regulate  eNOS  activation  through  
Ser1177  phosphorylation  137,  which  is  suggestive  of  a  potential  vasodilatory  effect  
in  the  short  term.  Moreover,  a  recent  study  in  healthy  human  males  confirmed  
this  dilatory  effect,  in  which  intravenous  treatment  with  AICAR  caused  an  
increase  in  heart  rate  and  forearm  blood  flow  paired  with  a  decrease  in  arterial  
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pressure  36.  Similar  observations  have  also  been  reported  in  hypertensive  rats  as  
well  34.  Additionally,  there  is  an  intriguing  emergence  of  a  positive  feedback  
system  between  eNOS  and  AMPK,  in  which  NO  can  activate  the  AMPK  through  
the  sGC  (soluble  guanylate  cyclase)/cGMP  signaling  to  increase  Ca2+/CaMKK  
(calmodulin-­‐‑dependent  protein  kinase  kinase)  activation  of  AMPK  and  further  
activation  of  eNOS  and  NO  production  138.  Furthermore,  administration  of  
AMPK  activator  AICAR  has  been  shown  to  mitigate  hypertension  in  several  
experimental  animal  models  complicated  by  high  blood  pressure  34-36,139,  but  few  
have  directly  focused  on  the  potential  anti-­‐‑hypertensive  effects  of  AMPK  
stimulation.  
As  discussed  in  Chapter  V  of  this  dissertation,  we  have  recently  reported  
AICAR  treatment  (50mg/kg  b.i.d)  ameliorated  RUPP-­‐‑induced  hypertension,  
angiogenic  imbalance,  and  endothelial  dysfunction  26.  Similar  to  our  exercise  
study  in  the  RUPP  model  27,  AICAR  improved  circulating  free  VEGF  and  
decreased  sFlt-­‐‑1  in  the  RUPP.  Notably,  placental  and  renal  markers  of  oxidative  
stress  and  anti-­‐‑oxidative  capacity  were  also  mitigated  with  AICAR  treatment  in  
the  RUPP  26.  Interestingly,  no  detrimental  effects  were  observed  in  the  fetal  or  
placental  weights  when  normal  pregnant  or  RUPP  dams  received  the  AICAR  
treatment  26.  In  fact,  AICAR  administration  mitigated  RUPP  resorption  rates  26,  
suggesting  an  overall  beneficial  effect  on  the  RUPP  conceptus  development.  
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Verily,  the  interpretations  from  these  studies  are  limited  as  our  previous  study  
does  not  elucidate  the  exact  role  of  AMPK  signaling  in  the  effects  of  AICAR  
administration,  and  future  studies  are  required.  
SUMMARY  AND  PERSPECTIVES  
Preeclampsia  has  long  been  recognized  as  a  leading  cause  of  maternal  and  
fetal  morbidity  and  mortality  worldwide.  While  great  strides  have  been  made  in  
recent  years  to  understand  the  pathological  progression  and  ontogeny  of  PE,  the  
cause  of  this  syndrome  remains  enigmatic.  Further,  though  the  number  of  
prospective  studies  of  PE  treatment  and  prevention  has  been  limited,  
retrospective  epidemiological  reports  have  aided  and  focused  research  efforts.  Of  
the  numerous  reports  of  potential  modalities  for  PE  prevention,  exercise  training  
has  been  widely  recognized  for  its  potential  to  decrease  PE  development;  
however,  the  molecular  contributions  are  still  unclear.  Recently,  several  
experimental  and  clinical  reports  have  concluded  exercise  training  before  and  
during  gestation  can  elicit  a  myriad  of  protective  effects  that  collectively  mitigate  
the  development  of  PE.    
The  effects  of  exercise  have  recently  been  focused  on  factors  mediating  
angiogenic  balance,  as  exercise  training  in  pregnancy  has  been  shown  to  alter  the  
expression  of  VEGF  and  PlGF.  Our  initial  hypothesis  focused  on  the  role  of  
VEGF  production  during  exercise  to  combat  the  effects  of  sFlt-­‐‑1  secretion  from  
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the  placenta,  but  the  putative  role  of  VEGF  or  PlGF  in  exercise  training  effects  of  
PE  are  still  unclear.  Our  most  recent  observation  suggest  exercise  training  also  
decreases  plasma  sFlt-­‐‑1  in  the  RUPP  rat  (unpublished  observation),  which  lend  
further  explanation  to  the  improvement  in  VEGF  or  PlGF  bioavailability  in  
previous  studies  from  our  laboratory  and  others.  Further  studies  to  isolate  the  
specific  roles  of  these  angiogenic  factors  are  underway,  and  should  provide  an  
interesting  avenue  for  further  clinical  research.  
Additionally,  the  role  of  AICAR  administration  has  led  to  several  exciting  
new  hypotheses  to  pursue.  Firstly,  AICAR,  or  known  by  its  moniker  “the  
exercise  mimetic”,  was  initially  used  to  elucidate  a  potential  mechanism  by  
which  exercise  could  also  be  mediating  the  development  of  hypertension  
following  placental  ischemia.  As  hypothesized,  AICAR  mitigated  the  angiogenic  
imbalance,  endothelial  dysfunction,  and  hypertension  in  the  RUPP  model.  These  
exciting  results  suggest  AMPK  could  be  a  novel  target  for  PE  treatment  and  
prevention.  It  is  important  to  note  the  role  of  AMPK  remains  unknown  in  the  
effects  of  AICAR  and  exercise  training  in  a  model  of  PE.  Nevertheless,  the  
protective  effects  of  AICAR  in  the  RUPP  model  suggest  of  a  novel  
pharmacological  therapy  to  prevent  PE  development.  Further,  with  no  
detrimental  effects  observed  in  the  normal  pregnant  dams,  further  investigation  
in  AICAR  other  potent  AMPK  activators  should  be  assessed  for  potential  PE  
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prophylaxis.    Additional  to  the  observations  of  AICAR  and  exercise  in  the  RUPP  
model,  there  is  a  need  to  examine  the  roles  of  other  pathological  contributors  to  
progression,  including  the  innate  and  adaptive  immune  activation,  as  well  as  the  
additional  role  of  central  control  of  vasomotor  activity.  
In  concert,  we  believe  there  are  promising  and  specific  roles  for  both  
exercise  training  and  AICAR  to  treat  or  prevent  the  onset  of  preeclamptic  
hypertension.  Furthermore,  as  the  mechanisms  of  each  modality  are  still  unclear,  
the  data  chapters  of  this  dissertation  use  innovative  and  hypothesis-­‐‑driven  
approaches  to  elucidate  these  contributing  mechanisms.    
  





PART  1:  IN  VIVO  METHODOLOGY  
Animal  Husbandry  
Studies  were  performed  in  age-­‐‑matched  female  Sprague  Dawley  rats  
purchased  from  Charles  River  (Portage,  MI)  or  Harlan  Laboratories  
(Indianapolis,  IN).  Animals  were  housed  in  a  temperature-­‐‑controlled  room  
(23°C)  with  a  12:12  light:dark  cycle.  All  food  and  water  was  provided  ad  libitum.  
All  animal  experimental  procedures  executed  were  in  accordance  with  National  
Institutes  of  Health  guidelines  for  care  and  use  of  animals.  Additionally  All  
experimental  protocols  were  approved  by  the  Institutional  Animal  Care  and  Use  
Committee  (IACUC)  at  the  University  of  Oregon.    
Reduced  Uteroplacental  Perfusion  Pressure  Surgery  
The  RUPP  procedure  is  a  well-­‐‑established  and  robust  model  for  studying  
the  link  between  placental  ischemia  induced  hypertension  in  the  pregnant  rat  
25,140.  In  brief,  hand-­‐‑made  silver  clips  were  placed  on  the  lower  abdominal  aorta  
(0.203-­‐‑mm  inner  diameter  (ID))  above  the  iliac  bifurcation  and  also  on  branches  
(0.100-­‐‑mm  ID)  of  both  the  right  and  left  ovarian  arteries  supplying  the  uterus  on  
day  14  of  pregnancy  (term  =  21).  Together,  these  act  to  reduce  both  the  main  
uterine  artery  blood  flow,  and  any  compensatory  blood  flow  of  the  ovarian  
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arteries.  Figure  3.1  depicts  the  anatomy  of  the  surgical  procedure.  Normal  




Figure  3.1.  Reduced  Utero-­‐‑Placental  Perfusion  Pressure  (RUPP)  
Procedure.  On  day  14  of  gestation,  one  clip  (0.203  mm  ID)  is  placed  on  the  
abdominal  aorta  superior  to  the  iliac  bifurcation,  and  two  additional  clips  are  
placed  on  the  ovarian  feeder  arteries  to  prevent  compensatory  blood  flow.  Figure  
courteously  provided  by  Jeffrey  Gilbert,  redepicts  the  previously  published  
model  details  by  Dr.  Granger  and  colleagues  73.  
  
  
Voluntary  Exercise  Training  
Rats  assigned  to  the  exercise  cohort  were  allowed  24-­‐‑hour  voluntary  
access  to  stainless  steel  rodent  wire  activity  wheels  (Lafayette  Instruments,  USA),  
and  weekly  running  distance  and  time  were  measured  by  the  activity  wheel  










Figure 5. The Reduced Utero-Placental Perfusion (RUPP)
model. Methods: Rats in in the RUPP groups undergo this
surgical procedure on day 14 of pregnancy to place silver clips
on the ovarian arteries a d inferior abdominal aorta. Normal
pregnant (NP) controls undergo a sham procedure.
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Voluntary  wheel  running  was  chosen  over  forced  exercise  for  this  study  to  
minimize  potentially  deleterious  effects  due  to  stress  or  overtraining  that  have  
been  reported  previously  with  treadmill  running  and  swimming  in  Sprague-­‐‑
Dawley  rats.    
Breeding  
Animals  were  bred  by  pairing  a  female  and  male  rat  of  similar  ages  in  a  
cage  with  a  1”  raised  wire  rack.  Marker  of  coitus  was  confirmed  by  daily  
monitoring  for  the  presence  of  a  seminal  plug.  Day  of  gestational  age  (dGA)  was  
assigned  as  dGA  0  with  the  presence  of  at  least  two  seminal  plugs.  Animals  that  
failed  to  breed  were  excluded  from  the  studies.  
Arterial  Blood  Pressure  Measurement  
Animals  were  instrumented  on  day  18  of  gestation  with  an  indwelling  
catheter,  and  arterial  pressure  was  determined  in  conscious  rats  on  day  19  of  
gestation.  On  day  18  of  gestation,  a  catheter  of  heat-­‐‑stretched  PE-­‐‑50  polyvinyl  
tubing  was  introduced  to  the  left  common  carotid  artery,  and  advanced  
approximately  3cm  while  the  animal  was  under  isoflurane  anesthesia.  Catheters  
were  exteriorized  through  the  back  of  the  neck  with  subcutaneous  tunneling.  On  
day  19  of  gestation,  animals  were  placed  in  Plexiglas®  restraining  cages,  and  
direct  pressures  were  monitored  using  a  blood  pressure  transducer  
(ADInstruments)  for  60  minutes  following  a  fixed  30  minute  stabilization  period.  
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Mean  arterial  pressure  was  averaged  over  the  recorded  time.  Additionally,  heart  
rate  was  analyzed  over  the  hour  period  from  the  arterial  pressure  measurements  
using  LabChart  8.0  software  (ADInstruments).  
Necropsy  and  Tissue  Collection  
For  all  in  vivo  experiment  termination,  rats  were  placed  under  isoflurane  
anesthesia,  and  a  midline  ventral  incision  was  made  to  isolate  the  abdominal  
aorta  for  arterial  blood  collection.  Arterial  blood  from  the  abdominal  aorta  was  
collected  for  subsequent  assays  into  unlined  and  EDTA-­‐‑lined  Corvac®  sterile  
tubes  for  serum  and  plasma  processing,  respectively.  Secondary  confirmation  of  
death  was  done  by  pneumothorax  and  removal  of  heart.  Heart,  kidney,  fetal,  and  
placental  weights  were  recorded,  as  were  resorptions  and  implantations.  All  
collected  tissues  for  subsequent  analysis  were  flash  frozen  in  liquid  nitrogen  and  
stored  at  −80°C.  
Mulvany  Microvessel  Wire  Myography  
Following  necropsies  on  day  19  of  gestation,  secondary  and  tertiary  
mesenteric  arterioles  were  isolated  and  cleaned  of  all  surrounding  adipose  and  
connective  tissues  under  a  dissection  microscope.  1-­‐‑2mm  vessel  segments  were  
then  mounted  on  two  40µμm  stainless  steel  wires  and  attached  to  a  wire  
myograph  (DMT,  Denmark)  to  allow  for  isometric  force  recordings.  Vessels  were  
normalized  to  tensions  that  proportionally  modeled  100mmHg  using  the  
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normalization  module  in  LabChart  8.0  (ADInstruments,  USA).  
After  a  10  minute  period  for  equilibration  in  a  Kreb’s  buffer  (130mM  
NaCl,  4.7mM,  1.2mM  KH2PO4,  1.2mM  MgSO4,  1.6mM  CaCl2,  14.9mM  NaHCO3,  
5.5mM  glucose  ,  pre-­‐‑constriction  was  obtained  by  exposing  the  vessels  to  an  
isosmotic,  high-­‐‑potassium  physiological  saline  solution  (K-­‐‑PSS)  (74.7mM  NaCl,  
60mM  KCl,  1.8  KH2PO4,  1.2mM  MgSO4,  1.6mM  CaCl2,  14.9mM  NaHCO3,  5.5mM  
glucose).  Following  a  triple  washout  period  with  Kreb’s  buffer,  a  stabilized  
vascular  constriction  was  achieved  by  the  addition  of  the  thromboxane  A2  
analogue  U46619  (5  µμM).  Endothelial-­‐‑dependent  vasorelaxation  was  evaluated  
with  a  cumulative  dose  response  curve  to  acetylcholine  (Ach;  1x10-­‐‑9–1x10-­‐‑5  M).  
Further,  endothelial-­‐‑independent  vasodilation  and  smooth  muscle  function  were  
assessed  with  a  cumulative  dose  response  curve  to  sodium  nitroprusside  (SNP,  
1x10-­‐‑9–1x10-­‐‑5  M).  Following  each  relaxation  curve,  a  single  dose  of  0.1mM  SNP  
was  given  to  confirm  smooth  muscle  integrity.  At  experiment  termination,  
exposure  to  K-­‐‑PSS  was  used  to  assess  vessel  viability  and  functional  decay.  Data  







PART  2:  IN  VITRO  METHODOLOGY  
Cell  Culture  Technique  and  Conditions  
Immortalized  human  villous  trophoblast  cells  (BeWo)  and  primary  human  
umbilical  vascular  endothelial  cells  (HUVECs)  were  purchased  from  American  
Type  Culture  Collection  (ATCC,  USA).  Prior  to  experimental  protocols,  cells  
were  grown  to  manufacturer’s  recommendations.  Briefly,  cells  were  grown  to  70-­‐‑
80%  confluence  in  a  75cm2  flask  (Corning  Inc.,  USA)  under  5%  CO2/20%  O2,  and  
re-­‐‑plated  at  1x105  cells/well  in  a  24-­‐‑well  plate  for  further  treatment.  BeWo  cells  
were  cultured  with  F12K  basal  media  (ATCC),  and  HUVECs  were  cultured  with  
vascular  cell  basal  media  (ATCC).  Growth  media  were  supplemented  with  10%  
fetal  bovine  serum,  100  µμg/ml  streptomycin,  100  U/ml  penicillin  (ATCC).    
Vascular  Endothelial  Tube  Formation  Assay  
To  assess  angiogenic  potential  in  isolated  sera  20,26,27,141,  an  in  vitro  
measurement  of  endothelial  tubule  formation  was  used.  In  a  96-­‐‑well  plate,  30µμl  
of  growth  factor-­‐‑reduced  Matrigel®  (BD  Biosciences)  was  added  to  each  well,  
and  incubated  for  30  minutes  at  37˚C  to  allow  for  adequate  polymerization.  
Primary  human  vascular  endothelial  cells  (HUVECs)  of  passages  1-­‐‑3  were  plated  
at  1x105  cells/mL.  Cells  were  suspended  and  cultured  in  a  serum-­‐‑free  vascular  
cell  basal  medium  (ATCC).  Further,  after  overnight  thaw  at  4˚C,  serum  samples  
from  animal  treatment  groups  were  vortexed,  and  added  to  a  well  to  reach  5%  
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(v/v).  Tubule  formation  was  assessed  at  100X  optical  zoom  with  a  digital  
inverted  compound  microscope  (Axio  Observer,  Zeiss)  and  Zen  imaging  and  
analysis  software  (Zeiss).  Total  tube  count  was  assessed  by  at  least  two  
individual  investigators  that  were  blinded  to  the  identity  of  the  experimental  
groups.  Values  from  each  observer  were  averaged  to  obtain  final  counts.  
Placental  Explant  Isolation  and  Culture  
Normal  pregnant  dams  were  euthanized  and  whole-­‐‑placentas  were  
isolated  on  day  19  of  gestation.  Tissues  were  collected  in  ice-­‐‑cold  sterile  PBS.  
Under  a  dissection  microscope,  the  decidua  and  trophospongium  were  carefully  
dissected  away  to  isolate  the  anchoring  villi  bundles.  Approximately  10-­‐‑15mg  of  
villous  tissue  were  excised  and  weighed  prior  to  culture.  The  explants  were  
cultured  in  a  24-­‐‑well  plate  on  150µμl  of  Growth  Factor  Reduced  Matrigel®  (BD  
Biosciences)  and  1mL  of  50/50  Dulbecco’s  Modified  Eagle’s  Medium:  Ham’s  F-­‐‑12  
with  10%  Fetal  Bovine  Serum,  100  µμg/ml  streptomycin,  100  U/ml  penicillin,  and  
25  µμg/ml  ascorbic  acid  142-144.  Tissues  were  conditioned  in  a  CO2/O2  gas  incubator  
at  either  physiological  normoxia  (8%  O2)  or  at  hypoxia  (1%  O2).  Experimental  





Figure  3.2.  Placental  Villi  Explant  Isolation  and  Culture  Protocol.  
  
  
PART  3:  TISSUE  AND  SAMPLE  PROCESSING  
Protein  Extraction  and  Quantification  
Total  soluble  protein  was  extracted  from  tissues  and  cultured  cells  in  a  
radioimmunoprecipitation  assay  (RIPA)  lysis  buffer  supplemented  with  
phenylmethanesulphonylfluoride  in  dimethyl  sulfoxide,  sodium  orthovanadate  
and  a  protease  inhibitor  cocktail  (Santa  Cruz  Biotechnology,  Inc.,  Santa  Cruz,  
CA).  The  concentration  of  soluble  protein  in  each  homogenate  was  determined  
using  the  bicinchoninic  acid  method  (Pierce  Biotechnology,  USA).  Renal  tissue  
position  (right  or  left)  was  chosen  at  random,  and  placental  samples  were  




















SDS-­‐‑PAGE  and  Western  Blotting  
Protein  (50  µμg)  was  separated  by  electrophoresis  on  4-­‐‑20%  sodium  
dodecyl  sulfate  (SDS)  polyacrylamide  separating  gels  (Life  Technologies,  USA)  
then  transferred  to  polyvinylidene  fluoride  (PVDF)  membranes  (BioRad,  USA)  
and  stained  with  0.5%  ponceau  to  confirm  the  transfer  across  each  gel.  The  
images  of  the  ponceau  stained  membranes  were  digitized  with  a  flatbed  scanner.    
The  membranes  were  then  washed  and  incubated  one  hour  at  room  
temperature  in  commercially  available  non-­‐‑mammalian  protein  blocking  buffer  
(LI-­‐‑COR  Biosciences,  USA).    Membranes  were  incubated  in  blocking  solution  
containing  commercially  available  antibodies  (0.1µμg/mL)  overnight  at  4˚C.  
Membranes  were  washed  and  incubated  for  one  hour  with  the  appropriate  
fluorescent  protein-­‐‑conjugated  secondary  antibodies  (7.5ng/ml,  LI-­‐‑COR  
Biosciences,  USA).  The  immune-­‐‑reactive  bands  were  imaged  and  quantified  
using  the  Odyssey  dual-­‐‑channel  fluorescent  imaging  system  and  Image  Studio  
2.0  software  (LI-­‐‑COR  Biosciences,  USA).  Specificity  of  primary  antibodies  
(negative  controls)  was  evaluated  by  imaging  membranes  with  the  primary  
antibody  omitted.  




EXERCISE  TREATMENT  TO  MITIGATE  PLACENTAL  ISCHEMIA  
INDUCED  HYPERTENSION  AND  ANGIOGENIC  IMBALANCE  IN  AN  
EXPERIMENTAL  MODEL  OF  PREECLAMPSIA  
Part  1  of  Chapter  IV  is  in  preparation  for  publication  with  Haley  E.  
Gillham,  Karen  W.  Needham,  and  Jeffrey  S.  Gilbert  as  co-­‐‑authors.  I  performed  
the  experimental  work  along  with  the  technical  assistance  of  H.E.  Gillham  and  
K.W.  Needham.  J.S.  Gilbert  provided  editorial  assistance.  J.S.  Gilbert  provided  
editorial  assistance  and  project  funding.  
Additionally,  Parts  2-­‐‑3  of  this  chapter  are  in  preparation  for  publication  
with  Haley  E.  Gillham,  Karen  W.  Needham,  and  Jeffrey  S.  Gilbert  as  co-­‐‑authors.  I  
performed  the  experimental  work  along  with  the  technical  assistance  of  H.E.  
Gillham  and  K.W.  Needham.  J.S.  Gilbert  provided  project  funding.  
PART  1:  EXERCISE  DURING  GESTATION  TO  IMPROVE  VEGF    
  






Preeclampsia  (PE)  is  newly  defined  as  a  new-­‐‑onset  hypertension  
accompanied  by  markers  of  one  of  the  following:  renal  and  liver  dysfunction,  
thrombocytopenia,  pulmonary  edema,  or  cerebral  disturbances,  near  or  after  the  
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20th  week  of  gestation.  PE  is  a  leading  cause  of  fetal  and  maternal  morbidity  and  
mortality  in  the  U.S.41  and  worldwide  42.  Following  the  presentation  of  PE,  
treatment  options  are  currently  limited  to  supportive  care  and  induction  of  
delivery  if  symptoms  progress  41,44.  Further,  as  many  clinical  reports  suggest  PE  
increases  both  the  mother’s  and  child’s  lifetime  risk  of  cardiovascular  and  
metabolic  disease  development  145-148,  development  and  further  investigation  of  
possible  treatments  for  and  prevention  of  preeclamptic  pregnancies  is  highly  
favorable  to  improve  maternal  and  fetal  health.    
Although  the  etiology  of  preeclampsia  remains  unclear,  poor  placental  
perfusion  is  regarded  by  many  as  the  initiating  event  in  the  development  of  
hypertension  and  angiogenic  imbalance  in  preeclampsia  48,140,149.  This  ischemic  
environment  stimulates  several  pro-­‐‑hypertensive  factors,  including  sFlt-­‐‑1  
(soluble  Fms-­‐‑like  tyrosine  kinase-­‐‑1)  and  VEGF  (vascular  endothelial  growth  
factor).  An  imbalance  of  pro-­‐‑  and  anti-­‐‑angiogenic  factors  (e.g.  decreased  
VEGF/PlGF,  increased  sFlt-­‐‑1)  is  observed  to  contribute  to  the  development  of  
hypertension  in  both  human  and  animal  models  of  PE,  and  improvement  of  the  
angiogenic  potential  through  VEGF  administration  has  promising  therapeutic  
potential  20,28,29,150.  Similarly,  non-­‐‑pharmacological  modalities  such  as  exercise  
have  been  sought  out  to  improve  plasma  angiogenic  balance  through  
endogenous  stimulation  of  VEGF  27,75,117.    
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Exercise  is  well-­‐‑known  to  mitigate  hypertension  in  the  non-­‐‑pregnant  state  
and  recent  studies  have  explored  the  possibility  that  vigorous  physical  activity  
may  serve  as  a  therapeutic  or  preventative  modality  107-109.    We  and  others  have  
observed  exercise  before  and  during  gestation  increases  VEGF  in  rodents  27,75,  
and  placental  growth  factor  (PlGF)  in  women  117.  Further,  we  and  others  have  
previously  observed  exercise  before  and  during  gestation  mitigates  hypertension  
in  several  models  27,118,119  of  preeclampsia.  Nevertheless,  whether  these  same  
benefits  are  shared  with  exercise  training  initiated  at  the  onset  of  pregnancy  
remains  unclear.  Therefore,  we  hypothesized  (Figure  4.1)  voluntary  exercise    
  
  
Figure  4.1.  Overarching  Exercise  Hypothesis.  RUPP-­‐‑induced  hypertension  
and  endothelial  dysfunction  is  expected  to  be  prevented  by  exercise  training  
prior  to  and  during  gestation  by  improving  plasma  VEGF  concentrations.  RBF:  
Renal  Blood  Flow;  TPR:  Total  Peripheral  Resistance.  
Maternal	  Plasma	  VEGF
Placental	  sFlt-­‐1
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initiated  at  the  beginning  of  gestation  will  improve  angiogenic  potential  and  
attenuate  placental  ischemia  induced  hypertension  in  the  rat.    
Methods    
Animals  
Studies  were  performed  between  the  University  of  Oregon  and  the  
University  of  Minnesota  Medical  School-­‐‑Duluth  with  female  Sprague-­‐‑Dawley  
rats  purchased  from  Harlan  Laboratories  (Indianapolis,  IN)  and  Charles  River  
Laboratories  (Wilmington,  MA).  Animals  were  housed  in  a  temperature-­‐‑  
controlled  room  (23°C)  with  a  12:12  light:dark  cycle.  All  experimental  procedures  
executed  were  completed  in  accordance  with  National  Institutes  of  Health  
guidelines  for  use  and  care  of  animals  and  were  approved  by  the  Institutional  
Animal  Care  and  Use  Committee  (IACUC)  at  the  University  of  Oregon  and  
University  of  Minnesota.  Six-­‐‑week-­‐‑old  rats  were  given  one  week  of  wheel  access  
with  three  other  animals  to  learn  to  use  the  exercise  wheel  27.  The  animals  were  
then  bred,  and  assigned  day  of  gestation  (dGA)  0  when  ≥2  copulation  plugs  are  
observed  27.  Animals  to  exercise  during  pregnancy  (ED)  were  housed  separately  
with  voluntary  access  to  an  activity  wheel  (Lafayette  Instruments,  Model  80859;  
Lafayette,  IN),  and  sedentary  treated  animals  had  no  wheel  access.  Dams  were  
assigned  to  sedentary  normal  pregnant  (NP)  (n=8)  and  RUPP  (n=8)  groups  or  
exercise  during  pregnancy  (NP+ED  (n=8);  RUPP+ED  (n=8)).  The  timeline  of  the  
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experimental  protocol  is  depicted  in  Figure  4.2.  
  
  
Figure  4.2.  Voluntary  Exercise  Experimental  Timeline.  9-­‐‑week-­‐‑old  female  
Sprague  Dawley  rats  train  for  1  week  prior  to  pregnancy  to  learn  how  to  use  the  
exercise  wheels.  Dams  were  then  bred,  and  allowed  access  to  exercise  wheels  
upon  confirmation  of  coitus.  RUPP/sham  was  performed  on  day  14.  Blood  
pressures  and  tissues  collected  on  day  19.  
  
Reduced  Uterine  Perfusion  Pressure  (RUPP)  Procedure  
The  RUPP  procedure  is  a  well-­‐‑characterized  and  widely  accepted  model  
140  for  studying  the  link  between  placental  ischemia  and  hypertension  in  the  
pregnant  rat  and  has  been  described  in  detail  previously27.  Briefly,  a  silver  clip  
(0.203-­‐‑mm  inner  diameter  (ID))  was  placed  on  the  lower  abdominal  aorta,  
superior  to  the  common  iliac  bifurcation.  Two  additional  clips  (0.100-­‐‑mm  ID)  
were  placed  on  the  branches  of  both  the  right  and  left  ovarian  arteries  on  day  14  
of  gestation  (term=21  days).  Half  of  the  NP  dams  underwent  a  sham  surgery,  
which  included  an  abdominal  midline  incision  and  suture.  After  observing  no  
differences  in  the  angiogenic  factors  and  blood  pressures  these  animals  were  
grouped  with  the  NP  rats.      
  
Non-pregnant 9 week 
old females arrive
Resume voluntary exercise





RUPP or Sham 
surgery 
(dGA 14)




Measurement  of  MAP  in  Chronically  Instrumented  Conscious  Rats  
Animals  were  instrumented  with  an  indwelling  arterial  catheter  of  the  
common  carotid  artery  on  day  17  of  gestation.  On  day  19,  unanesthetized  mean  
arterial  pressure  (MAP)  was  measured  using  a  fluid-­‐‑filled  pressure  transducer  
(ADInsruments,  Colorado  Springs,  CO)  26,27,151.    
Conceptus  Measurements  and  Serum  Collection  
After  blood  pressure  measurement,  the  dams  were  placed  under  3%  
isoflurane  anesthesia,  and  a  midline  ventral  incision  was  made  to  isolate  the  
abdominal  aorta  for  arterial  plasma  and  serum  collection  as  reported  previously  
27,151.  After  exsanguination,  a  pneumothorax  and  cardiac  excision  were  used  to  
confirm  death.  Blood  was  collected  for  subsequent  assays  into  blank  and  EDTA-­‐‑
lined  Corvac®  tubes  for  serum  and  plasma  processing,  respectively  (Sherwood  
Davis,  St.  Louis,  MO).  Fetal  weight,  placental  weight,  and  number  of  resorptions  
were  recorded  in  the  manner  described  previously  27,151.  All  tissues  collected  for  
subsequent  analysis  were  flash  frozen  in  liquid  nitrogen  and  stored  at  -­‐‑80˚C.  
Enzyme-­‐‑Linked  Immunosorbant  Assays  
Plasma  concentration  of  free  VEGF  was  measured  using  commercially  
available  enzyme  linked  immunosorbant  assay  (ELISA)  kits  (R&D  Systems,  
Quantikine®;  Minneapolis,  MN,  Part:  MMV00)  according  to  the  manufacturer’s  
directions  as  described  previously  26,27,151.  
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Endothelial  Tube  Formation  Assay  
Angiogenic  balance  was  further  assessed  in  the  serum  of  pregnant  rats  in  
vitro  as  previously  reported  26,27  in  two  separate  experiments  and  each  was  
performed  in  duplicate.  HUVECs  (human  umbilical  vascular  endothelial  cells)  
were  plated  at  5x105  cells/mL  (100µμl/well)  onto  96-­‐‑well  plate  lined  with  growth-­‐‑
factor-­‐‑reduced  Matrigel®  (BD  Biosciences,  Bedford,  MA).  Five  microliters  of  
serum  from  each  group  (NP,  RUPP,  NP+ED,  RUPP+ED)  was  introduced  to  the  
100µμl  cell  media.  Cells  were  incubated  at  37°C,  20%  O2,  5%  CO2.  Total  number  of  
tubule  formations  per  frame  was  assessed  at  100X  optical  zoom  with  a  digital  
inverted  compound  microscope  and  ImageJ  analysis  software  (National  
Institutes  of  Health,  Bethesda,  MD).  Total  tube  count  was  assessed  by  at  least  two  
investigators  that  were  blinded  to  the  identity  of  the  experimental  groups.  Values  
from  each  observer  were  averaged  to  obtain  final  counts.  
Antioxidant  Capacity  and  Oxidative  Stress  
Placental  tissue,  amniotic  fluid,  and  plasma  oxidative  stress  was  assessed  
by  measuring  total  antioxidant  capacity  and  lipid  peroxidation,  carried  out  as  
previously  reported  26,152.  Total  antioxidant  capacity  was  assessed  in  placental  
tissue,  amniotic  fluid,  and  maternal  plasma  by  measured  by  using  a  Trolox-­‐‑
equivalent  antioxidant  capacity  (TEAC)  assay  kit  (Cayman  Chemical  Company,  
Ann  Arbor,  MI).  Additionally,  lipid  peroxidation  was  measured  in  maternal  
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serum  using  a  TBARS  (thiobarbituric  acid  reactive  substances)  commercial  assay  
kit  (Cayman  Chemical  Company,  Ann  Arbor,  MI).  All  assays  were  performed  in  
duplicate  and  according  to  the  manufacturers’  directions.  
Statistical  Analysis  and  Calculations  
All  data  are  presented  as  mean  ±  SD,  and  statistical  significance  was  
accepted  when  p<.05.  Comparisons  were  made  with  a  one-­‐‑way  analysis  of  
variance  test  combined  with  a  Bonferroni  post-­‐‑hoc  test  were  employed.  Statistical  
calculations  were  made  with  GraphPad  Prism  version  5.00  for  Windows  
(GraphPad  Software,  San  Diego,  CA  USA).  
Results  
Voluntary  Running  Wheel  Activity  
Similar  to  our  previous  observations  27,  voluntary  running  distance    on  the  
activity  wheels  did  not  differ  between  the  NP+ED  and  RUPP+ED  groups  
throughout  gestation.  As  reported  previously  27,  (*p<.05)  the  distance  run  in  the  

























Figure  4.3.  Exercise  Measured  by  Weekly  Distance.  Distance  per  
gestational  week  no  different  between  NP  and  RUPP.  Across  both  groups,  time-­‐‑
dependent  decrease  (*p<.05  vs.  Week  1  and  2)  in  distance  run  was  observed  in  
week  3.  NP,  normal  pregnant  control;  RUPP,  reduced  uterine  perfusion  
treatment;  ED,  exercise  during  gestation.  *p<.05,  time  effect.  Data  presented  as  
mean±SD;  n=6-­‐‑8  per  group.  
  
Mean  Arterial  Pressure  
At  day  19  of  gestation,  arterial  blood  pressure  was  increased  (p<.05)  
(Figure  4.4)  in  the  RUPP  compared  to  NP  rats.  No  effect  of  exercise  was  observed  
in  either  the  RUPP+ED  or  NP+ED  blood  pressure  measurements.  Together,  
exercise  initiated  at  the  onset  of  gestation  did  not  attenuate  RUPP  hypertension.  
46	  
	  
























Figure  4.4.  Mean  Arterial  Pressure  on  Day  19.  The  RUPP-­‐‑induced  increase  
(*p<.05  vs.  NP)  in  blood  pressure  was  slightly  attenuated  (p=.06)  by  exercise  
during  (ED)  gestation.  NP  107±9;  *RUPP  120±13;  NP+ED  98±9;  RUPP+ED  119±11  
mmHg.  *p<.05  vs.  NP;  †p<.05  vs.  RUPP.  Data  presented  as  mean±SD.    
  
Circulating  VEGF  and  Angiogenic  Potential    
As  displayed  in  Figure  4.5,  circulating  free  VEGF  was  decreased  (p<.05)  in  
the  RUPP  compared  to  the  NP  group  and  exercise  increased  (p<.05)  plasma  
VEGF  in  RUPP+ED  but  not  NP+ED  rats.  Angiogenic  potential  measured  by  
HUVEC  total  tubule  formation  was  decreased  (p<.05)  in  the  RUPP  compared  to  
the  NP  controls,  and  increased  (p<.05)  in  the  RUPP+ED  compared  to  the  RUPP.  
Together,  these  data  (depicted  in  Figure  4.5,  bottom  panel)  indicate  RUPP-­‐‑
induced  angiogenic  imbalance  is  improved  with  exercise  during  pregnancy.  
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Figure  4.5.  Plasma  VEGF  and  Serum  Angiogenic  Potential.  (Top  Panel)  
Free  VEGF  levels  in  maternal  plasma  were  decreased  (p<.05)  in  the  RUPP  
compared  to  NP,  and  exercise  improved  (†p<.05)  the  VEGF  bioavailability  in  the  
RUPP+ED.  NP  924±61;  *RUPP  503±64;  NP+ED  803±104;  †RUPP+ED  
824±56pg/mL.  (Panel  B)  Primary  HUVEC  microtubule  formation  was  improved  
(†p<.05)  when  exposed  to  serum  from  RUPP+ED  dams  compared  to  the  
sedentary  RUPP.  NP  7.5±1.5;  *RUPP  6.1±0.6;  NP+ED  7.9±0.5;  RUPP+ED  






Tissue  and  Circulating  Oxidative  Stress  and  Antioxidant  Capacity    
RUPP  decreased  (p<.05)  TEAC  in  amniotic  fluid  compared  to  the  NP,  but  
had  no  effect  on  placental  tissue  or  plasma  TEAC  (Figures  4.6a-­‐‑c).  Exercise  
during  RUPP  pregnancy  had  no  effect  on  TEAC  in  placenta,  amniotic  fluid,  or  
maternal  plasma.  Amniotic  fluid  TEAC  in  NP+ED  was  decreased  (p<.05)  
compared  to  the  NP  control,  but  no  effect  was  observed  in  the  maternal  plasma  
or  placental  extract.  Lipid  peroxidation  measured  by  malondialdehyde  (MDA)  
levels  in  maternal  serum  was  increased  in  the  RUPP  compared  to  the  NP,  and  
was  not  attenuated  by  exercise  training  during  pregnancy  in  the  RUPP+ED  
treatment  group  (Figure  4.6d).    
Maternal  and  Fetal  Morphometric  Data  at  Necropsy  
Maternal  and  fetal  weights  were  decreased  (p<.05)  in  the  RUPP  compared  
to  NP,  and  exercise  during  gestation  had  no  significant  effect  in  either  NP+ED  or  
RUPP+ED  groups  (Table  4.1).  Additionally,  placental  weights  were  decreased  
(p<.05)  with  RUPP  compared  to  NP,  as  well  as  a  decreased  weight  observed  in  
the  NP+ED  vs.  NP  (p<.05).  Placental  efficiency,  measured  by  a  ratio  of  fetal  and  
placental  weight,  was  also  decreased  (p<.05)  in  the  RUPP  vs.  NP,  but  also  
decreased  (p<.05)  in  NP+ED.  Finally,  resorption  percentage  was  increased  in  the  
RUPP  compared  to  the  NP  control  group,  and  RUPP+ED  was  observed  to  have  a  





Figure  4.6.  Tissue  and  Systemic  Oxidative  Stress  and  Anti-­‐‑Oxidant  
Potential.  (Panel  A)  Trolox-­‐‑equivalent  antioxidant  capacity  (TEAC)  levels  were  
not  affected  by  RUPP  placental  tissue  compared  to  the  NP,  and  no  exercise  effect  
was  observed  in  RUPP.  NP  0.37±0.04;  *RUPP  0.32±0.03;  NP+ED  0.30±0.06;  
RUPP+ED  0.27±0.14  Trolox  equivalent  (µμM).  (Panel  B)  Amniotic  fluid  TEAC  was  
decreased  (*p<.05)  in  the  RUPP  and  NP+ED  compared  to  the  NP.  NP  1.61±0.71;  
*RUPP  0.57±0.61;  NP+ED  0.77±0.21;  RUPP+ED  0.76±0.34  Trolox  equivalent  (µμM).  
(Panel  C)  Plasma  TEAC  was  not  effect  by  RUPP  or  exercise  treatment.  NP  
3.11±0.58;  *RUPP  2.26±0.95;  NP+ED  2.74±0.37;  RUPP+ED  2.92±0.62  Trolox  
equivalent  (µμM).  (Panel  D)  Serum  lipid  peroxidation  (measured  by  
malonyldialdehyde  formation)  was  increased  (*p<.05)  in  RUPP  with  respect  to  
NP,  and  no  effect  from  exercise  observed.  NP  11.8±2.5;  *RUPP  19.7±3.7;  NP+ED  


























































































Table  4.1.  Maternal  and  Conceptus  Morphometric  Data  at  Necropsy.    
  Treatments  
Maternal   Fetal   Placental   Placental  
%  Resorption  




305.7±10.7   2.58±0.18   0.50±0.05   6.3±1.1   1.1±3.1  
RUPP  
(n=9)  
*268.2±10.1   *2.18±0.21   *0.44±0.05   *4.9±0.6   *73.1±7.2  
NP+ED  
(n=8)  
308.2±12.7   *2.15±0.16   *0.42±0.06   *4.9±1.1   2.6±1.3  
RUPP+ED  
(n=8)  
286.4±7.6   1.97±0.32   0.41±0.07   4.9±0.7   †38.2±8.6  
Note.  *p<.05  indicates  different  from  NP.  †p<.05  indicates  different  from  RUPP.  




The  current  study  presents  intriguing  and  novel  findings  in  regard  to  the  
effects  of  exercise  initiated  at  the  beginning  of  gestation  (ED)  in  the  RUPP  model  
of  preeclampsia.  In  contrast  to  our  initial  hypothesis,  exercise  training  during  
gestation  did  not  prevent  placental  ischemia  induced  hypertension,  despite  
restoration  of  plasma  VEGF  and  angiogenic  potential  following  exercise  training  
during  gestation  in  the  RUPP  dam.  Additionally,  ED  treatment  did  not  mitigate  
the  RUPP-­‐‑induced  oxidative  stress,  and  had  no  observed  effect  on  fetal-­‐‑placental  
development.  These  data  collectively  suggest  an  exercise  regimen  started  at  the  
beginning  of  gestation  does  not  mitigate  the  RUPP-­‐‑induced  hypertension  in  the  
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rat,  but  promotes  a  restored  angiogenic  balance.  
Though  the  mechanisms  underlying  the  pathogenesis  of  PE  are  not  
completely  defined,  placental  ischemia  is  commonly  regarded  as  the  initiating  
event  resulting  in  angiogenic  imbalance,  renal  and  vascular  dysfunction  and  
increased  blood  pressure  45,150,153,154.  Previous  clinical  20,29  and  experimental  28,151  
observations  support  the  important  role  of  impaired  angiogenic  balance  in  
hypertension  during  preeclampsia,  and  mitigating  this  angiogenic  imbalance  
attenuates  or  completely  abolishes  the  hypertension  in  several  rodent  models  of  
preeclampsia    28,70,71.  Indeed  the  current  study  shows  that  exercise  during  
pregnancy  only  improves  angiogenic  balance  in  RUPP  rats  but  does  not  
attenuate  RUPP-­‐‑induced  hypertension.  
Exercise  During  Pregnancy  and  Angiogenic  Balance  
Firstly,  RUPP  hypertension  was  not  affected  by  exercise  during  pregnancy  
only,  despite  the  observed  improvement  of  maternal  circulating  free  VEGF  and  
serum  angiogenic  potential.  This  is  an  interesting  observation,  as  these  data  
contrast  with  our  previously  reported  benefits  of  both  exercise  before  and  during  
(EBD)  gestation  27  and  exogenous  VEGF  infusion  28.  To  note,  our  previous  
exercise  study  reported  an  increase  in  plasma  VEGF  of  approximately  80%  with  
exercise  before  and  during  gestation  in  the  RUPP,  and  the  current  study  only  
reports  a  60%  increase.  However,  this  is  unlikely  the  single  difference  between  
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the  EBD  and  ED  treatments,  as  approximately  25%  improvement  of  VEGF  
bioavailability  have  been  reportedly  effective  in  the  mitigation  of  RUPP-­‐‑induced  
hypertension  28.  Moreover,  the  data  from  the  current  study  suggest  a  moderate  
increase  in  VEGF  and  angiogenic  potential  following  exercise  may  not  be  the  
major  contributor  to  the  blood  pressure  lowering  effect  from  exercise  previously  
observed  by  our  group  75  and  others  105,115,117-119.  In  concert  with  these  previous  
reports,  the  current  study  suggests  the  previously  reported  benefits  of  EBD  may  
be  largely  due  to  the  training  prior  to  the  pregnancy  as  opposed  to  the  ED  
treatment  in  the  current  study.    
Exercise  and  Oxidative  Stress  
In  our  previous  studies  of  exercise  before  and  during  (EBD)  pregnancy  
27,75,  the  EBD  treatment  improved  antioxidant  capacity  and  reduced  oxidative  
stress  systemically.  However,  the  current  study  reports  unaltered  or,  in  some  
cases,  exacerbated  oxidative  stress  in  the  RUPP+ED  and  NP+ED  compared  to  
their  respective  controls.  Together,  these  observations  suggest  exercise  training  
prior  to  pregnancy  may  be  necessary  to  stimulate  an  (anti)oxidative  buffer  and  
prevent  vascular  endothelial  and  placental  dysfunction  following  placental  





Fetal  and  Placental  Effects  of  Exercise  Initiated  During  Gestation  
No  effects  on  fetal-­‐‑placental  morphometrics  were  observed  in  the  
RUPP+ED  dams,  indicating  neither  an  amelioration  nor  exacerbation  of  the  
RUPP-­‐‑induced  fetal-­‐‑placental  growth  restriction.  Similar  effects  have  been  
reported  in  women  who  recorded  a  mild-­‐‑moderate  exercise  regimen  through  20  
weeks  of  gestation  116.  Interestingly,  Clapp  and  colleagues  reported  in  normal  
pregnant  women,  exercise  initiated  during  pregnancy  improved  both  fetal  and  
placental  weight  at  mid-­‐‑gestation  121;  however,  this  stimulation  of  fetal-­‐‑placental  
development  was  not  observed  in  the  current  study’s  normal  pregnant  or  RUPP  
controls.  This  difference  may  be  attributed  to  the  small  timing  variation,  as  these  
women  began  exercising  halfway  through  gestation  and  the  current  study’s  rats  
began  exercising  immediately  following  breeding.  Future  studies  should  be  
pursued  to  elucidate  these  potential  timing  differences  in  exercise  adaptations  
during  gestation,  as  this  could  provide  crucial  information  in  which  exercise  
could  be  a  potential  treatment  following  diagnosis  rather  than  just  prevention.  
Exercise  and  Timing  
One  potentially  important  difference  between  the  two  exercise  treatments,  
EBD  and  ED,  could  rely  on  the  hemodynamic  and  vascular  adaptations  to  
exercise  in  the  pre-­‐‑trained  and  sedentary  groups  at  the  start  or  initial  stages  of  
pregnancy.  Exercise  is  certainly  well-­‐‑known  to  stimulate  both  peripheral-­‐‑  and  
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central-­‐‑mediated  hemodynamic  shifts  as  well  as  tissue  neo-­‐‑angiogenesis  78,155,156.  
Further,  uterine  blood  flow  during  exercise  is  decreased  in  both  normal  and  
complicated  pregnancies  during  strenuous  exercise  157,158,  as  splanchnic  blood  
flow  is  decreased  and  skeletal  muscle  blood  flow  is  quickly  increased.  However,  
Hart  and  colleagues  concluded  exercise  training  during  normal  and  preeclamptic  
pregnancies  increases  uterine  blood  flow  following  a  moderate  exercise  bout  157,  
but  few  studies  have  followed  to  support  these  findings  since  this  study  and  
ACOG  contraindication  110.  It  is  possible  the  exercise  training  prior  to  pregnancy  
allows  for  an  increased  ischemic  tolerance,  perfusion  capacitance,  or  peripheral  
auto-­‐‑regulation  of  blood  flow  that  is  not  developed  if  exercise  is  initiated  at  the  
beginning  of  gestation,  as  previously  postulated  in  humans  105,122,159.  Indeed,  
further  investigations  using  a  molecular  and  hypothesis-­‐‑driven  approach  are  
required  to  elucidate  these  adaptation  differences  observed  in  the  current  study.    
Conclusion  
The  present  data  support  our  initial  hypothesis  of  an  improvement  in  
VEGF  availability  and  angiogenic  potential  with  exercise-­‐‑during  (ED)  treatment  
in  RUPP.  However,  our  hypothesis  of  mitigated  RUPP-­‐‑induced  hypertension  
was  not  supported  as  blood  pressure  remained  increased  compared  to  NP.  Taken  
together,  these  findings  suggest  exercise  or  training  status  may  be  an  important  
factor  when  prescribing  exercise  during  pregnancies;  especially  those  at  high  risk  
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for  hypertensive  disorders.  
In  the  next  section  of  this  chapter,  we  will  evaluate  the  effectiveness  of  
exercise  before  and  during  gestation  while  preventing  a  restoration  of  
bioavailable  VEGF.  This  approach  will  allow  us  to  assess  the  role  of  angiogenic  
balance  in  the  cardiovascular  effects  of  exercise  training  prior  to  and  during  
gestation  in  a  model  of  placental  ischemia  induced  hypertension.  
PART  2:  ISOLATING  THE  ROLE  OF  ANGIOGENIC  BALANCE  AND  VEGF  
BIOAVAILABILITY  IN  THE  ANTI-­‐‑HYPERTENSIVE  EFFECTS  OF  EXERCISE    





   Preeclampsia  (PE)  is  a  pervasive,  pregnancy-­‐‑specific  syndrome  defined  by  
new  onset  hypertension  and  proteinuria.  Additionally,  PE  is  often  associated  
with  increased  soluble  VEGF  Receptor-­‐‑1  (sFlt-­‐‑1),  decreasing  the  bioavailability  of  
vascular  endothelial  growth  factor  (VEGF)  creating  angiogenic  imbalance  
leading  to  endothelial  dysfunction  and  hypertension.  We  recently  reported  
exercise  training  attenuates  placental  ischemia-­‐‑induced  hypertension  and  
restores  angiogenic  balance  but  the  mechanism  remains  unclear  27.  The  previous  
section  in  this  chapter  reports  exercise  initiated  at  the  start  of  gestation  does  
improve  VEGF  bioavailability,  but  was  not  effective  in  lowering  RUPP  
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hypertension,  raising  the  question  of  the  central  role  of  improved  plasma  VEGF  
in  the  anti-­‐‑hypertensive  effect  of  exercise  27.  Specifically,  we  27,75  and  others  117  
have  recently  reported  exercise  training  in  normal  pregnancy  improved  
circulating  VEGF  and  PlGF  bioavailability  in  rodents  and  humans,  respectively.  
However,  it  remains  unclear  whether  the  improvement  in  circulating  angiogenic  
balance  is  necessary  for  in  the  anti-­‐‑hypertensive  effects  of  exercise.  
  Moreover,  we  aimed  to  elucidate  if  this  mechanism  is  contributing  to  the  
blood  pressure  lowering  effects  we  have  previously  observed  in  the  RUPP  
model.  Thus,  we  hypothesized  a  sustained  angiogenic  imbalance  through  
recombinant  sFlt-­‐‑1  infusion  would  antagonize  VEGF  bioavailability  and  prevent  




Studies  were  performed  at  the  University  of  Oregon  with  female  Sprague-­‐‑
Dawley  rats  purchased  from  Harlan  Laboratories  (USA).  Animals  were  housed  
in  a  temperature-­‐‑controlled  room  (23°C)  with  a  12:12  light:dark  cycle.  All  
experimental  procedures  executed  were  completed  in  accordance  with  National  
Institutes  of  Health  guidelines  for  use  and  care  of  animals  and  were  approved  by  
the  University  of  Oregon’s  Institutional  Animal  Care  and  Use  Committee.    
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Voluntary  Exercise  Training  Protocol  
Three-­‐‑week-­‐‑old  rats  were  given  one  week  of  wheel  access  as  a  group  of  4-­‐‑
5  to  learn  to  use  the  activity  wheel  (Lafayette  Instruments,  USA;  Model  80859)  27.  
Further,  the  animals  were  then  separated,  and  given  individual  access  for  six  
weeks.  Following  the  six  weeks  of  voluntary  training,  the  animals  were  then  
bred,  and  assigned  day  of  gestation  age  (dGA)  0  when  ≥2  copulation  plugs  are  
observed  27.  Sedentary  cohorts  were  housed  without  activity  wheel  access.  Dams  
were  assigned  to  the  following  treatments:  normal  pregnant  (NP),  NP+sFlt1,  
NP+Ex/sFlt1;  RUPP,  RUPP+Ex,  RUPP+Ex/sFlt1.  Experimental  protocol  timeline  is  
depicted  below  (Figure  4.7).    
  
  
Figure  4.7.  Voluntary  Exercise  Experimental  Timeline.  3-­‐‑week-­‐‑old  female  
Sprague  Dawley  rats  train  for  6  weeks  prior  to  pregnancy.  RUPP/sham  is  
performed  on  day  14.  Saline-­‐‑  or  sFlt-­‐‑1-­‐‑filled  osmotic  pumps  were  also  implanted  
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Reduced  Utero-­‐‑Placental  Pressure  (RUPP)  Procedure  and  Osmotic  Pump  Implant  
The  RUPP  procedure  is  a  well-­‐‑characterized  and  widely  accepted  model  
140  for  studying  the  link  between  placental  ischemia  and  hypertension  in  the  
pregnant  rat  and  has  been  described  in  detail  previously  27.  Briefly,  a  silver  clip  
(0.203-­‐‑mm  inner  diameter  (ID))  was  placed  on  the  lower  abdominal  aorta,  
superior  to  the  common  iliac  bifurcation.  Two  additional  clips  (0.100-­‐‑mm  ID)  
were  placed  on  the  branches  of  both  the  right  and  left  ovarian  arteries  on  day  14  
of  gestation  (term=21  days).    
During  the  same  procedure,  Osmotic  pumps  (Alzet,  USA;  Model  2001)  
were  implanted  intra-­‐‑peritoneal  on  dGA14  to  chronically  deliver  recombinant  
mouse  (rm)-­‐‑sFlt1  (RD  Systems,  USA)  at  500ng/ul/hr  or  saline  vehicle  containing  a  
mouse  Fc-­‐‑IgG  control  from  gestational  dGA14-­‐‑d19,  when  blood  pressures  and  
tissues  were  collected.  This  dose  of  sFlt-­‐‑1  has  been  previously  shown  160  to  cause  
an  increase  in  mean  arterial  pressure  in  pregnant  rats,  and  this  blood  pressure  
effect  was  further  confirmed  in  our  pilot  experiments.  NP,  NP+sFlt1  and  RUPP  
data  are  also  used  in  Part  3  of  Chapter  V  as  these  studies  were  run  in  parallel.  
Measurement  of  MAP  in  Chronically  Instrumented  Conscious  Rats  
Animals  were  instrumented  with  an  indwelling  arterial  catheter  of  the  left  
common  carotid  artery  on  day  18  of  gestation.  On  day  19,  unanesthetized  mean  
arterial  pressure  (MAP)  was  measured  directly  using  a  fluid-­‐‑filled  pressure  
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transducer  (ADInsruments,  Colorado  Springs,  CO)  26,27,151.  Animals  were  allowed  
30  minutes  to  adjust  to  the  restraining  cages,  and  blood  pressures  were  recorded  
for  the  60  minutes  following.    
Conceptus  Measurements  and  Serum  Collection  
After  blood  pressure  measurement,  the  dams  were  placed  under  3%  
isoflurane  anesthesia,  and  a  midline  ventral  incision  was  made  to  isolate  the  
abdominal  aorta  for  arterial  plasma  and  serum  collection  as  reported  previously  
27,151.  After  exsanguination,  a  pneumothorax  and  cardiac  excision  were  used  to  
confirm  death.  Blood  was  collected  for  subsequent  assays  into  blank  and  EDTA-­‐‑
lined  Corvac®  tubes  for  serum  and  plasma  processing,  respectively  (Sherwood  
Davis,  St.  Louis,  MO).  Fetal  weight,  placental  weight,  and  number  of  resorptions  
were  recorded  in  the  manner  described  previously  27,151.  All  tissues  collected  for  
subsequent  analysis  were  flash  frozen  in  liquid  nitrogen  and  stored  at  -­‐‑80˚C.  
Mulvany  Microvessel  Wire  Myography  
Following  necropsies  on  day  19  of  gestation,  secondary  and  tertiary  
mesenteric  arterioles  were  isolated  and  cleaned  of  all  surrounding  adipose  and  
connective  tissues  under  a  dissection  microscope.  Vessel  segments  1-­‐‑2mm  in  
length  were  mounted  and  suspended  with  two  40µμm  stainless  steel  wires  and  
attached  to  a  wire  myograph  (DMT,  Denmark)  to  allow  for  isometric  force  
recordings.  Vessels  were  normalized  to  tensions  that  proportionally  modeled  
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100mmHg  using  the  normalization  module  in  LabChart  8.0  (ADInstruments,  
USA).  
After  a  10  minute  period  for  equilibration  in  a  Kreb’s  buffer  (130mM  
NaCl,  4.7mM,  1.2mM  KH2PO4,  1.2mM  MgSO4,  1.6mM  CaCl2,  14.9mM  NaHCO3,  
5.5mM  glucose  ,  pre-­‐‑constriction  was  obtained  by  exposing  the  vessels  to  an  
isosmotic,  high-­‐‑potassium  physiological  saline  solution  (K-­‐‑PSS:  74.7mM  NaCl,  
60mM  KCl,  1.8  KH2PO4,  1.2mM  MgSO4,  1.6mM  CaCl2,  14.9mM  NaHCO3,  5.5mM  
glucose).  Following  a  triple  washout  period  with  Kreb’s  buffer,  a  stabilized  
vascular  constriction  was  achieved  by  the  addition  of  the  thromboxane  A2  
analogue  U46619  (5  µμM).  Endothelial-­‐‑dependent  vasorelaxation  was  evaluated  
with  a  cumulative  dose  response  curve  to  acetylcholine  (Ach;  1x10-­‐‑9–1x10-­‐‑5  M).  
Further,  endothelial-­‐‑independent  smooth  muscle  function  was  assessed  with  a  
cumulative  dose  response  curve  to  sodium  nitroprusside  (SNP,  1x10-­‐‑9–1x10-­‐‑5  M).  
Following  each  relaxation  curve,  a  single  dose  of  0.1mM  SNP  was  given  to  
confirm  smooth  muscle  integrity.  At  experiment  termination,  exposure  to  K-­‐‑PSS  
was  used  to  assess  vessel  viability  and  functional  decay.  Data  is  presented  as  
mean±SD  of  the  per  cent  vasorelaxation  from  U46619  contraction  force.  
Enzyme-­‐‑Linked  Immunosorbant  Assays  
Plasma  concentration  of  free  VEGF  was  measured  using  commercially  
available  enzyme  linked  immunosorbant  assay  (ELISA)  kits  (R&D  Systems,  
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Quantikine®;  Minneapolis,  MN,  Part:  MMV00)  according  to  the  manufacturer’s  
directions  as  described  previously  26,27,151.  
Endothelial  Tube  Formation  Assay  
Angiogenic  balance  was  further  assessed  in  the  serum  of  pregnant  rats  in  
vitro  as  previously  reported  26,27  in  two  separate  experiments  and  each  was  
performed  in  duplicate.  HUVECs  (human  umbilical  vascular  endothelial  cells)  
were  plated  at  5x105  cells/mL  (100ul/well)  onto  96-­‐‑well  plate  lined  with  growth-­‐‑
factor-­‐‑reduced  Matrigel®  (BD  Biosciences,  USA).  Five  microliters  of  serum  from  
each  group  was  introduced  to  the  100µμl  cell  media.  Cells  were  incubated  at  37°C,  
20%  O2,  5%  CO2.  Average  tubule  length  per  frame  was  assessed  at  100X  optical  
zoom  with  a  digital  inverted  compound  microscope  and  ImageJ  analysis  
software  (National  Institutes  of  Health,  Bethesda,  MD).  Tubule  lengths  were  
assessed  by  at  least  two  investigators  that  were  blinded  to  the  identity  of  the  
experimental  groups.  Values  from  each  observer  were  averaged  to  obtain  final  
counts.  
Statistical  Analysis  and  Calculations  
All  data  are  presented  as  mean  ±  SD,  and  statistical  significance  was  
accepted  when  p<.05.  Comparisons  within  NP  and  RUPP  groups  were  evaluated  
with  a  one-­‐‑way  analysis  of  variance  test  combined  with  a  Bonferroni  post-­‐‑hoc  
test  were  employed.  Comparison  between  NP  and  RUPP  controls  was  analyzed  
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by  a  t-­‐‑test.  Statistical  calculations  were  made  with  GraphPad  Prism  version  5.00  
for  Windows  (GraphPad  Software,  San  Diego,  CA  USA).  
Results  
Voluntary  Running  Wheel  Activity  
Prior  to  gestation,  the  animals  averaged  approximately  52.6±4.7  km/week  
(95%  CI:  43.1-­‐‑62.0).  After  breed,  average  weekly  exercise  distance  in  the  first  and  
second  weeks  of  gestation  was  decreased  (*p<.05)  in  comparison  to  average  
distance  prior  to  gestation.  This  is  likely  a  response  to  pregnancy,  as  virgin  
controls  that  failed  to  breed  (n=4)  resumed  (39.3±3.5  km/week)  their  training  
regimen  upon  reintroduction  to  the  activity  cages.  Average  exercise  distances  
prior  to  and  during  gestation  are  presented  in  Figure  4.8.    
Further,  a  decrease  (†p<.05)  was  observed  in  week  3  in  all  groups  
compared  to  average  distance  run  in  weeks  1  and  2,  suggesting  a  gestational  age  
dependent  relationship.  Moreover,  no  significant  difference  (p>.05)  in  gestational  












































































Figure  4.8.  Weekly  Exercise  Distance.  Across  all  animals,  exercise  distance  
per  week  was  decreased  (*p<.05)  with  pregnancy  (Weeks  1  and  2).  A  further  
decrease  (†p<.05)  was  observed  in  week  3  in  all  groups  compared  to  weeks  1  and  
2.  *P<.05  vs.  NP.  
  
  
Mean  Arterial  Pressure  
Infusion  of  rm-­‐‑sFlt1  in  NP  animals  resulted  in  an  increased  (p<.05)  mean  
arterial  pressure  (MAP)  when  compared  to  the  vehicle-­‐‑treated  NP  controls  
(depicted  in  Figure  4.9).  Additionally,  exercise  (EX)  training  attenuated  this  
effect,  as  MAP  was  no  longer  elevated  compared  to  NP  control  values.  Similarly,  
RUPP  caused  an  increase  (p<.05)  in  MAP  vs.  NP,  and  Ex  treatment  obviated  

















































Figure  4.9.  Mean  Arterial  Pressure  on  Day  19.  Infusion  of  sFlt1  in  normal  
pregnant  dams  increased  (*p<.05)  mean  arterial  pressure  (MAP),  and  exercise  
(EX).  RUPP  had  increased  (*p<.05)  MAP  vs.  NP,  and  Ex  mitigated  (†p<.05)  RUPP  
hypertension  despite  a  chronic  infusion  of  sFlt-­‐‑1.  NP  105±9;  *NP+sFlt  119±7;  
NP+Ex/sFlt  116±13mmHg;  *RUPP  129±4;  RUPP+Ex  104±N/A;  †RUPP+Ex/sFlt  
120±4mmHg.  *p<.05  vs.  NP;  †p<.05  vs.  RUPP.  Data  presented  as  mean±SD.  
RUPP+Ex  sample  size  limited  to  one  due  to  insufficient  blood  pressure  
recordings.  NP,  NP+sFlt1  and  RUPP  data  is  also  reported  in  Chapter  V,  Part  3.  
  
  
Vascular  Endothelial  Function  
   Endothelial  function  of  mesenteric  arterioles  (200-­‐‑400µμm  diameter)  was  
assessed  by  a  logarithmic  dose-­‐‑response  curve  to  acetylcholine  (Ach)  following  
pre-­‐‑constriction  to  thromboxane  A2  mimetic,  U46619  (5µμM).  Normal  pregnant  
(NP)  dams  receiving  sFlt-­‐‑1  infusion  (NP+sFlt1)  demonstrated  a  decreased  (p<.05)  
relaxation  potential  compared  to  NP  controls.  Moreover,  exercise  training  
attenuated  this  effect,  where  no  difference  between  NP+Ex/sFlt1  and  NP  was  
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observed.  Additionally,  RUPP  caused  a  decrease  in  vasorelaxation  to  Ach  
compared  to  NP,  which  was  also  restored  (p<.05)  with  Ex  treatment.  Moreover,  
Ex  treatment  improved  (p<.05)  vasorelaxation  potential  in  the  RUPP+Ex/sFlt1  
cohort  with  respect  to  RUPP.  Data  is  depicted  in  Figure  4.10a-­‐‑b.  
Plasma  Free  VEGF  and  sFlt-­‐‑1Balance  
As  we  have  previously  observed,  free  VEGF  concentration  in  maternal  
plasma  was  decreased  (p<.05)  RUPP  vs.  NP  controls.  No  effect  of  sFlt-­‐‑1  infusion  
or  exercise  was  observed  in  either  NP  or  RUPP  groups’  VEGF  levels.  Data  is  
depicted  below  in  top  panel  of  Figure  4.11.  Likewise,  sFlt-­‐‑1  concentration  in  
maternal  plasma  was  increased  (p<.05  vs.  NP)  with  sFlt-­‐‑1  infusion  in  the  
NP+sFlt1  dams,  which  confirmed  successful  peptide  delivery  (Figure  4.11,  
bottom  left  panel).  No  additional  effect  of  exercise  was  observed  in  the  NP  
animals.  Similarly,  the  infusion  of  sFlt-­‐‑1  in  the  RUPP+Ex/sFlt1  treatment  group  
resulted  in  an  increase  (p<.05)  in  plasma  sFlt-­‐‑1  vs.  RUPP  controls.    
Used  as  an  indicator  of  angiogenic  balance,  the  ratio  of  VEGF:sFlt-­‐‑1  
(Figure  4.11,  bottom  right  panel)  was  decreased  (p<.05)    in  NP+sFlt-­‐‑1  and  
NP+Ex/sFlt-­‐‑1  compared  to  NP  controls.  Additionally,  the  VEGF:sFlt-­‐‑1  ratio  in  the  
RUPP+Ex/sFlt1  treatment  was  decreased  (p<.05)    vs.  RUPP.  Together,  these  data  
suggest  the  infusion  of  rm-­‐‑sFlt1  maintained  an  elevated  plasma  sFlt-­‐‑1,  and  


























































Figure  4.10.  Mesenteric  Vascular  Endothelial  Function.  (Top  Panel)  
Endothelial  function  measured  by  vasodilation  of  isolated  mesentery  arterioles  to  
acetylcholine  was  improved  by  Ex  in  both  NP  (*p<.05)  and  (Bottom  Panel)  RUPP  
(†p<.05)  groups,  despite  sFlt-­‐‑1  infusion.  No  effects  on  smooth  muscle  function  
were  observed  in  SNP  curve  (endothelial-­‐‑independent  vasodilation)  (Data  not  
shown).  *p<.05  vs.  NP;  †p<.05  vs.  RUPP.  Data  presented  as  mean±SD;  n=4-­‐‑8  per  
group.  Data  analyzed  between  groups  across  each  dose.  NP,  NP+sFlt1  and  RUPP  






























































































































Figure  4.11.  Plasma  VEGF,  sFlt-­‐‑1,  and  VEGF:sFlt-­‐‑1  Balance.  (Top  Panel)  
RUPP  had  decreased  (*p<.05)  bioavailable  VEGF  compared  to  NP.  No  effect  of  
sFlt-­‐‑1  infusion  in  either  NP  or  RUPP  groups  were  observed.  NP  920±335;  
*NP+sFlt  1291±358;  *NP/Ex+sFlt  1197±475;  *RUPP  500±182;  RUPP/Ex  510±117;  
RUPP/Ex+sFlt  528±297  pg/mL.  (Bottom  Left  Panel)  sFlt-­‐‑1  was  increased  (*p<.05)  
in  NP+sFlt1,  and  NP+Ex/sFlt1  vs.  NP.  Additionally,  RUPP+Ex/sFlt1  treatment  
increased  (†p<.05)  plasma  sFlt-­‐‑1  vs.  RUPP  controls.  NP  86±52;  *NP+sFlt  470±108;  
*NP+Ex/sFlt  360±178;  *RUPP  78±33;  †RUPP+Ex  52±2;  RUPP+Ex/sFlt  
400±281pg/mL.  (Bottom  Right  Panel)  The  ratio  of  bioavailable  VEGF:sFlt-­‐‑1  was  
decreased  by  sFlt-­‐‑1  infusion  in  both  NP+sFlt1  and  NP+Ex/sFlt1  vs.  NP  controls.  
sFlt-­‐‑1  infusion  in  RUPP+Ex/sFlt1  was  further  decreased  compared  to  RUPP  
VEGF:sFlt-­‐‑1  values.  NP  13.3±8.0;  *NP+sFlt  2.5±0.8;  *NP+Ex/sFlt  6.3±3.6;  *RUPP  
7.3±3.8;  †RUPP+Ex  12.9±N/A;  RUPP+Ex/sFlt  1.4±1.2  AU.  *p<.05  vs.  NP;  †p<.05  vs.  
RUPP.  RUPP+Ex  data  are  limited  to  n=2  due  to  insufficient  sample  availability.  
NP,  NP+sFlt1  and  RUPP  data  is  also  reported  in  Chapter  V,  Part  3.  
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Serum  Angiogenic  Potential  
Serum  angiogenic  potential  was  assessed  by  culture  of  human  vascular  
endothelial  cells  (HUVECs)  in  the  presence  of  5%  (v/v)  animal  sera,  followed  by  
measurement  of  microtubule  formation.  Firstly,  NP+sFlt1  exhibited  a  decreased  
(p<.05  vs.  NP)  average  tubule  size,  and  remained  decreased  (p<.05  vs.  NP)  in  the  
NP+Ex/sFlt1  treatment  group  (see  Figure  4.12).  Further,  serum  from  RUPP  dams  
had  a  decreased  tubule  formation  compared  to  NP  controls.  No  additional  effects  












































Figure  4.12.  Serum  Angiogenic  Potential.  Serum  angiogenic  potential  was  
decreased  in  HUVEC  cells  exposed  to  serum  from  NP+sFlt,  NP+Ex/sFlt1  and  
RUPP  vs.  NP  (*p<.05).  No  additional  effects  were  observed  in  the  RUPP  groups.  
NP  235±17;  *NP+sFlt  137±33;  NP+Ex/sFlt  182±31;  *RUPP  205±15;  †RUPP+Ex  
230±34;  RUPP+Ex/sFlt  213±14µμm.  A  sample  picture  of  NP  vs.  RUPP  tubule  
formation  is  provided  (scale  bar  =  100µμm).  *p<.05  vs.  NP;  †p<.05  vs.  RUPP.  Data  




Maternal  and  Fetal  Morphometrics  
No  effect  on  maternal  or  conceptus  morphometrics  was  observed  between  
NP  and  NP+sFlt1.  Interestingly,  there  was  a  decrease  in  maternal  and  fetal  
weight,  as  well  as  an  increase  in  placental  weight  and  fetal  demise  in  
NP+Ex/sFlt1  vs.  NP.  Also,  as  we  have  previously  reported,  RUPP  caused  a  
decrease  (p<.05)  in  maternal,  fetal,  and  placental  weight  compared  to  NP,  and  
increased  (p<.05  vs.  NP)  fetal  demise  rate.  Ex  treatment  obviated  (p<.05)  
resorption  rate  in  RUPP+Ex  compared  to  RUPP,  and  sFlt-­‐‑1  infusion  prevented  
this  effect.  Data  is  summarized  below  in  Table  4.2.  
Table  4.2.  Maternal  and  Conceptus  Morphometric  Data  at  Necropsy.    
  Treatments   Maternal   Fetal   Placental   %  Resorption  
Weight  (g)   Weight  (g)   Weight  (g)  
NP  
(n=10)   311±30   2.25±0.12   0.46±0.03   2.6±5.8_  
NP+sFlt1  
(n=8)  
288±16   2.27±0.24   0.49±0.08   0.9±2.4_  
NP+Ex/sFlt1  
(n=9)  
*277±34   *2.06±0.32   *0.60±0.19   *26.8±35.4  
RUPP  
(n=10)  
*259±19   *1.79±0.26   *0.36±0.07   *68.1±23.7  
RUPP+Ex  
(n=3)  
260±18   1.98±0.06   0.39±0.04   †34.4±22.1  
RUPP+Ex/sFlt1  
(n=7)  
245±33   1.90±0.35   0.40±0.07   46.9±1.2  
Note.  *p<.05  indicates  different  from  NP.  †p<.05  indicates  different  from  RUPP.  
Data  presented  as  mean±SD.  NP,  NP+sFlt1  and  RUPP  data  is  also  reported  in  





To  verify  the  role  of  the  VEGF:sFlt-­‐‑1  axis  and  angiogenic  balance  in  the  
anti-­‐‑hypertensive  effects  of  exercise  training  before  and  during  pregnancy,  we  
employed  an  infusion  of  recombinant  sFlt-­‐‑1  on  NP  and  RUPP  to  induce  and  
maintain  suppression  of  bioavailable  VEGF  throughout  exercise  treatment.  It  
was  hypothesized  that  the  effects  of  exercise  training  in  the  RUPP  model  is  
dependent  on  the  stimulation  of  bioavailable  VEGF.  To  this  end,  we  sought  to  
antagonize  VEGF  signaling  with  an  infusion  of  recombinant  sFlt-­‐‑1.  As  intended,  
sFlt-­‐‑1  infusion  sustained  a  suppression  of  bioavailable  sFlt-­‐‑1  and  VEGF:sFlt-­‐‑1  
balance  in  both  NP  and  RUPP  cohorts  through  exercise  treatment,  and  permitted  
us  to  isolate  the  role  of  the  VEGF:sFlt-­‐‑1  axis  in  both  NP  and  RUPP  sub-­‐‑groups.  
Interestingly,  these  data  collectively  do  not  support  our  initial  hypothesis,  where  
exercise  treatment  mitigated  RUPP-­‐‑induced  hypertension  and  endothelial  
dysfunction  despite  the  infusion  of  sFlt-­‐‑1  and  decreased  free  VEGF:sFlt-­‐‑1.    
Blood  Pressure  and  Exercise  in  Pregnancy  
As  previously  reported  by  Gilbert  and  colleagues  27,  exercise  is  observed  
to  attenuate  RUPP  induced  hypertension.  Though  in  the  current  study,  RUPP+Ex  
treatment  had  insufficient  evidence  to  confirm  this  previous  report,  we  observed  
exercise  training  prior  to  and  during  gestation  to  attenuate  the  RUPP  
hypertension  despite  the  infusion  of  recombinant  sFlt-­‐‑1.  This  suggests  the  anti-­‐‑
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hypertensive  effects  may  be  independent  of  VEGF:sFlt-­‐‑1  imbalance.  
Interestingly,  this  effect  was  not  observed  in  the  NP  cohorts  receiving  sFlt-­‐‑1  
infusion,  which  suggests  the  effects  are  largely  influenced  by  the  presence  of  
placental  hypoperfusion  due  to  RUPP.  Further  it  is  currently  unclear  whether  
these  disparate  effects  from  exercise  training  indicate  a  role  of  compromised  
placental  blood  flow  in  the  anti-­‐‑hypertensive  mechanism,  and  further  
investigation  is  required.  
In  regard  to  voluntary  exercise  distances  reported  in  this  study,  we  
observed  a  significant  decrease  in  weekly  exercise  distance  per  week  during  
weeks  1-­‐‑2  compared  to  before  gestation,  and  even  further  in  week  3.  This  
decrease  in  activity  has  previously  observed  in  gestation  week  3  in  normal  
pregnant,  sham  controls,  and  RUPP  dams  27,75,  so  the  decrease  in  voluntary  
activity  levels  is  likely  not  due  to  the  sham  or  RUPP  surgical  procedures.  
Similarly  observed  in  women,  a  decrease  in  voluntary  activity  has  also  been  
reported  in  exercise-­‐‑trained  pregnant  women,  who  have  a  decrease  in  activity  in  
early  pregnancy,  and  a  further  decrease  or  indolence  in  the  third  trimester  161.  
Moreover,  the  effects  of  exercise  training  on  blood  pressure  are  present  despite  a  
decrease  in  activity  in  week  3,  which  indicates  the  cardiovascular  benefits  and  




Exercise,  Angiogenic  Balance,  and  Endothelial  Function  
The  role  of  angiogenic  balance,  most  notably  through  the  VEGF/PlGF:sFlt-­‐‑
1  axis,  has  been  a  large  focus  of  the  preeclampsia  research  since  Karumanchi’s  
seminal  report  on  the  role  of  sFlt-­‐‑1  over  a  decade  ago  20.  Though  the  direct  role  of  
VEGF/PlGF  replacement  in  experimental  models  of  preeclampsia  is  quite  clear  
28,70,71,  it  is  unclear  whether  this  is  the  central  mechanism  for  other  modalities,  
such  as  exercise.  
In  regard  to  angiogenic  balance,  we  observed  a  decrease  in  bioavailable  
VEGF,  increase  in  sFlt-­‐‑1,  and/or  decreased  VEGF:sFlt-­‐‑1  in  the  RUPP  and  sFlt-­‐‑1  
infused  NP  cohorts.  Firstly,  exercise  did  not  improve  VEGF  bioavailability  in  the  
NP+Ex/sFlt1  or  RUPP+Ex/sFlt1  cohorts.  Similarly,  endogenous  plasma  sFlt-­‐‑1  and  
VEGF:sFlt-­‐‑1  in  plasma  was  also  unaffected  by  exercise  training  or  sFlt-­‐‑1  infusion  
in  the  NP  and  RUPP,  which  has  also  been  observed  in  experimental  models  of  PE  
118.  Moreover,  in  concert  with  the  blood  pressure  data,  these  results  suggest  
improved  angiogenic  balance  in  the  VEGF-­‐‑sFlt1  axis  is  not  required  for  exercise  
to  prevent  the  RUPP  hypertension.  Further,  these  data  contrast  with  our  
previous  hypothesis  and  reports  27,  and  suggest  the  anti-­‐‑hypertensive  effect  of  
exercise  in  the  RUPP  may  not  be  primarily  mediated  through  the  plasma  VEGF  




Additionally,  a  potential  convoluting  point  in  this  study  is  the  voluntary  
access  to  the  activity  wheels,  in  which  weekly  exercise  varied  (though  modestly)  
between  animals.  This  in  itself  raises  the  question  of  an  exercise  dose  response,  
and  for  the  potential  to  control  endogenous  VEGF  production.  Moreover,  there  
was  no  observed  association  between  VEGF  and  sFlt1  expression  and  exercise  
distance  (a)  prior  to  gestation,  and  (b)  exercise  distance  in  week  3  of  gestation  
(Figure  4.13).  In  summary,  we  did  not  observe  any  effect  of  either  distance  on  the  
expression  of  VEGF  or  sFlt-­‐‑1,  as  the  effects  appear  to  be  dichotomous.  
Furthermore,  the  minimum  training  threshold  to  gain  the  cardiovascular  benefits  
is  still  unknown,  and  would  be  an  intriguing  and  elucidating  investigation  for  
the  translation  of  the  current  and  previous  reports.  
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Figure  4.13.  Relationship  Between  Weekly  Exercise  Distance  and  Plasma  
Angiogenic  Factor  Balance.  Across  both  NP+Ex  and  RUPP+Ex  cohorts,  no  
relationship  is  observed  between  average  weekly  exercise  distance  prior  to  
gestation  (top  panel)  and  during  week  3  of  gestation  (bottom  panel)  and  plasma  




Regarding  the  effect  on  endothelial  function,  exercise  training  improved  
vascular  endothelial  function  in  both  RUPP  and  sFlt-­‐‑infused  NP  dams.  Further,  
in  the  RUPP  cohort,  endothelial  function  was  improved  regardless  of  sFlt-­‐‑1  
infusion,  which  further  suggests  these  effects  are  not  dependent  on  the  
restoration  of  normal  VEGF:sFlt-­‐‑1  plasma  levels  and  may  rely  on  other  
controlling  mechanisms.  Similarly,  serum  angiogenic  potential  was  observed  to  
be  improved  by  exercise  in  both  NP+sFlt1  and  RUPP  groups,  regardless  of  sFlt-­‐‑1  
infusion,  suggesting  endothelial  cell  function  is  improved.  These  data  also  
suggest  an  angiogenic  balance  may  actually  be  restored  in  the  sera  of  the  treated  
animals,  as  tubule  formation  was  improved  with  exercise.  Together,  although  
merely  speculative  at  this  point,  these  measurements  of  endothelial  function  
support  the  role  of  a  pathway  alternative  to  VEGF  signaling  that  is  mediating  the  
observed  cardiovascular  effects.    
Study  Limitations  
   It  should  be  noted  that  the  validity  and  “methodological  consistency”  of  
the  ELISA-­‐‑measured  angiogenic  factors,  particularly  VEGF,  have  been  recently  
called  into  question  by  Weissengerber  and  colleagues.  162.  While  we  did  not  
observe  the  wide  variability  and  difficulty  in  obtaining  comparable  values  in  free  
VEGF,  we  would  like  to  recognize  that  this  currently  is  an  area  of  concern  in  the  
preeclampsia  research  field.    We  also  failed  to  replicate  our  previous  published  
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observations  in  the  RUPP  in  regard  to  the  plasma  sFlt-­‐‑1  levels.  Without  these  
effects  in  RUPP,  the  interpretation  and  comparative  quality  of  the  angiogenic  
effects  in  RUPP  should  be  taken  into  consideration  in  future  work.  Moreover,  to  
further  supplement  the  measurement  of  angiogenic  balance,  additional  
measurements  of  circulating  sFlt-­‐‑1  and  serum  angiogenic  potential  (tubule  
formation  assay)  were  performed.  However,  we  feel  this  is  sufficient  
experimental  evidence  to  appropriately  interpret  the  current  data  at  this  time.  
   Additionally,  the  measurement  of  sFlt-­‐‑1  was  limited  to  one  measurement  
at  day  19,  and  the  timing  of  delivery  remains  unknown  without  repeated  
measurements  after  the  introduction  of  sFlt-­‐‑1.  To  this  end,  due  to  observation  to  
of  increased  sFlt-­‐‑1  levels  at  day  19  in  the  sFlt-­‐‑infused  animals,  we  are  confident  
in  the  method  of  delivery  and  the  presence  of  circulating  sFlt-­‐‑1  in  these  animals.  
Conclusion  
Collectively,  these  data  support  that  the  anti-­‐‑hypertensive  effects  of  
exercise  in  the  RUPP  model  were  not  dependent  on  the  restoration  of  VEGF:sFlt-­‐‑
1  balance  in  maternal  plasma.  More  importantly,  in  a  syndrome  with  very  
limited  options  in  both  prevention  and  treatment  modalities,  the  previously  
reported  beneficial  effects  of  exercise  in  preventing  preeclamptic-­‐‑like  
hypertension  are  further  supported  by  this  study.  Though  the  potential  clinical  
implications  are  exciting,  this  study  confirms  the  molecular  contributions  to  
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these  effects  should  be  further  evaluated  before  exercise  training  is  indicated  for  
preeclampsia  prevention.  Likewise,  if  these  the  pathways  activated  during  
exercise  are  revealed,  potential  pharmacological  modalities  could  be  further  
explored  as  well.  Furthermore,  a  potential  pathway  in  which  exercise  could  be  
functioning  through  will  be  examined  in  the  next  chapter,  in  which  a  parallel  
study  of  AMP-­‐‑activated  protein  kinase  (AMPK)  mediated  effects  will  be  





TREATMENT  IN  A  RAT  MODEL  OF  PLACENTAL  ISCHEMIA  INDUCED  
HYPERTENSION  
In  Chapter  V,  a  portion  of  the  data  in  Part  1  was  published  in  2012  in  the  
American  Journal  of  Physiology  -­‐‑  Heart  and  Circulation,  and  Ashley  J.  Bauer,  Karen  
W.  Needham,  Hans  C.  Dreyer,  and  Jeffrey  S.  Gilbert  are  co-­‐‑authors.  I  performed  
the  experimental  work  along  with  the  technical  assistance  of  A.J.  Bauer  and  K.W.  
Needham.  H.C.  Dreyer  and  J.S.  Gilbert  provided  editorial  assistance.  J.S.  Gilbert  
provided  project  funding.  
Parts  2-­‐‑3  of  Chapter  V  are  in  preparation  for  publication  with  Haley  E.  
Gillham,  Sarah  M.  Johnson,  Karen  W.  Needham,  and  Jeffrey  S.  Gilbert  as  co-­‐‑
authors.  I  performed  the  experimental  work  with  the  technical  assistance  of  co-­‐‑
authors  H.E.  Gillham,  S.M.  Johnson,  and  K.W.  Needham.  J.S.  Gilbert  provided  
project  funding.  




RIBOFURANOSIDE  (AICAR)  ADMINISTRATION  TO  IMPROVE  VEGF  
BIOAVAILABILITY  AND  PREVENT  HYPERTENSION  INDUCED  BY  
PLACENTAL  ISCHEMIA  
Introduction  
Preeclampsia,  a  pregnancy-­‐‑specific  syndrome,  is  the  leading  cause  of  fetal  
and  maternal  morbidity  and  mortality  across  the  world,  and  unfortunately  the  
incidence  has  been  increasing  in  recent  decades  10,40.  Currently,  there  are  limited  
treatments  available,  and  early  delivery  is  often  indicated  to  prevent  further  
progression  of  the  syndrome.  Consequently,  preeclampsia  is  the  leading  cause  of  
pre-­‐‑mature  delivery,  which  is  well-­‐‑known  to  have  numerous  deleterious  effects  
on  perinatal  and  life-­‐‑long  health  10,40.    
Recent  clinical  and  experimental  studies  suggest  dysregulation  of  
circulating  angiogenic  factors  results  in  an    angiogenic  imbalance  that  is  most  
notably  characterized  by  an  altered  ratio  of  pro-­‐‑angiogenic  (e.g.  vascular  
endothelial  growth  factor;  VEGF)  and  anti-­‐‑angiogenic  factors  (e.g.  soluble  VEGF  
receptor-­‐‑1;  sFlt-­‐‑1).  An  imbalance  favoring  increased  anti-­‐‑angiogenic  factors  has  
been  strongly  linked  to  the  etiology  of  hypertension  during  preeclampsia  
20,28,29,151.  Recent  studies  also  indicate  restoration  of  angiogenic  balance  can  
mitigate  an  increase  in  blood  pressure  observed  in  several  rodent  models  of  
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preeclampsia  20,22,27,28,163.  Moreover,  recent  experimental  and  clinical  observations  
of  hypertension  in  pregnancy  and  preeclampsia  have  shown  exercise  can  
mitigate  hypertension,  restore  angiogenic  balance,  and  endothelial  function  27,119.  
Despite  these  recent  findings,  the  exact  mechanisms  by  which    physical  activity  
improves  angiogenic  balance  and  decreases  blood  pressure  in  pregnancy  remain  
unclear  27,75.  
Recent  studies  have  revealed  some  of  the  metabolic  changes  observed  due  
to  exercise  training  can  be  stimulated  pharmacologically  139,164.  Of  the  several  
pharmacological  models  of  exercise  in  recent  literature,  AMP-­‐‑activated  protein  
kinase  (AMPK)  has  been  reported  as  a  major  regulator  of  or  contributor  to  
several  essential  metabolic  adaptations  observed  in  exercise  35,36,165-168.  Moreover,  
the  pharmacological  activation  of  AMPK  through  5-­‐‑aminoimidazole-­‐‑4-­‐‑
carboxamide-­‐‑3-­‐‑ribonucleoside  (i.e.  AICAR)  139,164,  an  adenosine  mimetic  37,169,  and  
has  been  shown  to  decrease  mean  arterial  pressure  in  hypertensive  rats  34.  
Further,  activation  of  the  AMPK  pathway  has  been  shown  to  regulate  increases  
in  VEGF  expression  127,  but  whether  or  not  this  occurs  with  AICAR  
administration  remains  unknown.  Therefore,  we  hypothesized  (Figure  5.1)  
AICAR,  a  potent  AMPK  stimulator,  would  stimulate  the  bioavailability  of  VEGF  
in  circulation,  improved  endothelial  function,  and,  most  importantly,  abrogate  




Figure  5.1.  Overarching  AICAR  Hypothesis.  RUPP-­‐‑induced  hypertension  
and  endothelial  dysfunction  is  expected  to  be  ameliorated  by  AICAR  treatment  





Studies  were  performed  in  timed-­‐‑pregnant  Sprague-­‐‑Dawley  rats  
purchased  from  Charles  River  (Wilmington,  MA)  or  Harlan  (Indianapolis,  IN).  
Animals  were  housed  in  a  temperature-­‐‑controlled  room  (23°C)  with  a  12:12  
light:dark  cycle.  All  experimental  procedures  executed  were  completed  in  
accordance  with  National  Institutes  of  Health  guidelines  for  use  and  care  of  
animals  and  were  approved  by  the  Institutional  Animal  Care  and  Use  
Committee  at  both  University  of  Minnesota  and  the  University  of  Oregon.  Dams  
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were  assigned  to  normal  pregnancy  (NP)  (n=8)  and  RUPP  (n=8)  groups  with  and  
without  AICAR  (Santa  Cruz  Biotechnology  Inc.,  Santa  Cruz,  CA)  treatment  
(NP+A  (n=6);  RUPP+A  (n=8)).  AICAR  treatment  was  introduced  by  
intraperitoneal  (i.p.)  injection  at  50mg/kg  twice  a  day  34,36,139  mixed  in  0.9%  sterile  
saline  solution,  and  controls  were  treated  with  a  0.9%  sterile  saline  solution  
vehicle.  Half  of  the  in  vivo  studies  for  each  group  were  completed  at  each  
institution.  
Reduced  Uterine  Perfusion  Pressure  (RUPP)  Procedure  
The  RUPP  procedure  is  a  robust  model  for  studying  the  link  between  
placental  ischemia  and  hypertension  in  the  pregnant  rat  and  has  been  described  
in  detail  previously  27,151.  In  brief,  silver  clips  were  placed  on  the  lower  abdominal  
aorta  (0.203-­‐‑mm  inner  diameter  (ID))  above  the  iliac  bifurcation  and  also  on  
branches  (0.100  mm  ID)  of  both  the  right  and  left  ovarian  arteries  supplying  the  
uterus  on  day  14  of  gestation  (term  =  21  days).  Four  normal  pregnant  dams  
underwent  a  sham  surgery,  which  included  the  midline  incision  and  suture.  
After  observing  no  differences  in  the  angiogenic  factors  and  blood  pressures  
these  animals  were  grouped  with  the  normal  pregnant  rats.      
Measurement  of  MAP  in  chronically  instrumented  conscious  rats  
Animals  were  instrumented  on  day  17  of  gestation  with  an  indwelling  
catheter  and  arterial  pressure  was  determined  in  both  groups  of  rats  on  day  19  of  
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gestation  as  described  previously  27.  Briefly,  on  day  17,  V-­‐‑3  tubing  (SCI)  catheters  
we  introduced  to  the  left  common  carotid  artery  while  the  animal  was  under  
isoflurane  anesthesia.  Catheters  were  exteriorized  through  the  back  of  the  neck  
following  subcutaneous  tunneling.  On  day  19,  animals  were  placed  in  restraining  
cages,  and  direct  pressures  were  monitored  using  a  blood  pressure  transducer  
(ADInstruments)  for  one  hour  following  a  30  minute  stabilization  period  19.  Mean  
arterial  pressure  (MAP)  was  averaged  over  the  hour  time  period.  Additionally,  
heart  rate  was  analyzed  over  the  hour  period  from  the  arterial  pressure  
measurements  using  LabChart  7.0.  
Conceptus  Measurements  and  Serum  Collection  
After  the  measurement  of  MAP,  the  dams  were  placed  under  isoflurane  
anesthesia  and  a  midline  ventral  incision  was  made  to  isolate  the  abdominal  
aorta  for  plasma  and  serum  collection  as  reported  previously  27,151.  Blood  was  
collected  for  subsequent  assays  into  Corvac®  sterile  serum  separator  tubes  
(Sherwood  Davis,  St.  Louis,  MO).  Blood  and  amniotic  fluid  glucose  
concentrations  were  measured  as  reported  previously  152.  Fetal  weight,  placental  
weight,  and  number  of  resorptions  were  recorded  in  the  manner  described  
previously  27,151.  All  collected  tissues  for  subsequent  analysis  were  flash  frozen  in  




Enzyme-­‐‑Linked  Immunosorbant  Assays  
Plasma  concentrations  of  free  VEGF  and  sFlt-­‐‑1  were  measured  using  
commercial  enzyme  linked  immunosorbant  assay  kits  (R&D  Systems,  
Quantikine®;  Minneapolis,  MN)  according  to  the  manufacturer’s  directions  as  
described  previously    27,151.Oxidative  stress  assays  
Protein  Extraction  and  Quantitation  
As  described  previously  27,75,  total  soluble  protein  was  extracted  from  
whole  placentas  in  radioimmunoprecipitation  assay  (RIPA)  lysis  buffer  
containing  phenylmethanesulphonylfluoride  (PMSF)  in  dimethyl  sulfoxide  
(DMSO),  sodium  orthovanadate  and  a  protease  inhibitor  cocktail  (Santa  Cruz  
Biotechnology,  Inc.,  Santa  Cruz,  CA).  Total  soluble  cellular  protein  concentration  
was  determined  using  the  bicinchoninic  acid  (BCA)  method  (Pierce  
Biotechnology,  Rockford,  IL).  Renal  tissue  position  (right  or  left)  was  chosen  at  
random,  and  placental  samples  were  carefully  selected  for  middle  position  on  
either  side  of  the  uterine  horns  27,75.  
Western  Blotting  
Western  blotting  was  carried  out  as  previously  reported  75,170.  Protein  (50  
µμg)  was  separated  by  electrophoresis  on  4-­‐‑20%  sodium  dodecyl  sulfate  (SDS)  
polyacrylamide  separating  gels  (Life  Technologies,  Grand  Island,  NY)  then  
transferred  to  nitrocellulose  membranes  (BioRad,  Hercules,  CA)  and  Ponceau  
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stained  to  assess  the  transfer  across  each  gel.  The  images  of  the  Ponceau  stained  
membranes  were  digitized  with  a  flatbed  scanner.    
The  membranes  were  then  incubated  one  hour  in  casein  blocking  solution  
(BioRad).  Membranes  were  incubated  in  blocking  solution  containing  
commercially  available  antibodies  (0.1µμg/mL)  overnight  at  4˚C  (phospho(Thr172)  
-­‐‑AMPKα  (40H9);AMPKα  (23A3);  Cell  Signaling  Technology).  Membranes  were  
washed  and  incubated  for  one  hour  with  the  appropriate  fluorescent  protein-­‐‑
conjugated  secondary  antibodies  (7.5ng/ml,  LI-­‐‑COR  Biosciences,  USA).  The  
immunoreactive  bands  were  imaged  and  quantified  using  the  Odyssey  dual-­‐‑
channel  fluorescent  imaging  system  and  Image  Studio  2.0  software  (LI-­‐‑COR  
Biosciences,  USA).  Specificity  of  primary  antibodies  (negative  controls)  was  
evaluated  by  imaging  membranes  with  the  primary  antibody  omitted.  
Endothelial  Tube  Formation  Assay  
Angiogenic  balance  was  further  assessed  in  the  serum  of  pregnant  rats  in  
vitro  as  previously  reported  27  in  two  separate  experiments  and  each  was  
performed  in  duplicate.  Firstly,  the  sera  collected  from  the  treatment  groups  (NP,  
RUPP,  NP+A,  RUPP+A)  were  introduced  to  human  umbilical  vascular  
endothelial  cell  (HUVEC)  solution  (plated  at  5x105  cells/mL)  and  monitored  for  
eight  hours  for  tubule  formation.  In  addition,  the  direct  effect  of  AICAR  was  also  
assessed  by  treating  cells  with  serum  from  NP  and  RUPP  and  adding  20µμM  
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AICAR  directly  to  the  media.  Total  number  of  tubule  formations  per  frame  was  
assessed  at  40X  optical  zoom  with  a  digital  inverted  compound  microscope  and  
ImageJ  analysis  software  (National  Institutes  of  Health,  Bethesda,  MD).  Total  
tube  count  was  assessed  by  at  least  two  individual  investigators  that  were  
blinded  to  the  identity  of  the  experimental  groups.  Values  from  each  observer  
were  averaged  to  obtain  final  counts.  
Statistical  Analysis  and  Calculations  
All  data  are  presented  as  mean  ±  SD,  and  statistical  significance  was  
accepted  when  p<.05.  Comparisons  were  made  with  a  one-­‐‑way  analysis  of  
variance  test  combined  with  a  Bonferroni  post-­‐‑hoc  test  were  employed.  Statistical  
calculations  were  made  with  GraphPad  Prism  version  5.00  for  Windows  
(GraphPad  Software,  San  Diego,  CA  USA).  
Results    
Effect  of  AICAR  on  Blood  Pressure  and  Heart  Rate  
RUPP  hypertension  was  ameliorated  with  AICAR  (p<.05)  (Figure  5.2),  and  
AICAR  had  no  effect  on  NP  blood  pressure.  Additionally,  there  were  no  
differences  in  resting  heart  rate  observed  between  treatment  groups  (Mean+SD:  



















Figure  5.2.  Mean  Arterial  Pressure  on  Day  19.  The  RUPP-­‐‑induced  increase  
in  blood  pressure  was  ameliorated  with  AICAR  (50mg/kg  b.i.d.)  treatment.  
Mean+SD:  NP  102±11;  *RUPP  125±12;  NP+A  106±8;  †RUPP+A  107±11mmHg.  
*p<.05  vs.  NP;  †p<.05  vs.  RUPP.    
  
  
Effects  of  AICAR  on  Plasma  VEGF,  sFlt-­‐‑1,  and  Serum  Angiogenic  Potential    
Free  VEGF  levels  in  maternal  plasma  were  decreased  (p<.05)  in  RUPP  vs.  
NP,  and  AICAR  increased  (p<.05)  VEGF  in  the  RUPP  when  compared  to  RUPP  
untreated.  Plasma  sFlt-­‐‑1  levels  were  increased  (p<.05)  in  RUPP  vs.  NP,  and  
RUPP+AICAR  circulating  sFlt-­‐‑1  was  decreased  (p<.05)  compared  to  RUPP.  Data  
is  depicted  in  Figure  5.3.  Moreover,  angiogenic  potential  was  increased  (p<.05)  
with  AICAR  treatment  in  the  RUPP  compared  to  the  untreated  RUPP  (Figure  
3A).  Also,  there  was  no  difference  observed  between  the  NP  and  NP+A.  
Moreover,  AICAR  did  not  have  a  direct  effect  on  HUVEC  tubule  formation  when  
added  to  NP  or  RUPP  sera-­‐‑treated  cells  (Figure  5.4).	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Figure  5.3  Plasma  Concentration  of  Free  VEGF  and  sFlt-­‐‑1.  (Left  Panel)  
Free  VEGF  in  maternal  plasma  was  decreased  (*p<.05)  in  the  RUPP,  and  
improved  (†p<.05)  in  the  RUPP+AICAR.  Mean+SD:  NP  864±100;  *RUPP  503±181;  
NP+A  708±358;  †RUPP+A  884±255  pg/mL.  (Right  Panel)  Plasma  sFlt-­‐‑1  was  
restored  back  to  NP  levels  in  the  RUPP  treated  with  AICAR,  and  significantly  
decreased  (P<.05)  compared  to  RUPP  controls.  Mean+SD:  NP  161±95;  *RUPP  

































Figure  5.4.  Serum  Angiogenic  Potential  and  Direct  Angiogenic  Effect  of  
AICAR.  (Left  Panel)  Angiogenic  potential  measured  by  HUVEC  microtubule  
formation  was  decreased  in  RUPP  serum  vs.  NP,  and  AICAR  improved  (†p<.05)  
tubule  number  in  RUPP+A  serum.  Mean+SD:  NP  57±30;  *RUPP  26±7;  NP+A  
67±29;  †RUPP+A  81±32  tubules/frame.  (Right  Panel)  Angiogenic  potential  of  NP  
or  RUPP  serum  was  not  affected  by  the  addition  of  AICAR  directly  (DA)  into  the  
culture  media.  Mean+SD:  NP  28±7;  *RUPP  12±4;  NP+DA  12±4;  RUPP+DA  27±11  





Measurement  of  Anti-­‐‑Oxidant  Capacity  and  Oxidative  Stress  
Placental  Trolox-­‐‑equivalent  antioxidant  capacity  (TEAC)  levels  were  
decreased  in  the  RUPP  compared  to  the  NP  (p<.05),  and  AICAR  treatment  
obviated  the  decrease  in  the  RUPP+A  (Figure  5.5a).  No  effect  on  TEAC  in  the  
kidney  was  observed  (Figure  5.5b).  Additionally,  placental  (Figure  5.5c)  and  
renal  (Figure  5.5d)  catalase  activity  (measured  by  formaldehyde  production)  was  
increased  by  RUPP,  and  decreased  (p<.05)  in  RUPP+A  with  respect  to  the  RUPP  
group.  
Tissue  AMPK  Activation    
The  ratio  of  phosphorylated  AMPKα  (pAMPKα)  to  total  AMPKα,  was  
increased  with  AICAR  treatment  in  RUPP  placenta  (p<.05)  compared  to  
untreated  RUPP,  NP,  and  NP+AICAR  animals  (Figure  5.6).    
Maternal  and  Fetal  Morphometric  and  Metabolic  Data  at  Necropsy  
Maternal  weights  and  fetal  weights  were  decreased  (p<.05)  in  the  RUPP  
compared  to  NP,  and  AICAR  had  no  significant  effect.  Placental  weight  was  
decreased  (p<.05)  in  RUPP  vs.  NP,  and  AICAR  mitigated  this  decrease.  Total  
litter  viability  per  cent  was  decreased  (p<.05)  in  RUPP  vs.  NP,  and  AICAR  
remediated  the  RUPP  resorption.  Lastly,  blood  glucose  and  amniotic  fluid  
glucose  were  not  changed  with  AICAR  treatment  in  either  normal  pregnant  or  





Figure  5.5.  Placental  and  Renal  Anti-­‐‑Oxidant  Capacity  and  Oxidative  
Stress.  (Panel  A)  Trolox-­‐‑equivalent  antioxidant  capacity  (TEAC)  levels  were  
decreased  in  the  RUPP  placenta  compared  to  the  NP  (*p<.05),  and  AICAR  
obviated  (†p<.05)  the  decrease  in  the  RUPP+A.  Mean+SD:  NP  0.38±0.14;  *RUPP  
0.20±0.05;  NP+A  0.38±0.09;  †RUPP+A  0.48±0.13  mM.  (Panel  B)  Renal  TEAC  levels  
were  decreased  (*p<.05)  in  RUPP  vs.  NP,  and  unaffected  by  AICAR  treatment  in  
RUPP.  NP  0.79±0.09;  *RUPP  0.61±0.10;  NP+A  0.58±0.20;  †RUPP+A  0.65±0.10  mM..  
(Panel  C)  Placental  catalase  activity  (measured  by  formaldehyde  production)  was  
increased  (*p<.05)  in  the  RUPP  vs.  NP,  and  decreased  (†p<.05)  in  RUPP+A  with  
respect  to  RUPP.  Mean+SD:  NP  16.6±4.3;  *RUPP  27.2±6.0;  NP+A  17.1±5.1;  
†RUPP+A  18.2±4.2  µμM.  (Panel  D)  Renal  catalase  activity  was  increased  (*p<.05)  in  
the  RUPP  vs.  NP,  and  remediated  (†p<.05)  in  RUPP+A  with  respect  to  RUPP.  
Mean+SD:  NP  75.2±34.8;  *RUPP  152.9±85.4;  NP+A  38.6±19.9;  †RUPP+A  34.3±9.0  





































































































Figure  5.6.  Placental  AMPK  Phosphorylation.  The  ratio  of  
phosphorylated  AMPKα  (pAMPKα)  to  total  AMPKα  was  increased  (†p<.05)  
with  AICAR  in  RUPP+A  placenta  compared  to  RUPP.  Mean+SD:  NP  0.19±0.08;  
*RUPP  0.18±0.09;  NP+A  0.16±0.07;  †RUPP+A  0.33±0.18  µμM..  *p<.05  vs.  NP;  †p<.05  




The  present  study  is  the  first  to  investigate  the  treatment  of  placental  
ischemia  induced  hypertension  with  5-­‐‑aminoimidazole-­‐‑4-­‐‑carboxamide-­‐‑3-­‐‑
ribonucleoside  (AICAR),  which  has  revealed  novel  evidence  of  restoration  of  
angiogenic  balance  and  abrogation  of  hypertension  in  an  experimental  model  of  
hypertension  in  preeclampsia.  Foremost,  the  hypertension  observed  in  our  
reduced  uterine  perfusion  pressure  (RUPP)  model  was  abrogated  with  
intraperitoneal  50mg/kg  b.i.d.  AICAR  treatment.  Secondly,  maternal  angiogenic  
balance  was  restored  in  the  RUPP  following  AICAR  treatment,  by  both  
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increasing  the  circulating  free  VEGF  and  decreasing  circulating  sFlt-­‐‑1.  These  
observations  were  further  supported  by  the  increased  microtubule  formation  in  
HUVECs  treated  with  serum  from  the  RUPP+AICAR  vs.  RUPP,  which  indicates  
an  increased  angiogenic  potential  and  suggests  an  increased  endothelial  function  
with  AICAR  in  the  RUPP.  Next,  the  RUPP-­‐‑associated  increase  in  oxidative  stress  
markers  were  attenuated  in  both  placenta  and  kidney  when  treated  with  AICAR.  
When  viewed  in  concert,  these  findings  suggest  AICAR  treatment  may  have  
several  beneficial  effects  on  the  hypertensive  phenotype  of  a  model  of  placental  
ischemia-­‐‑induced  hypertension.  
Table  5.1.  Maternal  and  Conceptus  Morphometric  and  Metabolic  Data.    
  Treatments  










Weight  (g)   Weight  (g)   Weight  (g)  
NP  
(n=8)  
337.8±4.5   2.27±0.04   0.48±0.01   95.6±1.9   82.6±7.4   137.4±15.1  
RUPP  
(n=8)  
*294.5±10.8   *2.05±0.06   *0.42±0.02   *47.9±8.5   101.7±7.7   129.8±13.6  
NP+A  
(n=5)  
342.3±7.7   2.34±0.05   0.50±0.03   98.8±1.2   81.0±13.8   166.7±33.5  
RUPP+A  
(n=7)  
*305.0±4.7   *2.08±0.06   †0.46±0.02   †69.8±11.1   79.0±9.2   99.7±31.7  
Note.  *p<.05  indicates  different  from  NP.  †p<.05  indicates  different  from  RUPP.  







Effects  of  AICAR  on  Blood  Pressure  and  Endothelial  Function  
Administration  of  an  adenosine  mimetics  similar  to  AICAR,  such  as  
Metformin,  has  long  been  recognized  to  improve  cardiovascular  function  and  
lower  blood  pressure  in  non-­‐‑pregnant  hypertensives  33,131,  but  the  mechanisms  
remain  uncharacterized  31-33,171.  Further,  recent  studies  have  shown  AICAR  can  
directly  improve  endothelial  function  and  lower  blood  pressure  in  rodent  models  
of  hypertension  and  improved  conduit  vessel  function  34,172.  Therefore,  our  
observation  that  AICAR  treatment  lowers  blood  pressure  is  in  agreement  with  
previous  reports  in  other  models  of  hypertension  34-36,  and  we  are  the  first  to  
report  these  effects  in  any  model  of  hypertension  during  pregnancy.    
It  has  been  noted  that  the  blood  pressure  effects  observed  in  this  model  
could  potentially  be  directly  from  AICAR  interaction  on  the  vascular  endothelial  
cells,  as  endothelial-­‐‑cell-­‐‑mediated  vasorelaxation  to  AICAR  has  been  shown  to  
be  dependent  on  both  NO  and  EDHF  production  172.  However,  the  vasodilatory  
properties  observed  by  Ford  and  colleagues  ex  vivo  are  transient  172,  and  the  
mechanisms  mediating  chronic  effects  of  AICAR  remain  unclear  35.  In  the  present  
study  blood  pressure  was  recorded  more  than  12  hours  after  the  final  
intraperitoneal  injection  of  AICAR,  suggesting  the  maternal  cardiovascular  
effects  of  AICAR  in  the  present  study  were  due  to  chronic  signaling  changes  
such  as  restoration  of  angiogenic  balance  rather  than  previously  reported  acute  
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mechanisms  172.  In  particular,  our  present  data  suggests  the  effects  of  AICAR  
administration  may  be  due  to  chronic  changes  in  factors  such  as  circulating  free  
VEGF  and  sFlt-­‐‑1  concentrations  that  in  turn  can  influence  cardiovascular  and  
renal  function,  rather  than  direct,  acute  vasodilatory  effects  of  AICAR  
administration.  These  observations  are  further  supported  by  our  tube  formation  
data  which  shows  chronic  in  vivo  treatment  alters  circulating  factors  and  
increases  tubule  formation  while  acute  treatment  with  AICAR  in  the  media  has  
no  effect.  This  also  suggests  that  cells  other  than  ECs  may  be  responsible  for  the  
changes  that  promote  tube  formation.  Further  studies  are  underway  to  identify  
which  cells  respond  to  AICAR  in  a  manner  consistent  with  pro-­‐‑angiogenic  
function.    
It  has  been  well  established  AICAR  can  mimic  many  of  the  metabolic  
effects  observed  in  moderate  physical  activity,  such  as  mitochondrial  biogenesis  
166-168,  decreased  lipogenesis  139,  increased  glucose  tolerance  35,36,139,165,168,173,  and  
AMPK  stimulation  139,165,172,174.  Moreover,  our  lab  has  recently  reported  exercise  
training  prior  to  and  during  gestation  has  several  beneficial  effects  on  maternal  
blood  pressure  and  angiogenic  balance  27.  While  the  present  study  reports  that  
AICAR  administration  appears  to  have  similar  cardiovascular  and  angiogenic  
balance  effects  as  exercise  in  RUPP  animals  27,75,  an  interesting  difference  is  
AICAR  did  not  directly  stimulate  the  production  of  VEGF  in  the  normal  
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pregnant  rats  27.  In  comparison  to  a  recent  study  of  adenosine  administration  and  
hypoxia-­‐‑dependent  mechanisms  in  placental  explants  143,  the  current  study  also  
suggests  these  effects  on  the  angiogenic  factors  may  be  ischemia-­‐‑  or  hypoxia-­‐‑
dependent.  In  addition,  this  study  also  suggests  gestational  AICAR  treatment  
may  hold  promise  as  a  therapeutic  independent  of  its  use  as  a  mimetic  of  
exercise.  While  these  findings  are  intriguing,  further  studies  are  required  to  
further  elucidate  the  mechanisms  by  which  AICAR  lowers  blood  pressure  and  
restores  angiogenic  balance.    
Angiogenic  Imbalance  and  AICAR  
The  effects  of  AICAR  on  angiogenic  balance  present  an  interesting  story  as  
AICAR  administration  appears  to  regulate  both  VEGF  and  sFlt-­‐‑1.  Indeed,  our  
initial  hypothesis  only  considered  effects  on  VEGF  via  AMPK  activation,  as  the  
regulation  of  sFlt-­‐‑1  via  AMPK  is  unclear  at  this  point.  Also,  it  is  important  to  note  
the  changes  following  AICAR  administration  on  the  angiogenic  balance  and  
blood  pressure  were  only  observed  in  the  RUPP,  and  not  the  normal  pregnant  
(NP).  This  further  suggests  a  possible  mechanism  that  is  mediated  by  the  
placental  ischemia  and/or  hypoxia.  Interestingly,  AICAR  has  been  used  to  
improve  ischemia-­‐‑reperfusion  injury  in  cardiac  tissue  during  coronary  bypass  
surgery  175,  which,  unsurprisingly,  may  have  similar  effects  in  other  tissues  such  
as  the  placenta.  Moreover,  these  specific  placental  ischemia-­‐‑dependent  
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mechanisms  have  been  proposed  before  in  in  vitro  models  143,  but,  we  are  the  first  
to  report  this  effect  of  adenosine-­‐‑mimetic  administration  in  a  model  of  placental  
ischemia-­‐‑induced  hypertension.  These  observations  are  further  supported  by  our  
placental  tissue  analysis  of  AMPK  phosphorylation,  in  which  AICAR-­‐‑induced  
increases  in  phosphorylation  of  AMPK  was  dependent  on  the  placental  ischemia  
induced  by  the  RUPP  procedure  and  not  observed  in  the  NP  placenta.  Taken  
together  with  the  MAP  and  angiogenic  balance  data,  AICAR  has  no  measured  
effect  on  the  normal  pregnant  dams  in  this  study.  We  also  observed  that  chronic  
AICAR  did  not  stimulate  AMPK  phosphorylation  in  skeletal  muscle  in  either  NP  
or  RUPP  groups.  Although  these  findings  are  interesting,  further  studies  are  
required  to  determine  if  this  is  a  tissue  or  pregnancy  specific  observation  or  if  the  
molecular  changes  are  dependent  on  hypoxia  or  chronic  ischemia.    
Systemic  and  Organ-­‐‑Specific  Oxidative  Stress  and  Anti-­‐‑Oxidant  Capacity  
In  addition  to  the  effects  on  the  angiogenic  balance,  RUPP-­‐‑associated  renal  
and  placental  markers  of  oxidative  stress  were  reduced  with  AICAR  treatment.  
Previous  work  has  shown  that  oxidative  stress  plays  an  important  role  in  
preeclampsia  and  RUPP  hypertension  100,140  and  our  present  observations  suggest  
that  the  effects  of  AICAR  may  be  mediated  by  a  combination  of  the  inhibition  of  
the  formation  of  reactive  oxygen  species  and  the  stimulation  of  antioxidant  
molecules.  Similar  to  our  observations  with  angiogenic  balance  this  effect  was  
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only  observed  in  the  RUPP  groups  following  AICAR  treatment,  suggesting  a  
dependence  on  the  presence  of  placental-­‐‑ischemia.  While  the  attenuation  of  these  
oxidative  stress  markers  in  the  RUPP+AICAR  coincide  with  the  stimulation  of  
bioavailable  VEGF  and  a  concomitant  production  or  maintenance  of  downstream  
anti-­‐‑oxidative  molecules,  whether  the  observed  effects  are  dependent  on  the  
VEGF  remains  unclear.  Further  studies  of  the  direct  and  indirect  antioxidant  
properties  of  AICAR  are  required  to  identify  the  exact  pathways  underlying  the  
present  observations.  
Study  Limitations  
While  we  feel  the  present  results  are  exciting,  it  is  important  to  recognize  
they  are  not  without  limitations.  While  our  current  hypothesis  focused  on  the  
previously  reported  links  between  purinergic  signaling  and  VEGF,  other  
angiogenic  factors  important  in  preeclampsia  such  as  sEng  163,176  may  also  be  
affected  by  AICAR  and  further  studies  are  planned  to  evaluate  these  
possibilities.  Moreover,  this  study  does  not  specifically  address  the  exact  role  of  
AMPK  signaling  and  additional  studies  are  planned  to  evaluate  the  exact  role  of  
that  pathway  in  angiogenic  balance.  Lastly,  the  source  of  the  changes  in  VEGF  
and  sFlt-­‐‑1  in  the  present  study  remain  unknown,  so  further  studies  are  required  
to  isolate  the  source.  Nevertheless,  studies  are  planned  to  further  investigate  the  
role  of  AMPK  on  AICAR’s  effects  in  vivo.  Further  studies  are  currently  aimed  at  
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the  effects  of  AICAR  specific  to  pregnancy,  the  cell-­‐‑type-­‐‑specific  (e.g.  placental,  
vascular  endothelial  cell,  skeletal  muscle)  effects,  and  the  source  of  and  
contribution  to  VEGF  and  sFlt-­‐‑1  control.    
Conclusion  
Taken  together,  the  effects  of  AICAR  in  the  RUPP  model  reveal  an  
interesting  potential  role  of  AMPK  activation  on  angiogenic  balance  and  
normotension  restoration.  Also  presented  are  encouraging  therapeutic  potential  
for  placental  ischemia-­‐‑induced  hypertension,  by  restoring  angiogenic  balance,  
abrogating  RUPP-­‐‑induced  hypertension,  and  having  no  reportable  deleterious  
effects  on  the  fetal-­‐‑placental  unit.  While  these  results  are  promising,  further  
pharmacological  studies  are  required  to  elucidate  the  exact  mechanisms  by  
which  AICAR  lowers  blood  pressure  and  restores  angiogenic  balance.  
In  the  next  section,  Part  2,  the  effects  of  AICAR  on  the  placenta  and  
vascular  endothelium  will  be  explored  to  further  elucidate  the  mechanism  by  







PART  2:  PLACENTAL  AND  VASCULAR-­‐‑SPECIFIC  EFFECTS  OF  AICAR  ON    
     




   In  Part  2  of  this  data  chapter,  tissue-­‐‑specific  effects  of  AICAR  
administration  are  explored  in  vascular  endothelium,  placental  cytotrophoblasts,  
as  well  as  placental  villous  syncytium.  Our  laboratory  has  recently  reported  the  
potent  AMP-­‐‑activated  kinase  (AMPK)  agonist  5-­‐‑aminimidazole-­‐‑4-­‐‑carboxamide-­‐‑
1-­‐‑β-­‐‑D-­‐‑ribofuranoside  (AICAR)  prevents  an  increase  in  arterial  blood  pressure  
and  restores  angiogenic  balance  (e.g.  increased  ratio  of  VEGF  to  sFlt-­‐‑1)  in  rats  
with  placental  ischemia  induced  hypertension  26.  However,  the  central  molecular  
mechanisms  linking  AMPK  and  VEGF/sFlt-­‐‑1  secretion  under  ischemic  stress  
remain  unknown.  Moreover,  stimulation  of  the  AMPK  pathway  has  recently  
been  reported  to  increase  VEGF  expression  127,128,  which  has  also  been  suggested  
to  be  the  mediating  mechanism  in  the  prevention  of  placental  ischemia  induced  
hypertension  in  preeclampsia.  Interestingly,  the  administration  of  adenosine,  
which  is  a  known  agonist  for  AMPK  activation,  reportedly  decreased  sFlt-­‐‑1  
production  in  placental  villi  under  hypoxic  conditions  143.  Also,  AMPK  activation  
is  observed  to  mitigate  apoptotic  and  ER  stress  signaling  cascades  in  various  
tissues,  including  vascular  endothelium  130,135,174,177,  which  is  further  suggestive  of  
its  protective  properties.      
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Though  AICAR  reportedly  improves  the  VEGF  and  sFlt-­‐‑1  balance  in  
maternal  circulation  in  the  RUPP  model  26,  the  tissue  specificity  also  remains  in  
question.  Several  reports  have  concluded  storage  pools  of  releasable  sFlt-­‐‑1  are  
primarily  sequestered  and  sourced  from  the  placenta  and  peripheral  vascular  
endothelium  during  preeclampsia  and  normal  pregnancy  65,68,74,178-180,  which  may  
be  tissues  affected  under  AICAR  treatment.  Therefore,  it  is  important  to  
investigate  each  tissue  in  vitro  to  further  understand  the  physiological  
applications  of  AICAR  treatment  in  preeclampsia.    
Thus,  the  aim  of  this  study  was  to  model  placental  ischemia  with  human  
placental  cytotrophoblast  (BeWo),  primary  umbilical  vascular  endothelial  
(HUVEC)  cells,  and  rat  placental  villous  explants  cultured  under  physiological  
hypoxic  conditions  to  determine  if  AICAR  modifies  angiogenic  factor  secretion.  
Further,  we  hypothesize  AICAR  treatment  will  prevent  the  imbalance  of  VEGF  




All  experimental  procedures  executed  were  completed  in  accordance  with  
National  Institutes  of  Health  guidelines  for  use  and  care  of  animals  and  were  
approved  by  the  Institutional  Animal  Care  and  Use  Committee  (IACUC)  at  the  
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University  of  Oregon.    Placentas  for  villous  explant  culture  were  isolated  on  day  
19  of  gestation  from  six  timed-­‐‑pregnant  Sprague-­‐‑Dawley  rats  purchased  from  
Harlan  Laboratories  (Indianapolis,  IN).  Animals  were  housed  in  a  temperature-­‐‑
controlled  room  (23°C)  with  a  12:12  light:dark  cycle.  
Placental  Explant  Isolation  and  Culture  
Normal  pregnant  dams  were  euthanized  and  whole-­‐‑placentas  were  
isolated  on  day  19  of  gestation.  Tissues  were  collected  in  ice-­‐‑cold  sterile  PBS.  
Under  a  dissection  microscope,  the  decidua  and  trophospongium  were  carefully  
dissected  away  to  isolate  the  anchoring  villi  bundles.  Approximately  10-­‐‑15mg  of  
villous  tissue  were  excised  and  weighed  prior  to  culture.  The  explants  were  
cultured  in  a  24-­‐‑well  plate  on  150µμl  of  Growth  Factor  Reduced  Matrigel®  (BD  
Biosciences)  and  1mL  of  50/50  Dulbecco’s  Modified  Eagle’s  Medium:  Ham’s  F-­‐‑12  
with  100  µμg/ml  streptomycin,  100  U/ml  penicillin,  and  25  µμg/ml  ascorbic  acid.  
Tissues  were  conditioned  in  a  CO2/O2  gas  incubator  at  either  physiological  
normoxia  (8%  O2)  or  at  hypoxia  (1%  O2)  in  the  presence  of  2mM  AICAR  for  24  
hours.  
HUVEC  and  BeWo  Cell  Culture  Technique  and  Conditions  
Immortalized  human  villous  trophoblast  cells  (BeWo)  and  primary  human  
umbilical  vascular  endothelial  cells  (HUVECs)  were  purchased  from  American  
Type  Culture  Collection  (ATCC,  USA).  Prior  to  experimental  protocols,  cells  
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were  grown  to  manufacturer’s  recommendations.  Briefly,  cells  were  grown  to  70-­‐‑
80%  confluence  in  a  75cm2  flask  (Corning  Inc.,  USA)  under  5%  CO2/20%  O2,  and  
re-­‐‑plated  at  1x105  cells/well  in  a  24-­‐‑well  plate  for  further  treatment.  BeWo  cells  
(Passages  20-­‐‑30)  were  cultured  with  F12K  basal  media  (ATCC),  and  HUVECs  
(passages  2-­‐‑4)  were  cultured  with  vascular  cell  basal  media  (ATCC).  Growth  
medias  were  supplement  with  10%  fetal  bovine  serum,  100  µμg/ml  streptomycin,  
100  U/ml  penicillin  (ATCC).    
Following,  cells  were  sub-­‐‑cultured  to  study  the  effects  of  AICAR  under  
physiological  normoxic  (8%  O2)  and  hypoxic  (1%  O2)  conditions.  Cells  were  
transferred  to  a  6-­‐‑well  culture  plate  at  1x105  cells/well  (1  mL),  and  grown  to  ~70%  
confluence.  After  a  serum  starvation  (~1-­‐‑2  hours),  cells  were  washed  twice  with  
sterile  PBS.  Sterile-­‐‑filtered,  serum-­‐‑less  media  supplemented  with  or  without  
AICAR  (2mM)  was  introduced  to  the  cells  and  cultured  at  the  specified  
conditions  for  24  hours.  Conditioned  media  and  cells  were  collected  for  further  
analysis.  All  treatments  were  run  in  sextuplet.    
Enzyme-­‐‑Linked  Immunosorbant  Assays  
Plasma  concentrations  of  free  VEGF  and  sFlt-­‐‑1  were  measured  using  
species-­‐‑matched  commercial  ELISA  (enzyme  linked  immunosorbant  assay)  kits  
according  to  the  manufacturer’s  directions  (R&D  Systems,  Quantikine®;  
Minneapolis,  MN)  as  described  previously  27,151.  
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Statistical  Analysis  and  Calculations  
All  data  are  presented  as  mean  ±  SD,  and  statistical  significance  was  
accepted  when  p<.05.  Comparisons  were  made  with  a  one-­‐‑way  analysis  of  
variance  test  combined  with  a  Bonferroni  post-­‐‑hoc  test  were  employed.  Statistical  
calculations  were  made  with  GraphPad  Prism  version  5.00  for  Windows  
(GraphPad  Software,  San  Diego,  CA  USA).  
Results  
Angiogenic  Factor  Production  in  Rat  Placental  Explant  Culture  
   In  cultured  placental  villous  explants,  isolated  at  day  19  of  normal  
gestation,  the  production  of  VEGF  was  increased  (p<.05)  with  24  hours  of  1%  O2  
treatment  compared  to  normoxic  controls.  Additionally,  no  effect  of  AICAR  on  
VEGF  production  was  observed  under  either  8%  or  1%  O2  conditions  (Figure  5.7,  
top  panel).  Similarly,  an  increased  (p<.05)  production  of  sFlt-­‐‑1  was  observed  in  
explants  cultured  in  1%  O2  conditions,  however,  this  effect  was  abrogated  by  the  
administration  of  AICAR,  suggesting  AICAR’s  angiogenic  effects  may  be  
hypoxic  and  sFlt-­‐‑1-­‐‑specific  (Figure  5.7,  bottom  panel).  
Cytotrophoblast  and  Vascular  Endothelium  Response  to  AICAR  Under  Hypoxic  Stress  
In  regard  to  angiogenic  factor  regulation  in  BeWo  cells  (human  
cytotrophoblast)  under  hypoxic  stress,  VEGF  production  was  moderately  
increased  (p<.05  vs.  8%  O2  control)  with  24  hour  exposure  to  hypoxic  condition,  
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and  no  effect  of  AICAR  was  observed  (see  Figure  5.8).  Moreover,  no  effect  of  




































Figure  5.7.  Placental  Explant  Secretion  of  VEGF  and  sFlt-­‐‑1.  (Top  Panel)  
VEGF  levels  in  the  conditioned  media  were  increased  when  exposed  to  1%  O2  
conditions  (*p<.05),  and  AICAR  had  no  effect  under  either  oxygen  conditions.  
Mean+SD:  8%  881  ±157;  8%+AICAR  844  ±134;  *1%  1194  ±262;  1%+A  1062±277  
pg/mL.  (Bottom  Panel)  Secretion  of  sFlt-­‐‑1  was  stimulated  (*p<.05)  in  1%  O2  
conditions,  and  the  effect  was  reversed  (†p<.05)  in  1%+AICAR.  Mean+SD:  8%  
1165  ±150;  8%+AICAR  1139  ±135;  *1%  1379  ±236;  1%+A  1012±110  pg/mL.    *p<.05  
vs.  8%  control;  †p<.05  vs.  1%  control.    
  
Moreover,  production  of  angiogenic  factors  VEGF  and  sFlt-­‐‑1  were  
markedly  effected  by  AICAR,  where  AICAR  increased  VEGF  secretion  well  as  
obviated  the  expression  of  sFlt-­‐‑1.  Overall,  this  data  suggests  AICAR  may  
directed  towards  the  vascular  endothelial  tissue  to  improve  angiogenic  factor  







































Figure  5.8.  BeWo  Angiogenic  Factor  Production.  (Top  Panel)  VEGF  
secretion  from  BeWo  cytotrophoblasts  was  not  affected  by  culture  under  1%  O2  
conditions,  and  AICAR  had  no  effect  under  either  oxygen  conditions.  Mean+SD:  
8%  74  ±5;  8%+AICAR  49  ±24;  *1%  112  ±23;  1%+A  107±47  pg/mL.  (Bottom  Panel)  
Secretion  of  sFlt-­‐‑1  from  BeWo  cells  were  not  affected  by  oxygen  nor  AICAR  
treatment.  Mean+SD:  8%  5  ±3;  8%+AICAR  5  ±2;  *1%  5  ±2;  1%+A  6±3  pg/mL.    







































Figure  5.9.  HUVEC  VEGF  and  sFlt-­‐‑1  Secretion.  (Top  Panel)  VEGF  
concentration  in  conditioned  media  was  increased  (*†p<.05)  with  AICAR  
treatment  under  both  8%  and  1%  O2  conditions  compared  to  their  respective  
controls.  Mean+SD:  8%  177±78;  8%+AICAR  414±156;  *1%  95±41;  1%+A  508±221  
pg/mL.  (Bottom  Panel)  Secretion  of  sFlt-­‐‑1  was  reduced  with  AICAR  treatment  in  
both  8%  and  1%  O2  conditions  compared  to  their  respective  controls.  Mean+SD:  
8%  910±158;  8%+AICAR  141±34;  *1%  874±129;  1%+A  414±113  pg/mL.  *p<.05  vs.  







   Sufficient  placental  health  and  function  is  essential  to  the  development  of  
a  fetus  throughout  gestation.  In  preeclamptic  pregnancies,  placental  function  is  
often  reduced,  due  to  a  failure  to  adapt  the  ischemic  environment  which  results  
in  the  concomitant  apoptotic  activation  181-183.  Regarding  the  current  study,  we  
hypothesize  AICAR  treatment  will  prevent  the  imbalance  of  VEGF  and  sFlt-­‐‑1  
expression  by  placental  tissue  explants  culture  under  hypoxic  conditions.  
Further,  several  novel  and  exciting  findings  are  presented,  which  begin  to  
elucidate  the  tissue-­‐‑specific  effects  of  AICAR  and  understand  its  role  in  
preeclampsia  treatment  and  prevention.    
AICAR  and  Angiogenic  Factor  Production  
To  measure  the  effect  of  AICAR  in  the  hypoxic  placental  tissue,  placental  
villi  bundles  were  isolated  from  rat  placentas  and  cultured  under  8%  or  1%  O2  
conditions  to  model  placental  ischemic  conditions.  Similar  to  previous  reports  
143,184,  secretion  of  VEGF  and  sFlt-­‐‑1  were  increased  under  24  hour  hypoxic  culture.  
Moreover,  as  hypothesized,  angiogenic  factor  secretion  was  normalized  by  
AICAR  treatment  in  placental  villous  explants.  Supporting  our  initial  hypothesis,  
sFlt-­‐‑1  production  under  hypoxia  was  attenuated  with  AICAR  treatment,  whereas  
VEGF  production  remained  unaffected.  Together,  these  observations  further  
confirm  our  previous  in  vivo  findings  in  the  RUPP  model  26.  These  data  are  
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substantiated  by  previous  reports  from  George  and  colleagues  143,  where  
adenosine  treatment  suppressed  the  production  of  sFlt-­‐‑1  under  hypoxia  in  
placental  villous  explant  culture.  As  AICAR  is  considered  as  an  adenosine  
mimetic  37,  these  mechanisms  are  likely  very  closely  related  or  shared.  Taken  
together,  the  current  study  confirms  the  potential  of  AICAR  and  other  similar  
molecules  in  the  control  of  angiogenic  factor  secretion,  specifically  sFlt-­‐‑1,  from  
the  placenta  under  ischemic  or  hypoxic  stress.  It  is  important  to  recognize  that  it  
is  unclear  whether  the  stimulation  of  VEGF  is  a  direct  result  from  suppression  of  
the  antagonistic  sFlt-­‐‑1,  and  further  studies  are  required.    
Additionally,  the  role  of  AMPK  remains  unclear  at  this  time  as  this  was  
not  measured,  and  further  study  is  required  its  contributions  to  angiogenic  factor  
release.  A  recent  study  185  in  cardiac  remodeling  in  hypertension  reported  a  direct  
effect  of  AMPK  activation  on  the  inhibition  of  NFAT  (nuclear  factor  of  activated  
T  cells)  family  activity,  which  is  a  known  positive  regulator  of  sFlt-­‐‑1  and  Flt-­‐‑1  
production  186-188.  To  this  end,  this  pathway  should  be  further  investigated  in  
placental  tissue  to  elucidate  this  fascinating  signaling  process  for  application  in  
preeclampsia.  
In  regard  to  cell-­‐‑specificity,  the  effects  of  AICAR  appear  to  be  particular  to  
vascular  endothelial  cells,  as  observed  in  the  HUVEC  culture  data.  Firstly,  
cultured  cytotrophoblasts  (BeWo)  were  not  responsive  to  AICAR  treatment,  
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which  suggests  the  effects  on  angiogenic  factor  production  observed  in  the  
villous  explant  culture  are  not  mediated  directly  through  the  cytotrophoblasts.  
Interestingly,  AICAR  suppressed  sFlt-­‐‑1  release  in  vascular  endothelial  cells  
under  hypoxic  conditions,  and  also  improved  VEGF  secretion.  These  
observations  provide  an  intriguing  avenue  for  further  investigation  in  the  
hypoxic-­‐‑specificity  in  the  effects  of  AICAR,  and  the  potential  role  for  AMPK  
activation  as  a  central  mediator.  
Study  Limitations  
Though  these  experiments  begin  to  elucidate  the  cell-­‐‑specific  effects  of  
AICAR  that  may  explain  the  previous  in  vivo  observations  in  Part  1  of  this  data  
chapter,  there  are  several  questions  remaining.  Firstly,  the  role  of  AMPK  in  the  
angiogenic  factor  and  cell  stress  signaling  remains  untested,  and  further  
experiments  are  required.  A  chemical  or  genetic  antagonism  of  AMPK  activity  
could  be  combined  with  the  current  experimental  protocol  to  elucidate  this  
intriguing  question.  Further,  examination  of  angiogenic  factor  mRNA  expression  
would  be  beneficial  to  reveal  the  effects  of  AICAR  treatment  on  sFlt-­‐‑1  and  VEGF  
expression,  and  if  the  observed  sFlt-­‐‑1  suppression  is  indeed  the  cause  for  an  
increase  in  VEGF  in  the  conditioned  media.    
Additionally,  the  timeline  of  the  protein  expression  changes  was  not  
analyzed  in  any  of  the  experiments.  For  instance,  for  how  long  and  how  quickly  
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after  hypoxic  exposure  does  the  expression  of  sFlt-­‐‑1  increase?  Though  this  is  
critical  information  in  the  minutia  of  the  pharmacology  and  clinical  application,  
we  feel  this  was  outside  of  the  scope  of  the  current  study.  
Conclusion  
Collectively,  the  present  study  provides  an  interesting  role  for  AICAR  in  
the  angiogenic  factor  secretion  profile  and  cell  stress  under  hypoxic  conditions,  
and  supports  the  concept  of  AICAR  administration  in  models  of  placental  
ischemia.  Moreover,  this  project  suggests  the  improvement  of  free  VEGF  in  our  
previous  in  vivo  report  appears  to  result  from  the  suppression  of  sFlt-­‐‑1  secretion  
from  placental  explants  under  hypoxic  stress,  which  provides  an  intriguing  and  
novel  target  for  preeclamptic  angiogenic  imbalance.  Though  further  studies  are  
required  to  fully  elucidate  the  molecular  mechanisms,  the  potential  clinical  
applications  of  AICAR  are  exciting  and  provide  an  avenue  for  pharmacological  
research  and  development  for  preeclampsia  treatment  and  prevention.  
   In  Part  3  of  this  data  chapter,  we  will  exam  the  role  of  the  angiogenic  
imbalance,  in  regard  to  the  sFlt-­‐‑1:VEGF  axis,  in  the  effects  of  AICAR  in  placental  
ischemia  induced  hypertension  and  angiogenic  imbalance.       
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PART  3:  ELUCIDATING  THE  ROLE  OF  ANGIOGENIC  BALANCE  AND    
  
VEGF  BIOAVAILABILITY  IN  THE  ANTI-­‐‑HYPERTENSIVE  EFFECTS  OF    
  




Though  the  etiology  of  preeclampsia  (PE)  is  unclear,  recent  studies  have  
implicated  the  imbalance  of  angiogenic  factors,  most  notably  through  the  
VEGF/PlGF:sFlt-­‐‑1  axis.  This  imbalance  has  been  a  large  focus  of  the  preeclampsia  
research  since  Karumanchi’s  seminal  report  on  the  role  of  sFlt-­‐‑1  over  a  decade  
ago  20.  Since  then,  several  experimental  modalities  studied  have  been  focused  on  
the  improvement  of  angiogenic  balance  to  mitigate  placental  ischemia  induced  
hypertension  26,27,71,118,141,  primarily  through  the  restoration  of  circulating  VEGF  to  
counteract  the  rise  in  sFlt-­‐‑1.    
Furthermore,  as  reported  in  Parts  I-­‐‑II  of  this  data  chapter,  AICAR  (5-­‐‑
aminoimidazole-­‐‑4-­‐‑carboxamide-­‐‑1-­‐‑β-­‐‑D-­‐‑ribofuranoside)  remediated  the  
hypertension  and  angiogenic  imbalance  in  the  RUPP  model,  potentially  through  
the  stimulation  of  VEGF  production  and/or  the  suppression  of  sFlt-­‐‑1.  Indeed,  the  
overall  anti-­‐‑hypertensive  effects  are  promising,  but  the  role  of  angiogenic  
imbalance  remains  in  question  in  regard  to  the  observed  cardiovascular  effects  of  
AICAR  in  a  model  of  placental  ischemia  induced  hypertension.  Therefore,  we  
hypothesized  the  anti-­‐‑hypertensive  effects  of  AICAR  would  be  prevented  by  
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maintaining  an  angiogenic  imbalance  by  chronic  infusion  of  recombinant  mouse  
(rm)-­‐‑sFlt1  in  an  animal  model  of  PE.      
Methods    
Animals  
All  experimental  procedures  executed  were  completed  in  accordance  with  
National  Institutes  of  Health  guidelines  for  use  and  care  of  animals  and  were  
approved  by  the  Institutional  Animal  Care  and  Use  Committee  (IACUC)  at  the  
University  of  Oregon.  Studies  were  performed  between  the  University  of  Oregon  
and  the  with  timed-­‐‑pregnant  Sprague-­‐‑Dawley  rats  purchased  from  Harlan  
Laboratories  (Indianapolis,  IN).  Animals  were  housed  in  a  temperature-­‐‑
controlled  room  (23°C)  with  a  12:12  light:dark  cycle.    
Reduced  Uterine  Perfusion  Pressure  (RUPP)  Procedure  
The  RUPP  procedure  is  a  well-­‐‑characterized  and  widely  accepted  model  
140  for  studying  the  link  between  placental  ischemia  and  hypertension  in  the  
pregnant  rat  and  has  been  described  in  detail  previously27.  Briefly,  a  silver  clip  
(0.203-­‐‑mm  inner  diameter  (ID))  was  placed  on  the  lower  abdominal  aorta,  
superior  to  the  common  iliac  bifurcation.  Two  additional  clips  (0.100-­‐‑mm  ID)  
were  placed  on  the  branches  of  both  the  right  and  left  ovarian  arteries  on  day  14  
of  gestation  (term=21  days).  NP  dams  underwent  a  sham  surgery,  which  
included  an  abdominal  midline  incision  and  suture.  After  observing  no  
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differences  in  the  angiogenic  factors  and  blood  pressures  these  animals  were  
grouped  with  the  NP  rats.      
AICAR  and  Recombinant  sFlt-­‐‑1  Administration  
On  gestational  day  14,  dams  were  assigned  to  normal  pregnancy  (NP)  
(n=8)  and  RUPP  (n=8)  groups  with  and  without  AICAR  (Santa  Cruz  
Biotechnology  Inc.,  Santa  Cruz,  CA)  treatment  (NP+A  (n=6);  RUPP+A  (n=8)).  
Animals  received  with  AICAR  from  days  14-­‐‑19  with  intraperitoneal  (i.p.)  
injection  of  50mg/kg  b.i.d.  by  a  0.5mL  0.9%  saline  vehicle.  All  other  animals  
received  a  0.5mL  0.9%  saline  vehicle  injection  as  control.    
Further,  recombinant  mouse  VEGF-­‐‑R1/Flt-­‐‑1-­‐‑Fc  chimera  (R&D  Systems,  
Minneapolis,  MN,  #471-­‐‑F1-­‐‑100;  500ng/ul/h)  or  vehicle  (0.9%  sterile  saline)  was  
chronically  administered  i.p.  from  days  14-­‐‑19  of  gestation  by  mini-­‐‑osmotic  pump  
(Alzet,  Cupertino,  CA,  Model  2001).  Control  groups  received  a  vehicle  (0.9%  
saline).  This  dose  has  previously  been  observed  to  increase  arterial  pressure  and  
plasma  sFlt-­‐‑1  levels  in  pregnant  rats  176,  and  was  further  confirmed  in  our  pilot  
studies.  NP,  NP+sFlt1  and  RUPP  data  are  also  reported  in  Part  2  of  Chapter  IV  as  
these  studies  were  run  in  parallel.    
Measurement  of  MAP  in  Chronically  Instrumented  Conscious  Rats  
Animals  were  instrumented  with  an  indwelling  arterial  catheter  of  the  left  
common  carotid  artery  on  day  18  of  gestation.  On  day  19,  unanesthetized  mean  
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arterial  pressure  (MAP)  was  measured  using  a  fluid-­‐‑filled  pressure  transducer  
(ADInsruments,  Colorado  Springs,  CO)  26,27,151.    
Conceptus  Measurements  and  Serum  Collection  
After  blood  pressure  measurement,  the  dams  were  placed  under  3%  
isoflurane  anesthesia,  and  a  midline  ventral  incision  was  made  to  isolate  the  
abdominal  aorta  for  arterial  plasma  and  serum  collection  as  reported  previously  
27,151.  After  exsanguination,  a  pneumothorax  and  cardiac  excision  were  used  to  
confirm  death.  Blood  was  collected  for  subsequent  assays  into  blank  and  EDTA-­‐‑
lined  Corvac®  tubes  for  serum  and  plasma  processing,  respectively  (Sherwood  
Davis,  St.  Louis,  MO).  Fetal  weight,  placental  weight,  and  number  of  resorptions  
were  recorded.  All  tissues  collected  for  subsequent  analysis  were  flash  frozen  in  
liquid  nitrogen  and  stored  at  -­‐‑80˚C.  
Mulvany  Microvessel  Wire  Myography  
Following  necropsies  on  day  19  of  gestation,  secondary  and  tertiary  
mesenteric  arterioles  were  isolated  and  cleaned  of  all  surrounding  adipose  and  
connective  tissues  under  a  dissection  microscope.  1-­‐‑2mm  vessel  segments  were  
then  mounted  on  two  40µμm  stainless  steel  wires  and  attached  to  a  wire  
myograph  (DMT,  Denmark)  to  allow  for  isometric  force  recordings.  Vessels  were  
normalized  to  tensions  that  proportionally  modeled  100mmHg  using  the  
normalization  module  in  LabChart  8.0  (ADInstruments,  USA).  
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After  a  10  minute  period  for  equilibration  in  a  Kreb’s  buffer  (130mM  
NaCl,  4.7mM,  1.2mM  KH2PO4,  1.2mM  MgSO4,  1.6mM  CaCl2,  14.9mM  NaHCO3,  
5.5mM  glucose  ,  pre-­‐‑constriction  was  obtained  by  exposing  the  vessels  to  an  
isosmotic,  high-­‐‑potassium  physiological  saline  solution  (K-­‐‑PSS)  (74.7mM  NaCl,  
60mM  KCl,  1.8  KH2PO4,  1.2mM  MgSO4,  1.6mM  CaCl2,  14.9mM  NaHCO3,  5.5mM  
glucose).  Following  a  triple  washout  period  with  Kreb’s  buffer,  a  stabilized  
vascular  constriction  was  achieved  by  the  addition  of  the  thromboxane  A2  
analogue  U46619  (5  µμM).  Endothelial-­‐‑dependent  vasorelaxation  was  evaluated  
with  a  cumulative  dose  response  curve  to  acetylcholine  (Ach;  1x10-­‐‑9–1x10-­‐‑5  M)  .  
Further,  endothelial-­‐‑independent  smooth  muscle  function  was  assessed  with  a  
cumulative  dose  response  curve  to  sodium  nitroprusside  (SNP,  1x10-­‐‑9–1x10-­‐‑5  M).  
Following  each  relaxation  curve,  a  single  dose  of  0.1mM  SNP  was  given  to  
confirm  smooth  muscle  integrity.  At  experiment  termination,  exposure  to  K-­‐‑PSS  
was  used  to  assess  vessel  viability  and  functional  decay.  Data  is  presented  as  
mean±SD  of  the  per  cent  vasorelaxation  from  U46619  contraction  force.  
Enzyme-­‐‑Linked  Immunosorbant  Assays  
Plasma  concentration  of  free  VEGF  was  measured  using  commercially  
available  enzyme  linked  immunosorbant  assay  (ELISA)  kits  (R&D  Systems,  
Quantikine®;  Minneapolis,  MN,  Part:  MMV00)  according  to  the  manufacturer’s  
directions  as  described  previously  26,27,151.  
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Endothelial  Tube  Formation  Assay  
Angiogenic  balance  was  further  assessed  in  the  serum  of  pregnant  rats  in  
vitro  as  previously  reported  26,27  in  two  separate  experiments  and  each  was  
performed  in  duplicate.  HUVECs  (human  umbilical  vascular  endothelial  cells)  
were  plated  at  5x105  cells/mL  (100µμl/well)  onto  96-­‐‑well  plate  lined  with  growth-­‐‑
factor-­‐‑reduced  Matrigel®  (BD  Biosciences,  Bedford,  MA).  Five  microliters  of  
maternal  serum  was  introduced  to  the  100µμl  cell  media.  Cells  were  incubated  at  
37°C,  20%  O2,  5%  CO2.  Average  tubule  length  was  assessed  at  100X  optical  zoom  
with  a  digital  inverted  compound  microscope  and  Zen  2012  software  (Carl  Zeiss,  
Inc.,  Thornwood  NY).    
Statistical  Analysis  and  Calculations  
All  data  are  presented  as  mean  ±  SD,  and  statistical  significance  was  
accepted  when  p<.05.  Comparisons  within  NP  and  RUPP  groups  were  evaluated  
with  a  one-­‐‑way  analysis  of  variance  test  combined  with  a  Bonferroni  post-­‐‑hoc  
test  were  employed.  Comparison  between  NP  and  RUPP  controls  was  analyzed  
by  an  unpaired  t-­‐‑test.  Statistical  calculations  were  made  with  GraphPad  Prism  







Mean  Arterial  Pressure  
At  day  19  of  gestation,  arterial  pressure  in  the  rm-­‐‑sFlt1  infused  normal  
pregnant  cohort  (NP+sFlt1)  was  increased  (p<.05)  in  comparison  to  NP  controls,  
and  remained  elevated  (p<.05  vs.  NP)  despite  AICAR  treatment  (50mg/kg,  b.i.d.).  
Moreover,  RUPP-­‐‑induced  hypertension  was  remediated  (p<.05)  with  AICAR  
treatment,  and  this  effect  was  reversed  (p<.05)  with  rm-­‐‑sFlt1  infusion.  Data  is  











































Figure  5.10.  Mean  Arterial  Pressure  on  Day  19.  Infusion  of  sFlt1  in  normal  
pregnant  dams  increased  (*p<.05)  mean  arterial  pressure  (MAP).  RUPP  increased  
(*p<.05)  MAP  vs.  NP,  and  AICAR  mitigated  (†p<.05)  mitigated  this  effect  in  
RUPP+A,  but  not  RUPP+A/sFlt1.  Mean+SD:  NP  105±9;  *NP+sFlt  119±7;  
NP+A/sFlt1  114±3;  *RUPP  129±4;  †RUPP+A  103±15;  RUPP+A/sFlt  136±6  mmHg.  
*p<.05  vs.  NP;  †p<.05  vs.  RUPP.  n=3-­‐‑8  per  group.  NP,  NP+sFlt1  and  RUPP  data  is  




Plasma  Angiogenic  Balance:  VEGF  and  sFlt-­‐‑1  
The  concentration  of  plasma  free  VEGF  was  not  affected  by  sFlt-­‐‑1  infusion  
in  the  NP+sFlt1  or  NP+A/sFlt1  treatment  groups  in  comparison  to  the  NP  control.  
As  we  have  previously  reported  26,27,151,  RUPP  decreased  bioavailable  VEGF  when  
compared  to  NP  controls,  and  AICAR  reversed  this  effect.  Moreover,  the  parallel  
treatment  sFlt-­‐‑1  infusion  with  AICAR  blocked  this  effect  on  VEGF  bioavailability  
in  the  RUPP  (Figure  5.11,  top  panel).    
Additionally,  plasma  sFlt-­‐‑1  levels  were  increased  (p<.05)  with  sFlt-­‐‑1  
infusion  in  the  NP  and  RUPP  cohorts  compared  to  their  respective  controls,  
which  confirmed  successful  peptide  delivery.  Further,  AICAR  treatment  did  not  
have  an  effect  NP+A/sFlt1  or  RUPP+A/sFlt1  compared  to  the  NP  and  RUPP  
groups,  respectively  (Figure  5.11,  bottom  left  panel).  Moreover,  the  ratio  of  
plasma  VEGF:sFlt-­‐‑1  remained  decreased  in  the  sFlt-­‐‑1  infused  NP  and  RUPP  
controls  despite  AICAR  treatment,  which  suggests  the  VEGF:sFlt-­‐‑1  angiogenic  
imbalance  was  maintained  by  sFlt-­‐‑1  infusion  (Figure  5.11,  bottom  right  panel).  
Vascular  Endothelial  Function  
   Endothelium-­‐‑dependent  vasodilation  potential  was  assessed  in  isolated  
mesenteric  arterioles  (200-­‐‑400µμm  diameter)  by  a  logarithmic  dose  response  to  
acetylcholine  (Ach)  (Figure  5.12).  With  respect  to  NP  controls,  rm-­‐‑sFlt1  infusion  






















































































































Figure  5.11.  Plasma  VEGF,  sFlt-­‐‑1,  and  VEGF:sFlt-­‐‑1  Balance.  (Top  Panel)  
RUPP  had  decreased  (*p<.05)  bioavailable  VEGF  compared  to  NP.  No  effect  of  
sFlt-­‐‑1  infusion  in  either  NP  or  RUPP  groups  were  observed.  NP  920±335;  
*NP+sFlt  1291±358;  *NP/A+sFlt  1209±378;  *RUPP  500±182;  RUPP/A  941±355;  
RUPP/A+sFlt  862±319  pg/mL.  (Bottom  Left  Panel)  sFlt-­‐‑1  was  increased  (*p<.05)  in  
NP+sFlt1,  and  NP+A/sFlt1  vs.  NP.  Additionally,  RUPP+A/sFlt1  treatment  
increased  (†p<.05)  plasma  sFlt-­‐‑1  vs.  RUPP  controls.  NP  76±47;  *NP+sFlt  470±108;  
*NP+A/sFlt  330±32;  *RUPP  78±33;  †RUPP+A  88±40;  RUPP+A/sFlt  651±260  pg/mL.  
(Bottom  Right  Panel)  The  ratio  of  bioavailable  VEGF:sFlt-­‐‑1  was  decreased  by  
sFlt-­‐‑1  infusion  in  both  NP+sFlt1  and  NP+A/sFlt1  vs.  NP  controls.  sFlt-­‐‑1  infusion  
in  RUPP+A/sFlt1  was  further  decreased  compared  to  RUPP  VEGF:sFlt-­‐‑1  values.  
NP  13.3±8.0;  *NP+sFlt  2.5±0.8;  *NP+A/sFlt  3.8±1.5;  *RUPP  7.3±3.8;  †RUPP+A  
10.0±5.5;  RUPP+A/sFlt  2.3±1.7  AU.  *p<.05  vs.  NP;  †p<.05  vs.  RUPP.  n=3-­‐‑10  per  




ameliorated  with  the  addition  of  AICAR  treatment  (Figure  5.12,  top  panel).    
In  regard  to  RUPP,  vasorelaxation  to  Ach  was  blunted  (p<.05  vs.  NP),  and  
AICAR  treatment  reversed  (p<.05  vs.  RUPP)  this  effect  (Figure  5.12,  bottom  
panel),  even  with  the  addition  of  sFlt-­‐‑1  infusion  in  the  RUPP+A  and  
RUPP+A/sFlt1  cohorts.  Additionally,  no  treatment  effects  were  observed  in  
smooth  muscle  function,  assessed  by  vasorelaxation  to  sodium  nitroprusside,  in  
either  NP-­‐‑  or  RUPP-­‐‑treatment  sub-­‐‑groups.  
Serum  Angiogenic  Potential  
Serum  angiogenic  potential  was  assessed  by  culture  of  human  vascular  
endothelial  cells  (HUVECs)  in  the  presence  of  5%  (v/v)  animal  sera,  followed  by  
measurement  of  microtubule  formation.  As  reported  in  the  previous  chapter,  
sFlt1-­‐‑infused  NP  animals  (NP+sFlt1)  had  a  decreased  (p<.05  vs.  NP)  angiogenic  
potential,  and  AICAR  treatment  in  NP+A/sFlt1  dams  restored  normal  tubule  
formation  potential  (Figure  5.13).  Moreover,  RUPP  sera  caused  a  decrease  (p<.05)  
in  tubule  formation  compared  to  NP  controls.  Further,  AICAR  treatment  in  both  
RUPP+A  and  RUPP+A/sFlt1  treatment  groups  had  no  effect  on  tubule  formation  






























































Figure  5.12.  Mesenteric  Arteriole  Vascular  Endothelial  Function.  (Top  
Panel)  After  constriction  to  thromboxane  mimetic  U46619,  NP+sFlt1  dams  
exhibited  a  decreased  (*p<.05)  vasodilation  potential  to  matched  doses  of  
acetylcholine  (Ach)  compared  to  NP,  AICAR  reversed  this  effect  despite  infusion  
of  sFlt-­‐‑1  in  NP+A/sFlt1.  (Bottom  Panel)  RUPP  caused  a  decrease  relaxation  to  
Ach  compared  to  NP  (gray),  and  AICAR  reversed  (†p<.05)  this  effect  in  both  
RUPP+A  and  RUPP+A/sFlt1.  Data  presented  as  mean+SD;  n=4-­‐‑6  per  group.  Data  
analyzed  between  groups  across  each  dose.  NP,  NP+sFlt1  and  RUPP  data  is  








































Figure  5.13.  Serum  Angiogenic  Potential.  Serum  angiogenic  potential  was  
decreased  in  NP+sFlt  and  RUPP  vs.  NP  (*p<.05).  Ex  treatment  in  RUPP  improved  
(†p<.05)  tubule  formation  vs.  RUPP.  Mean+SD:  NP  247±27;  *NP+sFlt  177±48;  
NP+A/sFlt  225±25;  *RUPP  176±39;  †RUPP+A  236±23;  RUPP+A/sFlt  248±39um.  A  
sample  picture  of  NP  vs.  RUPP  tubule  formation  is  provided  (scale  bar  =  100µμm).  
*p<.05  vs.  NP;  †p<.05  vs.  RUPP.  NP,  NP+sFlt1  and  RUPP  data  is  replicated  from  
Chapter  IV,  Part  2.  
  
Maternal  and  Conceptus  Morphometrics  
As  hypothesized  and  previously  reported,  RUPP  caused  a  decrease  (p<.05  
vs.  NP)  in  maternal,  fetal,  and  placental  weight,  as  well  as  an  increased  (p<.05  vs.  
NP)  rate  of  fetal  demise.  Infusion  of  rm-­‐‑sFlt1  in  NP  caused  a  decrease  in  maternal  
weight,  but  had  no  effects  on  fetal  or  placental  morphometrics.  As  previously  
reported  26,  AICAR  treatment  ameliorated  the  rate  of  fetal  demise,  however,  we  
did  not  observe  an  effect  maternal,  fetal,  or  placental  weights.  With  the  addition  
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of  rm-­‐‑sFlt1  infusion,  rates  of  fetal  demise  were  increased,  and  a  decrease  in  
placental  weight  was  also  observed.  Data  is  summarized  in  Table  5.2.  
Table  5.2.  Maternal  and  Conceptus  Morphometric  Data  at  Necropsy.    
  Treatments   Maternal   Fetal   Placental   %  Resorption  
Weight  (g)   Weight  (g)   Weight  (g)  
NP  
(n=10)  
311±8   2.28±0.07   0.50±0.02   1.5±1.5  
NP+sFlt1  
(n=8)  
*288±6   2.27±0.08   0.49±0.03   0.8±0.9  
NP+A/sFlt1  
(n=6)  
*267±12   2.41±0.21   0.51±0.01   8.5±4.3  
RUPP  
(n=10)  
*259±6   *1.82±0.14   *0.37±0.03   *73.0±10.3  
RUPP+A  
(n=7)  
267±8   1.97±0.04   0.45±0.02   †58.3±4.2  
RUPP+A/sFlt1  
(n=6)  
250.2±9.2   1.79±0.20   †0.43±0.02   70.0±14.3  
Note.  *P<.05  indicates  different  from  NP.  †P<.05  indicates  different  from  RUPP.  
Data  presented  as  mean±SD.  NP,  NP+sFlt1  and  RUPP  data  is  replicated  from  




The  current  study  presents  several  intriguing  and  novel  findings  
regarding  AICAR  treatment  in  a  model  of  placental  ischemia  induced  
hypertension.  Indeed,  the  data  from  this  project  support  our  initial  hypothesis  
and  suggest  AICAR’s  anti-­‐‑hypertensive  effects  are  dependent  on  a  restored  
angiogenic  imbalance.  An  unexpected  finding  was  the  restoration  of  endothelial  
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function  in  the  RUPP  appears  to  be  partially  independent  of  an  improvement  of  
plasma  VEGF:sFlt-­‐‑1  angiogenic  balance.    
AICAR,  Angiogenic  Balance,  and  Mean  Arterial  Pressure  
Similar  to  our  previous  observation  26,  AICAR  restored  the  angiogenic  
balance  and  endothelial  function  in  the  RUPP  dams.  Moreover,  we  are  the  first  to  
report  sFlt1-­‐‑induced  hypertension  in  the  normal  pregnant  dams  was  not  affected  
with  AICAR  treatment,  which  further  suggests  the  mechanism  of  AICAR  is  
specific  to  the  RUPP  and  potentially  dependent  on  placental  ischemia.  This  
explanation  for  the  specificity  to  RUPP  remains  unclear,  as  AICAR  has  been  
shown  to  effectively  lower  blood  pressure  in  several  non-­‐‑pregnant  animal  
models  of  hypertension  34,35,172.    
One  potential  explanation,  in  concert  with  our  previous  observations  26,189,  
is  AICAR’s  pharmacological  mechanism  is  mediated  through  the  suppression  of  
sFlt-­‐‑1  production.  Further,  this  would  account  for  the  absence  of  effect  on  
NP+sFlt1  blood  pressure,  as  well  as  the  RUPP  infused  with  sFlt-­‐‑1.  It  should  be  
noted  that  AICAR  and  AMPK  activation  may  also  improve  VEGF  production  as  
Ouchi  and  others  have  previously  reported  128;  however,  we  have  not  observed  
this  effect  in  the  NP  26.  Much  work  remains  needed  in  this  topic,  to  elucidate  the  
molecular  mechanisms  of  this  intriguing  effect.  
A  potential  mechanism  that  may  account  for  this  difference  is  a  potential  
123	  
	  
difference  in  extracellular  fluid  volume.  Briefly,  plasma  volume  has  been  
observed  to  be  decreased  in  PE  women  190-192  as  well  as  the  RUPP  rat  193,  and  
should  be  accounted  for  in  drug  administration  in  pregnancy  194.  Though  plasma  
and  extracellular  fluid  volume  was  not  directly  measured  in  the  current  study,  
one  could  speculate  a  difference  in  blood  volume  may  impact  the  effective  dose  
received.  As  a  difference  in  plasma  volume  is  not  necessarily  accounted  for  by  
total  bodyweight  normalization,  further  investigation  is  required.  
AICAR  and  Endothelial  Function    
Indeed,  AICAR  improved  endothelial-­‐‑dependent  vasorelaxation  in  
mesenteric  arterioles  in  both  NP  and  RUPP  cohorts  despite  a  concomitant  
infusion  of  sFlt-­‐‑1.  Together,  there  appears  to  be  an  alternative  mechanism  by  
with  AICAR  improved  endothelial  function,  as  angiogenic  imbalance  of  the  
VEGF:sFlt-­‐‑1  axis  was  maintained  throughout  AICAR  treatment.  Assumingly,  if  
the  effects  of  AICAR  were  specifically  targeted  on  restoring  endothelial  function,  
the  sFlt1-­‐‑induced  hypertension  in  the  NP  cohort  would  be  expected  to  be  
ameliorated;  yet,  this  was  not  observed.  Indeed,  AICAR  treatment  improved  the  
endothelial  function  in  both  NP+sFlt-­‐‑1  and  RUPP  cohorts,  and  these  effects  
appear  to  be  independent  of  angiogenic  balance  restoration  through  the  
VEGF:sFlt-­‐‑1  axis.  This  may  be  due  an  increase  in  eNOS  activation  or  coupling  in  
vascular  endothelium  and  smooth  muscle  cells,  which  are  directly  activated  by  
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AMPK  137,174,195;  nevertheless,  these  effects  were  not  measured  in  the  present  study  
and  should  be  pursued  in  the  future.  Moreover,  Chen  and  colleagues  have  
demonstrated  the  Ser1177  residue  is  phosphorylated  with  chronic  AMPK  
activation  in  endothelial  cells  137,  which  suggests  a  long  term  effect  on  NO  
synthesis  rather  than  the  acute  outcome  previously  presumed  by  Ford  and  
colleagues  34.  Though  the  specific  contributions  of  VEGF  and  sFlt1  remain  
unexamined,  the  role  of  VEGF-­‐‑sFlt1  axis  balance  in  this  model  of  PE  appears  to  
play  an  essential  role.  Further  studies  are  underway  to  isolate  the  roles  of  VEGF  
and  sFlt1  in  the  promising  therapeutic  potential  of  AICAR  treatment.    
Furthermore,  endothelial  function  was  improved  in  both  hypertensive  
treatment  groups,  RUPP  and  NP+sFlt1,  while  the  effect  on  blood  pressure  
appears  to  be  limited  to  the  RUPP  treatment.  The  reason  remains  unknown,  but  
may  include  mechanisms  that  were  not  addressed  in  this  study,  which  may  
include  the  immune,  central,  or  other  humoral  signaling  that  has  been  recently  
implicated  in  preeclampsia  etiology  51,196-202.  For  instance,  administration  of  
AICAR  in  endothelial  culture  has  been  previously  shown  to  decrease  monocyte  
adhesion  and  inflammatory  cytokine  release  203,  which  could  contribute  to  the  






Though  the  findings  in  this  study  are  intriguing,  these  experiments  are  not  
without  limitation.  Indeed,  the  infusion  of  sFlt-­‐‑1  was  shown  to  effectively  sustain  
angiogenic  imbalance  through  the  VEGF:sFlt-­‐‑1  axis,  this  approach  does  not  
dissect  the  individual  roles  of  VEGF  and  sFlt-­‐‑1  control  in  the  effects  of  AICAR.  
However,  the  ELISA  data  clearly  demonstrates  the  VEGF:sFlt-­‐‑1  angiogenic  
imbalance  in  maintained  with  rm-­‐‑sFlt1  infusion,  which  suggests  the  anti-­‐‑
hypertensive  effect  of  AICAR  treatment  is  largely  dependent  on  the  restoration  
of  angiogenic  balance.  To  this  end,  additional  studies  using  pharmacological  or  
genetic  dissection  methods  are  required  to  isolate  the  individual  roles  of  sFlt-­‐‑1  
and  VEGF  regulation  under  AICAR  treatment.    
   It  should  also  be  noted  that  the  validity  of  the  circulating  VEGF  
measurement  by  ELISA  (purchased  from  R&D  Systems,  Minneapolis,  MN)  have  
recently  been  challenged  by  Weissgerber  and  colleagues  162.  While  we  did  not  
observe  the  wide  variability  and  difficulty  in  obtaining  comparable  values  in  free  
VEGF  as  Weissgerber  has  previously  reported,  we  would  like  to  recognize  that  
this  currently  is  an  area  of  concern  in  preeclampsia  research.  We  also  failed  to  
replicate  our  previous  published  observations  in  the  RUPP  in  regard  to  the  
plasma  sFlt-­‐‑1  levels.  Without  these  effects  in  RUPP,  the  interpretation  and  
comparative  quality  of  the  angiogenic  effects  in  RUPP  should  be  taken  into  
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consideration  in  future  studies.  In  response  to  this  concern,  additional  
measurements  of  circulating  sFlt-­‐‑1  and  serum  angiogenic  potential  (tubule  
formation  assay)  to  further  support  this  data.  To  this  end,  we  feel  this  is  sufficient  
experimental  evidence  to  appropriately  interpret  the  current  data  and  the  role  of  
VEGF  bioavailability  in  the  effects  of  AICAR  in  the  RUPP  model.  
Conclusion  
In  concert  with  our  previous  studies,  the  current  study  confirms  AICAR  
treatment  following  RUPP  can  abrogate  he  development  of  hypertension  and  
endothelial  dysfunction.  Moreover,  the  effects  of  AICAR  appear  to  be  dependent  
on  the  restoration  of  angiogenic  balance  in  the  VEGF:sFlt-­‐‑1  axis.  Furthermore,  
while  the  present  study  begins  to  dissect  the  pharmacological  mechanism  of  
AICAR  treatment  in  the  RUPP  model  of  preeclampsia,  further  research  is  
required  to  reveal  the  mechanisms  of  AICAR’s  promising  anti-­‐‑hypertensive  
treatment  in  preeclampsia.  
  
  









In  Chapter  IV,  the  exercise  training  studies  revealed  several  interesting  
findings  in  the  RUPP  model  of  placental  ischemia  induced  hypertension.  First  
and  foremost,  the  hypertension  in  the  RUPP  model  was  attenuated,  and  even  
obviated  in  the  treatment  of  exercise  prior  to  and  during  gestation.  The  role  of  
exercise  treatment  that  is  initiated  at  gestation  ostensibly  is  not  effective  in  
remediating  the  hypertensive  response  to  placental  ischemia.  Additionally,  as  
hypothesized,  exercise  training  improved  angiogenic  balance  through  increasing  
bioavailable  VEGF,  and  decreasing  sFlt-­‐‑1,  the  role  of  VEGF:sFlt-­‐‑1.  However,  
when  the  VEGF:sFlt-­‐‑1  balance  was  sustained  throughout  treatment,  the  role  of  
angiogenic  balance  restoration  was  not  essential  for  the  blood  pressure  lowering  
effect  in  the  RUPP  dams.  Together,  these  findings  provide  an  intriguing  and  
novel  role  for  exercise  to  prevent  preeclamptic-­‐‑like  development  in  the  RUPP  rat,  
which  also  provide  a  strong  base  for  continued  research  in  the  molecular  
mechanism  of  the  observed  anti-­‐‑hypertensive  effect.  
Regarding  the  results  following  AICAR  treatment,  there  was  a  remarkable  
anti-­‐‑hypertensive  effect  in  the  RUPP  model,  while  having  no  observed  
deleterious  effects  on  the  fetal  and  placental  growth  in  either  normal  pregnant  or  
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RUPP  cohorts.  Moreover,  the  drug  appears  to  have  a  direct  effect  on  sFlt-­‐‑1  
secretion  in  vivo,  as  well  as  in  vitro  models  of  hypoxic  conditions  in  isolated  
placental  explants  and  cultured  vascular  endothelial  cells.  This  effect  alone  is  
quite  notable,  as  increased  plasma  sFlt-­‐‑1  remains  extremely  difficult  to  prevent  
or  control  in  clinical  practice  204.  To  note,  AICAR’s  anti-­‐‑hypertensive  effects  were  
not  observed  in  the  NP+sFlt1  PE  model,  and  were  reversed  by  sFlt-­‐‑1  infusion  in  
the  RUPP,  which  together  suggests  the  effects  of  AICAR  are  dependent  on  
placental  ischemia  as  well  as  the  potential  suppression  of  sFlt-­‐‑1.  
In  concert,  the  treatments  investigated  in  this  dissertation  offer  unique  
and  novel  treatment  modalities  in  the  prevention  of  preeclamptic-­‐‑like  
hypertension  in  the  pregnant  rat  (outlined  in  Figure  6.1),  and  potentially  the  
preeclampsia  in  humans.  It  is  with  great  hope  that  these  effects  are  translated  to  
human  pregnancies,  and  mediate  the  onset  of  this  costly  and  arduous  syndrome.  
Limitations  
   Though  the  findings  in  this  dissertation  are  exciting,  it  is  recognized  these  
studies  were  not  performed  without  limitation.  Firstly,  in  regard  to  exercise  
treatment,  the  exercise  distance  run  by  each  rat  was  not  controlled  for  across  or  
within  individual  studies.  To  control  for  these  distances,  the  mode  of  voluntary  
exercise  by  activity  wheel  would  likely  require  a  substitution  forced  activity  and  
daily  monitoring,  which  may  add  an  additional  convoluting  variable  of  stress.    
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Indeed,  these  components  would  be  beneficial  to  isolate  and  dissect  the  ideal  
exercise  training  time  and  intensity;  however,  these  fall  outside  of  the  current  
scope  of  the  projects  and  should  be  pursued  in  future  studies.  
  
Figure  6.1.  New  Working  Hypothesis  for  Exercise  and  AICAR  Treatments.  
We  report  placental-­‐‑ischemia-­‐‑induced  hypertension  is  mitigated  by  exercise  
training  prior  to  and  throughout  gestation  in  the  RUPP  rat  (†Specific  Aim  1).  
Further,  endothelial  function  and  the  hypertension  were  improved  with  exercise,  
and  were  not  dependent  on  the  restoration  of  VEGF:sFlt-­‐‑1  angiogenic  balance.  
Additionally,  AICAR  treatment  (‡Specific  Aim  2)  is  reported  to  ameliorated  
placental  ischemia  induced  hypertension,  and  is  indeed  dependent  on  restored  
VEF:sFlt-­‐‑1  balance.  Moreover,  AICAR  did  improve  endothelial  function  
independent  of  restored  angiogenic  balance,  which  suggests  an  alternative,  
contributing  pathway  to  the  mechanism.  Together,  these  effects  are  hypothesized  
to  be  offer  two  stages  of  intervention  to  prevent  the  preeclamptic  pathology  
following  increased  placental  ischemia.  RBF:  Renal  blood  flow;  TPR:  Total  
peripheral  resistance.  
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   An  additional  limitation  to  be  recognized  in  the  data  interpretation  is  the  
effect  of  AICAR  or  EBD  (Exercise  Before  and  During  gestation)  on  angiogenic  
balance  within  the  VEGF:sFlt-­‐‑1  axis.  Firstly,  the  VEGF  concentrations  reported  
across  each  in  vivo  study  vary  widely,  and  this  is  likely  due  to  the  methodological  
inconsistencies  raised  recently  by  Dr.  Weissgerber  and  colleagues  162.  Further,  the  
previously  reported  effects  of  RUPP  on  plasma  sFlt-­‐‑1  were  not  replicated  in  the  
later  studies  of  each  chapter.  Though  these  rats  presented  with  increased  mean  
arterial  pressure  in  comparison  to  sham/vehicle  controls,  the  expected  increase  in  
plasma  sFlt-­‐‑1  was  not  observed.  This  may  be  due  to  methodological  
inconsistency  within  the  assay,  but  may  also  indicate  the  current  cohort  of  rats  
did  not  respond  to  RUPP  in  the  predicted  manner.  Further,  Banek  and  colleagues  
have  recently  reported  the  timing  of  the  RUPP  procedure  in  the  gestational  
timeline  is  essential  to  provoke  the  imbalance  of  VEGF  and  sFlt-­‐‑1  9.  Specifically,  
animals  that  underwent  the  RUPP  surgery  on  day  12  vs.  day  14  of  gestation  
presented  with  an  increased  mean  arterial  pressure  in  the  five  days  following  
surgery,  yet  no  effect  on  plasma  sFlt-­‐‑1.  Furthermore,  it  is  possible  the  animals  in  
the  current  studies  that  did  not  respond  to  RUPP  as  hypothesized  were  mistimed  
in  pregnancy,  as  only  the  presence  of  the  seminal  plug  was  used  to  time  the  
pregnancy  (day  0  at  plug  day).  To  avoid  this  potential  convoluting  factor  in  
future  work,  Doppler  confirmation,  as  well  as  fetal  size/weight  should  be  utilized  
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in  parallel  to  seminal  plug  observation  to  control  for  gestational  timing.  
FUTURE  DIRECTIONS  
While  the  effects  of  exercise  before  and  during  gestation  are  quite  exciting,  
several  key  questions  remain  to  be  answered  in  order  to  understand  the  
mechanisms  of  the  cardiovascular  effects.  Firstly,  the  role  of  VEGF:sFlt-­‐‑1  balance  
in  the  maternal  circulation  appears  to  be  vital  to  the  cardiovascular  effects  of  
AICAR  treatment,  whereas  exercise  remediated  the  placental  ischemia  induced  
hypertension  despite  a  sustained  VEGF:sFlt-­‐‑1  imbalance.  This  difference  may  be  
suggestive  of  a  novel  pathway  which  was  not  accounted  for  in  the  initial  
hypothesis,  which  may  include  the  other  humoral,  immune,  or  neural  
contributions  to  PE  pathology  discussed  in  Chapter  II.  Furthermore,  the  role  of  
VEGF  and  sFlt-­‐‑1  in  the  effects  of  exercise  appears  to  be  secondary  in  the  overall  
effect  in  the  RUPP  model.  This  observation  is  quite  intriguing,  as  it  suggests  
treatment  of  preeclampsia  may  be  pursued  through  mechanisms  outside  of  
angiogenic  factors.  
An  additional  question  remaining  in  this  story  is  the  direct  effects  of  both  
exercise  and  AICAR  treatments  on  the  systemic  and  organ-­‐‑specific  
hemodynamics.  Exercise  is  well  known  to  further  increase  stroke  volume  and  
cardiac  output  that  is  already  elevated  with  pregnancy,  as  well  as  further  
decrease  total  peripheral  resistance  123,156,205,206.  In  regard  to  AICAR,  only  one  
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study  has  been  completed  in  healthy  men  to  suggest  acute  effects  of  AICAR  
administration  may  improve  cardiac  output  and  decrease  peripheral  vascular  
resistance.  Unfortunately,  the  cardiovascular  effects  of  chronic  AICAR  
administration  remain  poorly  understood  36,  and  require  further  investigation.  
Further,  as  placental  blood  flow  is  assumed  to  be  reduced  by  the  RUPP’s  
mechanical  restriction  of  the  primary  source  of  arterial  blood  flow,  AICAR  and  
exercise  are  likely  to  cause  tissue-­‐‑specific  adaptations  at  the  tissue  level  to  thrive  
under  such  ischemic  conditions.  These  effects  are  yet  to  be  elucidated,  and  
should  be  pursued  in  future  studies.    
INFERENCE  AND  APPLICATION  OF  EXERCISE  AND  AICAR  TREATMENT  
TO  PREVENT  PREECLAMPSIA    
While  both  exercise  prior  to  and  during  pregnancy  and  AICAR  treatment  
mitigated  the  model  placental  ischemia  induced  hypertension.  Taken  together,  
the  clinical  application  from  these  studies  is  intriguing,  where  it  allows  the  
potential  interventional  moments  at  two  moments  during  the  preconception  and  
late-­‐‑gestation  phases.    
As  discussed  in  Chapter  IV,  the  role  of  exercise  in  prevention  of  the  
hypertension  and  vascular  dysfunction  following  placental  ischemia  is  
dependent  on  the  time  of  training  initiation  in  the  pregnant  rat.  Specifically,  if  
exercise  was  initiated  6  weeks  previous  to,  and  sustained  through  gestation,  the  
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RUPP  hypertension  was  ameliorated,  whereas  training  initiated  following  
conception  was  not  effective.  Combined  with  the  very  supportive  
epidemiological  reports,  these  studies  demonstrate  a  potential  prophylactic  
modality  for  women  planning  on  becoming  pregnant.  Though  exciting,  the  
mechanisms  and  long-­‐‑term  effects  of  the  exercise  training  treatment  still  require  
thorough  investigation.    
Indeed,  while  exercise  initiated  at  gestation  in  the  RUPP  model  was  not  
effective  in  mitigating  the  hypertension  at  the  end  of  gestation,  AICAR  treatment  
following  RUPP  appears  to  fill  that  void  of  treatment.  As  the  effects  described  in  
Chapter  V  suggest  an  intriguing  role  for  AICAR  treatment,  the  preventative  
effects  were  also  paralleled  by  no  observed  deleterious  effects  in  either  the  
normal  pregnant  or  RUPP.  Further,  these  findings  also  open  a  door  for  the  
further  exploration  of  AICAR  to  extend  the  length  or  gestation  or  even  use  as  a  
prophylactic  pharmaceutical  for  preeclampsia.  Certainly,  the  offspring  of  these  
AICAR-­‐‑treated  pregnancies  were  not  thoroughly  studied,  and  much  further  
investigation  is  required.  
Though  admittedly  speculative  at  this  point,  this  collection  of  work  
outlines  an  intriguing,  and  relatively  inexpensive,  approach  to  prevent  the  onset  
of  preeclampsia  if  impairment  of  placental  perfusion  is  to  occur.  In  the  ideal  
clinical  situation,  the  physician  could  advise  a  woman  who  is  planning  on  
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becoming  pregnant  to  start  a  mild-­‐‑moderate  exercise  training  regimen  (e.g.  
jogging,  swimming,  bicycling,  etc.).  Once  pregnancy  is  confirmed,  the  woman  
could  be  advised  to  continue  a  mild-­‐‑moderate  exercise  training  program  
throughout  the  remainder  of  gestation.  From  our  findings  in  the  RUPP  rat,  and  
in  the  recent  epidemiological  reports,  exercise  training  could  prevent  the  
development  of  hypertension  that  may  develop  if  there  is  an  impaired  placental  
perfusion  due  to  spiral  arterial  malformation.  In  addition  to  this  theoretical  
application,  if  a  woman  is  not  regularly  exercising  prior  to  gestation,  could  
AICAR  be  used  following  the  detection  of  interrupted  placental  perfusion?  Since  
we  have  observed  no  deleterious  effects  in  either  the  normal  pregnant  or  RUPP  
dams,  the  potential  for  prophylactic  treatment  with  AICAR  remains  possible.  
However,  long-­‐‑term  studies  in  cardiovascular  and  neural  development  of  the  
offspring  are  required  to  make  this  conclusion  and  begin  clinical  trial.    
Together,  these  modalities  may  offer  two  stages  of  defense  against  the  
development  of  hypertension  and  endothelial  dysfunction  associated  with  
preeclampsia.  These  findings  in  this  dissertation  are  clearly  an  exciting  and  
promising  venture  to  be  further  pursued  through  both  basic  science  and  clinical  
research  to  tackle  one  of  the  oldest  and  detrimental  threats  to  maternal  and  fetal  
health  worldwide.    
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